LANXESS Solutions US (CEMJQ) 10-K 24 Feb 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
In Billions, except Share data in Millions, unless otherwise specified	Dec. 31, 2013	Jan. 31, 2014	Jun. 30, 2013
Document and Entity Information	'	'	'
Entity Registrant Name	'Chemtura CORP	'	'
Entity Central Index Key	'0001091862	'	'
Document Type	'10-K	'	'
Document Period End Date	31-Dec-13	'	'
Amendment Flag	'false	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Filer Category	'Large Accelerated Filer	'	'
Entity Public Float	'	'	$2
Entity Common Stock, Shares Outstanding	'	96.5	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
In Millions, except Per Share data, unless otherwise specified	Dec. 31, 2013
Consolidated Statements of Operations	'
NET SALES	$2,231
COSTS AND EXPENSES	'
Cost of goods sold	1,721
Selling, general and administrative	229
Depreciation and amortization	101
Research and development	40
Facility closures, severance and related costs	42
OPERATING INCOME	98
Interest expense	-60
Loss on early extinguishment of debt	-50
Other income, net	9
Reorganization items, net	-1
(Loss) earnings from continuing operations before income taxes	-4
Income tax expense	-18
(Loss) earnings from continuing operations	-22
Earnings (loss) from discontinued operations, net of tax	25
Loss on sale of discontinued operations, net of tax	-180
Net (loss) earnings	-177
Net (loss) earnings attributable to Chemtura	-177
BASIC AND DILUTED PER SHARE INFORMATION - ATTRIBUTABLE TO CHEMTURA:	'
(Loss) earnings from continuing operations, net of tax (in dollars per share)	($0.23)
Earnings (loss) from discontinued operations, net of tax (in dollars per share)	$0.26
Loss on sale of discontinued operations, net of tax (in dollars per share)	($1.84)
Net (loss) earnings attributable to Chemtura (in dollars per share)	($1.81)
Basic weighted - average shares outstanding (in shares)	97.7
Diluted weighted - average shares outstanding (in shares)	97.7
AMOUNTS ATTRIBUTABLE TO CHEMTURA STOCKHOLDERS:	'
(Loss) earnings from continuing operations, net of tax	-22
Earnings (loss) from discontinued operations, net of tax	25
Loss on sale of discontinued operations, net of tax	-180
Net (loss) earnings attributable to Chemtura	($177)

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive (Loss) Income (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Consolidated Statements of Comprehensive (Loss) Income	'	'	'
Net (loss) earnings	($177)	$100	$120
Other comprehensive (loss) income, net of tax:	'	'	'
Foreign currency translation adjustments	-60	-6	-35
Unrecognized pension and other post-retirement benefit costs	208	-76	-35
Comprehensive (loss) income	-29	18	50
Comprehensive loss (income) attributable to the non-controlling interest	'	1	-1
Comprehensive (loss) income attributable to Chemtura	($29)	$19	$49

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
CURRENT ASSETS	'	'
Cash and cash equivalents	$549	$363
Accounts receivable	361	345
Inventories	415	398
Other current assets	158	123
Assets held for sale	4	'
Current assets of discontinued operations	'	383
Total current assets	1,487	1,612
NON-CURRENT ASSETS	'	'
Property, plant and equipment	724	655
Goodwill	179	177
Intangible assets, net	142	146
Other assets	172	169
Non-current assets of discontinued operations	'	271
Total Assets	2,704	3,030
CURRENT LIABILITIES	'	'
Short-term borrowings	117	5
Accounts payable	172	152
Accrued expenses	189	178
Income taxes payable	6	8
Liabilities held for sale	2	'
Current liabilities of discontinued operations	'	168
Total current liabilities	486	511
NON-CURRENT LIABILITIES	'	'
Long-term debt	781	871
Pension and post-retirement health care liabilities	246	386
Other liabilities	192	109
Non-current liabilities of discontinued operations	'	85
Total liabilities	1,705	1,962
STOCKHOLDERS' EQUITY	'	'
Common stock -$.01 par value, authorized - 500.0 shares, issued - 100.5 shares in 2013 and 100.4 shares in 2012	1	1
Additional paid-in capital	4,375	4,366
Accumulated deficit	-3,025	-2,848
Accumulated other comprehensive loss	-280	-428
Treasury stock at cost - 4.0 shares in 2013 and 2.4 shares in 2012	-73	-30
Total Chemtura stockholders' equity	998	1,061
Non-controlling interests - continuing operations	1	'
Non-controlling interests - discontinued operations	'	7
Total Non-controlling interests	1	7
Total stockholders' equity	999	1,068
Total Liabilities and Stockholders' Equity	$2,704	$3,030

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Millions, except Per Share data, unless otherwise specified
Consolidated Balance Sheets	'	'
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, Authorized shares	500	500
Common stock, Issued shares	100.5	100.4
Treasury stock at cost, shares	4	2.4

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
CASH FLOWS FROM OPERATING ACTIVITIES	'	'	'
Net (loss) earnings	($177)	$100	$120
Adjustments to reconcile net (loss) earnings to net cash provided by operating activities:	'	'	'
Loss on sale of discontinued operations	180	'	'
Gain on sale of business	'	'	-27
Impairment charges	7	47	4
Release of translation adjustment from liquidation of entities	-13	-21	'
Loss on early extinguishment of debt	50	1	'
Depreciation and amortization	123	139	140
Stock-based compensation expense	14	24	26
Reorganization items, net	'	1	2
Changes in estimates related to expected allowable claims	'	1	3
Provision for doubtful accounts	1	1	7
Equity income	-2	-3	-3
Deferred taxes	1	3	-6
Changes in assets and liabilities, net:	'	'	'
Accounts receivable	-20	-8	13
Inventories	-13	-1	-24
Other current assets	-14	-4	38
Other assets	-18	'	3
Accounts payable	20	30	-11
Accrued expenses	-18	-3	-39
Income taxes payable	5	-14	5
Pension and post-retirement health care liabilities	-59	-79	-82
Liabilities subject to compromise	'	'	-8
Other liabilities	15	1	25
Other	-3	3	-4
Net cash provided by operating activities	79	218	182
CASH FLOWS FROM INVESTING ACTIVITIES	'	'	'
Proceeds from divestments, net	357	9	8
Payments for acquisitions, net of cash acquired	-3	'	-35
Capital expenditures	-170	-149	-154
Net cash provided by (used in) investing activities	184	-140	-181
CASH FLOWS FROM FINANCING ACTIVITIES	'	'	'
Proceeds from 2021 Senior Notes	450	'	'
Payments on 2018 Senior Notes, includes premium on tendering of notes	-396	'	'
(Payments on) proceeds from Term Loan	-102	125	'
Proceeds from other long term borrowings	31	'	'
Payments on other long term borrowings	-4	'	'
(Payments on) proceeds from other short term borrowings, net	-1	-3	3
Payments for debt issuance and refinancing costs	-12	-2	'
Common shares acquired	-54	-20	-22
Proceeds from exercise of stock options	8	5	1
Net cash (used in) provided by financing activities	-80	105	-18
CASH AND CASH EQUIVALENTS	'	'	'
Effect of exchange rates on cash and cash equivalents	1	2	-4
Change in cash and cash equivalents	184	185	-21
Cash and cash equivalents at beginning of year	365	180	201
Cash and cash equivalents at end of year	549	365	180
Cash and cash equivalents at end of year - Continuing operations	549	363	179
Cash and cash equivalents at end of year - Discontinued operations	'	$2	$1

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (USD $)	Total	Common Stock	Treasury Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Non Controlling Interests
In Millions, unless otherwise specified
Balance at Dec. 31, 2010	$971	$1	'	$4,305	($3,068)	($276)	$9
Balance (in shares) at Dec. 31, 2010	'	95.6	'	'	'	'	'
Increase (Decrease) in Stockholders' Equity	'	'	'	'	'	'	'
Net (loss) earnings	120	'	'	'	119	'	1
Equity adjustment for translation of foreign currencies	-35	'	'	'	'	-35	'
Unrecognized pension and post-retirement plan costs, net of deferred tax benefit (expense) of $16 million in 2013, $14 million in 2012, and $1 in 2011	-35	'	'	'	'	-35	'
Issuance of reorganized Chemtura common stock	19	'	'	19	'	'	'
Issuance of reorganized Chemtura common stock (in shares)	'	2.4	'	'	'	'	'
Dividends attributable to the non-controlling interest	-1	'	'	'	'	'	-1
Stock-based compensation	29	'	'	29	'	'	'
Common shares acquired	-22	'	-22	'	'	'	'
Common shares acquired (in shares)	'	'	2	'	'	'	'
Other issuances (in shares)	'	0.3	'	'	'	'	'
Balance at Dec. 31, 2011	1,046	1	-22	4,353	-2,949	-346	9
Balance (in shares) at Dec. 31, 2011	'	98.3	2	'	'	'	'
Increase (Decrease) in Stockholders' Equity	'	'	'	'	'	'	'
Net (loss) earnings	100	'	'	'	101	'	-1
Equity adjustment for translation of foreign currencies	-6	'	'	'	'	-6	'
Unrecognized pension and post-retirement plan costs, net of deferred tax benefit (expense) of $16 million in 2013, $14 million in 2012, and $1 in 2011	-76	'	'	'	'	-76	'
Issuance of reorganized Chemtura common stock	1	'	'	1	'	'	'
Issuance of reorganized Chemtura common stock (in shares)	'	2.1	'	'	'	'	'
Dividends attributable to the non-controlling interest	-1	'	'	'	'	'	-1
Stock-based compensation	24	'	'	24	'	'	'
Stock options exercised	5	'	4	1	'	'	'
Stock options exercised (in shares)	'	'	-0.3	'	'	'	'
Common shares acquired	-20	'	-20	'	'	'	'
Common shares acquired (in shares)	'	'	1.4	'	'	'	'
Other issuances	-5	'	8	-13	'	'	'
Other issuances (in shares)	'	'	-0.7	'	'	'	'
Balance at Dec. 31, 2012	1,068	1	-30	4,366	-2,848	-428	7
Balance (in shares) at Dec. 31, 2012	'	100.4	2.4	'	'	'	'
Increase (Decrease) in Stockholders' Equity	'	'	'	'	'	'	'
Net (loss) earnings	-177	'	'	'	-177	'	'
Equity adjustment for translation of foreign currencies	-60	'	'	'	'	-60	'
Unrecognized pension and post-retirement plan costs, net of deferred tax benefit (expense) of $16 million in 2013, $14 million in 2012, and $1 in 2011	208	'	'	'	'	208	'
Divestiture	-6	'	'	'	'	'	-6
Stock-based compensation	14	'	'	14	'	'	'
Stock options exercised	8	'	7	1	'	'	'
Stock options exercised (in shares)	'	'	-0.5	'	'	'	'
Common shares acquired	-54	'	-54	'	'	'	'
Common shares acquired (in shares)	'	'	2.4	'	'	'	'
Other issuances	-2	'	4	-6	'	'	'
Other issuances (in shares)	'	0.1	-0.3	'	'	'	'
Balance at Dec. 31, 2013	$999	$1	($73)	$4,375	($3,025)	($280)	$1
Balance (in shares) at Dec. 31, 2013	'	100.5	4	'	'	'	'

Consolidated_Statements_of_Sto1

Consolidated Statements of Stockholders' Equity (Parenthetical) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Consolidated Statements of Stockholders' Equity	'	'	'
Unrecognized pension and post-retirement plan costs, net of deferred tax expense	$16	$14	$1

NATURE_OF_OPERATIONS_AND_SUMMA

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2013
NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	1) NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Nature of Operations
	Chemtura Corporation, together with our consolidated subsidiaries is dedicated to delivering innovative, application-focused specialty chemical. Our corporate headquarters is located at 1818 Market Street, Suite 3700, Philadelphia, PA 19103. Our principal executive offices are located at 1818 Market Street, Suite 3700, Philadelphia, PA 19103 and at 199 Benson Road, Middlebury, CT 06749. We operate in a wide variety of end-use industries, including agriculture, automotive, construction, electronics, lubricants, packaging, plastics for durable and non-durable goods, and transportation.
	When we use the terms "Corporation," "Company," "Chemtura," "Registrant," "We," "Us" and "Our," unless otherwise indicated or the context otherwise requires, we are referring to Chemtura Corporation and our consolidated subsidiaries.
	We are the successor to Crompton & Knowles Corporation ("Crompton & Knowles"), which was incorporated in Massachusetts in 1900 and engaged in the manufacture and sale of specialty chemicals beginning in 1954. Crompton & Knowles traces its roots to the Crompton Loom Works incorporated in the 1840s. We expanded the specialty chemical business through acquisitions in the United States and Europe, including the 1996 acquisition of Uniroyal Chemical Company, Inc. ("Uniroyal"), the 1999 merger with Witco Corporation ("Witco") and the 2005 acquisition of Great Lakes Chemical Corporation ("Great Lakes"). Since the Great Lakes acquisition, we have progressively focused our portfolio, divesting businesses that did not fit with the strategic criteria we have established for our portfolio. Recent divestitures include our antioxidants and UV stabilizers ("Antioxidant") and Consumer Products businesses during 2013.
	Basis of Presentation
	The accompanying Consolidated Financial Statements include the accounts of Chemtura and our wholly-owned and majority-owned subsidiaries that we control. Other affiliates in which we have a 20% to 50% ownership interest or a non-controlling majority interest are accounted for in accordance with the equity method. Other investments in which we have less than 20% ownership are recorded at cost. All significant intercompany balances and transactions have been eliminated in consolidation.
	Our Consolidated Financial Statements have been prepared in conformity with U.S. generally accepted accounting principles ("GAAP"), which require us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.
	Certain prior year amounts have been reclassified to conform to the current year's presentation. These changes did not have a material impact on previously reported results of operations, cash flows or financial position.
	We operated as a debtor-in-possession ("DIP") under the protection of the United States Bankruptcy Court for the Southern District of New York (the "Bankruptcy Court") from March 18, 2009 (the "Petition Date") through November 10, 2010 (the "Effective Date"). From the Petition Date through the Effective Date, our Consolidated Financial Statements were prepared in accordance with Accounting Standards Codification ("ASC") Section 852-10-45, Reorganizations—Other Presentation Matters ("ASC 852-10-45") which requires that financial statements, for periods during the pendency of our voluntary petitions for relief under Chapter 11 of Title 11 of the United States Code (the "Chapter 11") filings, distinguish transactions and events that are directly associated with the reorganization from the ongoing operations of the business. Accordingly, certain income, expenses, realized gains and losses and expenses for losses that were realized or incurred in the Chapter 11 cases were recorded in Reorganization items, net in our Consolidated Statements of Operations. In connection with our emergence from Chapter 11 on November 10, 2010, we recorded certain "plan effect" adjustments to our Consolidated Financial Statements as of the Effective Date in order to reflect certain expenses of our plan of reorganization (the "Plan"). As of December 31, 2013, the Bankruptcy Court has entered orders granting final decrees closing all of the Debtors' Chapter 11 cases except the Chapter 11 case of Chemtura Corporation. See Note 17—Emergence from Chapter 11 for a further discussion.
	Accounting Policies
	Revenue Recognition
	Substantially all of our revenues are derived from the sale of products. Revenue is recognized when risk of loss and title to the product is transferred to the customer. Revenue is recorded net of taxes collected from customers that are remitted to governmental authorities with the collected taxes recorded as current liabilities until remitted to the respective governmental authorities. Our products are sold subject to various shipping terms. Our terms of delivery are included on our sales invoices and order confirmation documents.
	Customer Rebates
	We accrue for the estimated cost of customer rebates as a reduction of sales. Customer rebates are primarily based on customers achieving defined sales targets over a specified period of time. We estimate the cost of these rebates based on the likelihood of the rebate being achieved and recognize the cost as a deduction from sales when such sales are recognized. Rebate programs are monitored on a regular basis and adjusted as required. Our accruals for customer rebates were $10 million and $14 million at December 31, 2013 and 2012, respectively. Customer rebates are included as a reduction to accounts receivable on our Consolidated Balance Sheet.
	Operating Costs and Expenses
	Cost of goods sold ("COGS") includes all costs incurred in manufacturing goods, including raw materials, direct manufacturing costs and manufacturing overhead. COGS also includes warehousing, distribution, engineering, purchasing, customer service, environmental, health and safety functions, and shipping and handling costs for outbound product shipments. Selling, general and administrative ("SG&A") expenses include costs and expenses related to the following functions and activities: selling, advertising, legal, provision for doubtful accounts, corporate facilities and corporate administration. SG&A also includes accounting, information technology, finance and human resources, excluding direct support in manufacturing operations, which is included as COGS. Research and development ("R&D") expenses include basic and applied research and development activities of a technical and non-routine nature. R&D costs are expensed as incurred. COGS, SG&A and R&D expenses exclude depreciation and amortization expenses which are presented on a separate line in our Consolidated Statements of Operations.
	Other Income (Expense), Net
	Other income (expense), net includes:
	(In millions)	2013			2012			2011
	Foreign exchange loss	$	(7	)	$	(6	)	$	(2	)
	Interest income		3			5			3
	Release of cumulative foreign currency translation adjustments from liquidation of entities		13			21			—
		$	9		$	20		$	1
	Allowance for Doubtful Accounts
	Included in accounts receivable are allowances for doubtful accounts in the amount of $11 million in 2013 and 2012. The allowance for doubtful accounts reflects a reserve representing our estimate of the amounts that may not be collectible. In addition to reviewing delinquent accounts receivable, we consider many factors in estimating our reserves, including historical data, experience, customer types, credit worthiness, and economic trends. From time to time, we may adjust our assumptions for anticipated changes in any of these or other factors expected to affect collection.
	Inventory Valuation
	Inventories are valued at the lower of cost or market. Cost is determined using the first-in, first-out ("FIFO") method.
	Property, Plant and Equipment
	Property, plant and equipment are carried at cost, less accumulated depreciation. Depreciation expense is principally computed on the straight-line method using the following ranges of asset lives: land improvements—3 to 20 years; buildings and improvements—2 to 40 years; machinery and equipment—2 to 25 years; information systems and equipment—2 to 10 years; and furniture, fixtures and other—1 to 10 years. See Note 5—Property, Plant and Equipment for further information.
	Renewals and improvements that significantly extend the useful lives of the assets are capitalized. Capitalized leased assets and leasehold improvements are depreciated over the shorter of their useful lives or the remaining lease term. Expenditures for maintenance and repairs are charged to expense as incurred.
	Intangible Assets
	Patents, trademarks and other intangibles assets are being amortized principally on a straight-line basis using the following ranges for their estimated useful lives: patents—5 to 20 years; trademarks—6 to 40 years; customer relationships—15 to 30 years; production rights—10 years; and other intangibles—5 to 50 years. See Note 6—Goodwill and Intangible Assets for further information.
	Recoverability of Long-Lived Assets and Goodwill
	We evaluate the recoverability of the carrying value of long-lived assets, excluding goodwill, whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Under such circumstances, we assess whether the projected undiscounted cash flows of our long-lived assets are sufficient to recover the existing unamortized cost of our long-lived assets. If the undiscounted projected cash flows are not sufficient, we calculate the impairment amount by discounting the projected cash flows using our weighted-average cost of capital. The amount of the impairment is written off against earnings in the period in which the impairment is determined.
	We evaluate the recoverability of the carrying value of goodwill on an annual basis as of July 31, or when events occur or circumstances change. See Note 6—Goodwill and Intangible Assets for further details.
	Income Taxes
	We account for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences of temporary differences between the carrying amounts and tax bases of assets and liabilities using enacted rates. The effect of a change in tax rates on deferred tax assets is recognized in income in the period that includes the enactment date.
	We recognize the financial statement effects of an uncertain income tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. We accrue for other tax contingencies when it is probable that a liability to a taxing authority has been incurred and the amount of the contingency can be reasonably estimated.
	Provision is made for taxes on undistributed earnings of foreign subsidiaries and related companies to the extent that such earnings are not deemed to be indefinitely reinvested.
	Environmental Liabilities
	Each quarter, we evaluate and review our estimates for future remediation, operation and management costs directly related to environmental remediation, to determine appropriate environmental reserve amounts. For each site where the cost of remediation is probable and reasonably estimable, we determine the specific measures that are believed to be required to remediate the site, the estimated total cost to carry out the remediation plan, the portion of the total remediation costs to be borne by us and the anticipated time frame over which payments to implement the remediation plan will occur. At sites where we expect to incur ongoing operations and maintenance expenditures, we accrue on an undiscounted basis, for a period of generally 10 years, those costs which are probable and reasonably estimable.
	Litigation and Contingencies
	In accordance with guidance now codified under ASC Topic 450, Contingencies, we record in our Consolidated Financial Statements amounts representing our probable and reasonably estimable liability for claims, litigation and guarantees. As information about current or future litigation or other contingencies becomes available, management assesses whether such information warrants the recording of additional expenses relating to those contingencies. See Note 18—Legal Proceedings and Contingencies for further information.
	Stock-Based Compensation
	We recognize compensation expense for stock-based awards issued over the requisite service period for each separately vesting tranche, as if multiple awards were granted. Stock-based compensation expense is measured at the date of grant, based on the fair value of the award. Stock-based compensation expense recognized was $14 million, $24 million, and $26 million for the years ended December 31, 2013, 2012 and 2011, respectively.
	Translation of Foreign Currencies
	Balance sheet accounts denominated in foreign currencies are translated at the current rate of exchange as of the balance sheet date, while revenues and expenses are translated at average rates of exchange during the periods presented. The cumulative foreign currency adjustments resulting from such translation are included in accumulated other comprehensive loss. Upon complete or substantial liquidation of any of our subsidiaries, the value of the cumulative translation adjustment of such subsidiaries prior to their liquidation is reported in net earnings.
	Cash Flows
	Cash and cash equivalents include bank term deposits with original maturities of three months or less.
	In 2012, we settled approximately $5 million in cash relating to our Chapter 11 cases. The $5 million paid in 2012, was paid from restricted cash. Additionally, in 2012 we issued approximately $26 million of common stock for the settlement of liabilities in accordance with the Plan.
	Cash payments included interest payments of $57 million in 2013, $58 million in 2012 and $57 million in 2011. Cash payments also included income tax payments, net of refunds of $21 million in 2013, $45 million in 2012 and $16 million in 2011.
	Accounting Developments
	In February 2013, the FASB issued ASU 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income ("ASU 2013-02"). The guidance in ASU 2013-02 requires an organization to present the effects on the line items of net income of significant amounts reclassified out of accumulated other comprehensive income, but only if the item reclassified is required under GAAP to be reclassified to net income in its entirety in the same reporting period. The guidance in ASU 2013-02 is effective for fiscal years beginning after December 15, 2012. The adoption of this guidance did not have a material impact on our results of operations of financial position because it only provides for enhanced disclosure requirements. Accordingly, we have included the enhanced footnote disclosure (see Note 11—Accumulated Other Comprehensive Loss).
	In March 2013, the FASB issued ASU 2013-05, Parent's Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity ("ASU" 2013-05"). The amendments in ASU 2013-05 address the accounting for the cumulative translation adjustment when a parent either sells a part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets that is a nonprofit activity or a business within a foreign entity. The amendments are effective prospectively for fiscal years (and interim reporting periods within those years) beginning after December 15, 2013 (early adoption is permitted). We do not anticipate the adoption of this amendment will have a material impact on our financial statements.
	In July 2013, the FASB issued ASU No. 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists, providing guidance on the presentation of unrecognized tax benefits in the financial statements as either a reduction to a deferred tax asset or either a liability to better reflect the manner in which an entity would settle at the reporting date any additional income taxes that would result from the disallowance of a tax position when net operating loss carryforwards, similar tax losses or tax credit carryforwards exist. The amendments in this ASU do not require new recurring disclosures. The amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments in this ASU should be applied prospectively to all unrecognized tax benefits that exist at the effective date. We do not expect the adoption of the amendments in this ASU will have a significant impact on our financial statements.
	Risks and Uncertainties
	Our revenues are largely dependent on the continued operation of our manufacturing facilities. There are many risks involved in operating chemical manufacturing plants, including the breakdown, failure or substandard performance of equipment, operating errors, natural disasters, the need to comply with directives of, and maintain all necessary permits from, government agencies as well as potential terrorist attacks. Our operations can be adversely affected by raw material shortages, labor force shortages or work stoppages and events impeding or increasing the cost of transporting our raw materials and finished products. The occurrence of material operational problems, including but not limited to the events described above, may have a material adverse effect on the productivity and profitability of a particular manufacturing facility. With respect to certain facilities, such events could have a material effect on Chemtura as a whole.
	Our operations are also subject to various hazards incident to the production of industrial chemicals. These include the use, handling, processing, storage and transportation of certain hazardous materials. Under certain circumstances, these hazards could cause personal injury and loss of life, severe damage to and destruction of property and equipment, environmental damage and suspension of operations. Claims arising from any future catastrophic occurrence at any one of our facilities may result in us being named as a defendant in lawsuits asserting potential claims.
	We perform ongoing credit evaluations of our customers' financial condition including an assessment of the impact, if any, of prevailing economic conditions. We generally do not require collateral from our customers. We are exposed to credit losses in the event of nonperformance by counterparties on derivative instruments when utilized. The counterparties to these transactions are major financial institutions, which may be adversely affected by global economic impacts. However, we consider the risk of default to be minimal.
	International operations are subject to various risks which may or may not be present in U.S. operations. These risks include political instability, the possibility of expropriation, restrictions on dividends and remittances, instabilities of currencies, requirements for governmental approvals for new ventures and local participation in operations such as local equity ownership and workers' councils. Currency fluctuations between the U.S. dollar and the currencies in which we conduct business have caused and will continue to cause foreign currency transaction gains and losses, which may be material. Any of these events could have an adverse effect on our international operations.

ACQUISITIONS_AND_DIVESTITURES

ACQUISITIONS AND DIVESTITURES	12 Months Ended
	Dec. 31, 2013
ACQUISITIONS AND DIVESTITURES	'
ACQUISITIONS AND DIVESTITURES	'
	2) ACQUISITIONS AND DIVESTITURES
	Acquisitions
	Solaris Acquisition
	On September 26, 2012, we announced that we entered into a Business Transfer Agreement ("BTA") with Solaris ChemTech Industries Limited ("Solaris ChemTech"), an Indian Company, and Avantha Holdings Limited, an Indian Company and the parent company of Solaris ChemTech (collectively, "Solaris"). As provided in the BTA, we have agreed to purchase from Solaris certain assets used in the manufacture and distribution of bromine and bromine chemicals for cash consideration of $142 million and the assumption of certain liabilities. The purchase price is subject to a post-closing net working capital adjustment. The transaction is subject to, among other things, receiving governmental approval for the transfer of rights to the brine resources from which bromine is extracted and is expected to close upon receipt of those approvals, the date of which is not yet known. The parties continue to explore whether there may be an alternative transaction structure to permit a closing of the transaction. However, as of this date, the parties have not yet developed an approach that they can implement.
	DayStar Acquisition
	On February 1, 2011, we announced the formation of DayStar Materials, LLC ("Daystar"), a joint venture with UP Chemical Co. Ltd. ("UP Chemical") that will manufacture and sell high purity metal organic precursors for the rapidly growing LED market in our Industrial Engineered Products segment. DayStar was a 50/50 joint venture and was being accounted for as an equity method investment. We made cash contributions of $6 million in 2011 in accordance with the joint venture agreement.
	On May 15, 2013, we purchased the remaining 50% interest in DayStar from our partner UP Chemical and DayStar became a consolidated entity. The purchase price was $3 million in cash which approximated the fair value of the remaining share of the assets and liabilities, primarily inventory and fixed assets, as of the purchase date. In addition, we reimbursed UP Chemical for a $3 million loan they had made to DayStar.
	ISEM Alliance
	On January 26, 2011, we announced the formation of ISEM S.r.l. ("ISEM"), a strategic research and development alliance with Isagro S.p.A., which would provide us access to two commercialized products and accelerate the development and commercialization of new active ingredients and molecules related to our Chemtura AgroSolutions segment. ISEM is a 50/50 joint venture between us and Isagro S.p.A. and is being accounted for as an equity method investment. Our investment in the joint venture was €20 million ($29 million) which was made in January 2011.
	During 2013, ISEM sold, in two separate transactions, its two product lines for a sum of €38 million ($51 million). We received a return of capital of €15 million ($20 million) and €2 million ($3 million) as a full repayment of a shareholder loan during 2013. The joint venture currently holds accounts receivable, inventory and other administrative and tax accruals. We anticipate the dissolution of this joint venture in 2014, at which time the remaining proceeds will be distributed to the partners.
	Discontinued Operations
	Consumer Divestiture
	In October 2013, we entered into a stock purchase agreement to sell our investment in the dedicated legal entities that constituted our Consumer Products business, including dedicated manufacturing plants in the U.S. and South Africa, to KIK Customer Products Inc. ("KIK") for $315 million in cash at closing. On December 31, 2013, we entered into an amendment to the stock purchase agreement, among other matters, to reduce the purchase price by $15 million reflecting the resolution of certain pre-closing matters, and completed the sale of the Consumer Products business for an adjusted purchase price of $300 million and the assumption by KIK of pension and other liabilities totaling approximately $8 million. The purchase price is subject to customary post-closing adjustments, primarily for working capital and assumed pension liabilities. The agreement specified a value of working capital based upon a twelve-month average against which working capital would be measured. To the extent working capital at closing was lower than this value, KIK would be compensated for the difference. If working capital was higher, we would be compensated. The impact of some of these adjustments was estimated in the cash paid at closing and a final reconciliation will occur in the first half of 2014.
	We recognized a pre-tax loss of $24 million ($25 million after-tax loss), which included a $39 million non-cash gain related to the release of accumulated other comprehensive loss ("AOCL") associated with the release of cumulative translation adjustments of the entities sold and the pension obligations transferred.
	In connection with the sale we entered into a transition service agreement and supply contact with KIK to supply products from our Adrian, MI facility. Under the terms of the supply contract, KIK has the option, exercisable for a period of six-months following the closing date, to purchase the net assets of the Adrian facility at a price that is below the carrying value of the net assets. Accordingly, we concluded the net assets of the Adrian facility met the criteria to be classified as assets held for sale and we recorded an impairment charge in December 2013 of $7 million to write-down the property, plant and equipment to its fair value less costs to sell.
	While the transaction represented the sale of stock in the dedicated legal entities that constituted the Consumer Products business, the below chart presents the underlying assets and liabilities of those legal entities as assets and liabilities of discontinued operations. Earnings and direct costs associated with our Consumer Products business have been presented as earnings (loss) from discontinued operations, net of tax in our Consolidated Statements of Operations for the current and comparative periods. All applicable disclosures included in the accompanying footnotes have been updated to reflect the Consumer Products business as a discontinued operation.
	(In millions)	December 31, 2013			2012
	Cash and cash equivalents	$	13		$	—
	Accounts receivable		55			60
	Inventories		64			70
	Current domestic tax assets reversed upon sale		7			7
	Other current assets, includes foreign deferred tax assets		8			12
	Property, plant and equipment		63			64
	Intangible assets, net		195			202
	Other assets		5			5
	Assets		410			420
	Accounts payable		16			23
	Accrued expenses		14			16
	Income taxes payable		—			4
	Pension and post-retirement health care liabilities		6			7
	Domestic tax liabilities reversed upon sale		44			43
	Other liabilities, includes foreign deferred tax liabilities		32			35
	Liabilities		112			128
	Net Assets	$	298		$	292
	The following table reconciles the adjusted cash proceeds to the pre-tax loss on the sale:
	(In millions)	December 31, 2013
	Cash consideration	$	300
	Pre-closing working capital and other adjustments		(36	)
	Cash proceeds		264
	Less direct items:
	Net assets sold or settled, excluding domestic tax liabilities reversed upon sale and included in tax effect		335
	Transaction costs and other(1)		10
	Post-closing adjustments, obligations and other, net		(18	)
	Less non-cash items:
	Release of AOCL—Pension		5
	Release of AOCL—cumulative translation adjustment		(44	)
	Pre-tax loss on sale of discontinued operations	$	(24	)
	-1
	Transaction costs include legal fees and other direct costs incurred to sell the business since October 1, 2013.
	Antioxidant Divestiture
	In November 2012, we entered into an asset purchase agreement with SK Blue Holdings, Ltd. ("SK"), an affiliate of SK Capital Partners III, L.P., to sell substantially all the assets of our Antioxidant operations (the "Antioxidant Sale"). The assets to be sold included, among others, trade receivables, inventory, our equity interest in two joint ventures, certain dedicated plants in the U.S., France and Germany, and certain dedicated assets in shared facilities. SK also agreed to assume certain liabilities related to the Antioxidant business. We were to retain assets that are shared with our other business components that exist in certain locations globally and utilize those assets under supply agreements with SK.
	In January 2013, we entered into an amended and restated asset purchase and contribution agreement with SK and Addivant USA Holdings Corp. ("Addivant") whereby SK and Addivant agreed, in addition to purchasing substantially all the assets of our Antioxidant business, to assume certain additional pension and environmental liabilities. The agreement provided for the actuarial valuation of net pension liabilities to be assumed to be updated shortly before the closing of the transaction. To the extent the updated values are a reduction of the net pension liability, the difference was to be applied to increase, by an equal amount, the value of the seller note to be issued at closing. To the extent the updated values were an increase in the net pension liability, the increase would be applied in equal amount first to reduce the value of the seller note and then if the seller note was extinguished, as a reduction to the cash consideration.
	In April 2013, we completed the sale of our Antioxidant business to SK and Addivant for consideration of $97 million, $9 million in preferred stock issued by Addivant, a seller note in the amount of $1 million issued by an affiliate of Addivant and the assumption by SK and Addivant of pension, environmental and other liabilities totaling approximately $91 million.
	At closing, the cash consideration was subject to the retention of certain assets, the finalization of pension assets and liabilities and the change in certain working capital components through the closing date. The impact of these adjustments was estimated in the cash paid at closing. During the third quarter of 2013, the net pension liability transferred to Addivant was finalized and the seller note was extinguished by these adjustments. Additionally, we paid $2 million in cash consideration as part of the adjustment. The final working capital adjustment remains to be agreed between the parties.
	Included as part of the consideration, we received 9.2 million shares of Series A Preferred Stock of Addivant with a face value of $9 million. These shares accrue dividends at escalating rates beginning at 7% in the first year and up to 11% in the third year and beyond which are payable upon declaration.
	We recognized a pre-tax loss of $164 million ($155 million after-tax), which included $121 million of non-cash charges related to the release of AOCL associated with the pension obligations transferred, the release of cumulative translation adjustments and the release of our non-controlling interest in a Korean joint venture. In connection with the sale, we entered into several ancillary agreements, including site sharing and supply agreements, a distribution agreement, and a transition service agreement.
	As a result of entering into this transaction beginning in 2012, we determined that discontinued operations treatment applied. Assets and liabilities included in the Antioxidant Sale have been presented as assets and liabilities of discontinued operations as of December 31, 2012. Additionally, earnings and direct costs associated with the Antioxidant business for the periods prior to the date of the sale have been presented as earnings (loss) from discontinued operations, net of tax for the current and comparative periods. All applicable disclosures included in the accompanying footnotes have been updated to reflect the Antioxidant business as a discontinued operation.
	The following is a summary of the assets and liabilities sold or settled related to the Antioxidant business as of April 30, 2013 and the assets and liabilities of discontinued operations as of December 31, 2012.
	(In millions)	April 30, 2013			2012
	Cash and cash equivalents	$	2		$	2
	Accounts and trade receivable		70			61
	Inventories		76			78
	Other current assets		2			4
Property, plant and equipment		48			44
Intangible assets, net		14			14
Other assets		32			31
Assets		244			234
Accounts payable		39			29
Accrued expenses		2			4
Income taxes payable		—			1
Pension and post-retirement health care liabilities		81			80
Other liabilities		11			11
Liabilities		133			125
Net Assets	$	111		$	109
Assets sold or settled consisted primarily of plant facilities located at Morgantown, West Virginia, Bay Minette, Alabama, Waldkraiburg, Germany and Catenoy, France; our shares in the Asia Stabilizers joint venture, located in Korea, a previously controlled consolidated entity; our shares in Gulf Stabilizers Industries, located in Saudi Arabia, a previously 49% owned equity method investment; certain dedicated operating equipment located at Latina, Italy and Elmira, Canada; intangible assets and working capital associated with the Antioxidants business.
We retained ownership of certain manufacturing assets that will be used to meet our obligations under the supply agreements in Canada, Italy, the United States, Taiwan, Mexico, and Brazil. The minimum terms of the supply agreements range from two to five years. Based on the terms of the supply agreements and the forecasted costs to meet our obligations under those
agreements, we have fair valued the supply agreements using Level 3 fair value techniques and included a $13 million charge to the loss on sale of discontinued operations in our Consolidated Statement of Operations.
The following table reconciles the adjusted cash proceeds to the pre-tax loss on the sale:
(In millions)	December 31, 2013
Cash consideration	$	97
Retained working capital and other adjustments		(10	)
Post-closing adjustments		(2	)
Cash proceeds		85
Preferred stock		9
Less direct items:
Net assets sold or settled		111
Transaction costs and other(1)		5
Post-closing obligations and other, net		8
Fair value of supply agreements		13
Less non-cash items:
Release of AOCL—pension		122
Release of AOCL—cumulative translation adjustment		6
Release of non-controlling interest		(7	)
Pre-tax loss on sale of discontinued operations	$	(164	)
-1
Transaction costs include legal fees and other direct costs incurred to sell the business since April 1, 2013.
Discontinued Operations—Consumer Products ("Consumer") and Antioxidant Divestitures
Earnings (loss) from discontinued operations for the years ended December 31, 2013, 2012 and 2011 and the loss from the sale of discontinued operations for the year ended December 31, 2013 consists of the following:
	Year Ended
(in millions)	2013			2013			2013			2012			2012			2012			2011			2011			2011
	Consumer			Antioxidant			Total			Consumer			Antioxidant			Total			Consumer			Antioxidant			Total
Net Sales	$	408		$	123		$	531		$	433		$	387		$	820		$	422		$	419		$	841
Earnings (loss) from discontinued operations:
Pre-tax earnings (loss)	$	24		$	4		$	28		$	33		$	(45	)	$	(12	)	$	29		$	31		$	60
Income tax (expense) benefit		(3	)		—			(3	)		(2	)		11			9			(3	)		(5	)		(8	)
Earnings (loss), net of taxes		21			4			25			31			(34	)		(3	)		26			26			52
Net loss (earnings) attributable to non-controlling interests		—			—			—			—			1			1			—			(1	)		(1	)
Earnings (loss), net of taxes—attributable to Chemtura	$	21		$	4		$	25		$	31		$	(33	)	$	(2	)	$	26		$	25		$	51
Loss on sale of discontinued operations:
Pre-tax loss	$	(24	)	$	(164	)	$	(188	)
Income tax (expense) benefit(a)		(1	)		9			8
Net loss	$	(25	)	$	(155	)	$	(180	)
(a)
Income tax expense on the sale of our Consumer Products business is primarily a cash tax charge for estimated U.S. Federal alternative minimum tax and state taxes. Deferred taxes in our non-U.S. entities are included in the calculation of the pre-tax loss on sale. However, the reversal of deferred tax assets and liabilities of our U.S. entities are included in tax expense, reflecting the election made to treat the sale of stock of the U.S. legal entities in the transaction as a sale of assets. The reversal of these U.S. net deferred tax liabilities increased the value of our consolidated U.S. net deferred tax assets against which we provide a valuation allowance. The result was that there was no net deferred tax expense. The income tax benefit on the sale of our Antioxidant business is primarily related to the domestic tax impacts of the release of AOCL related to pensions that was not offset by a valuation allowance and reduced by tax expense in various foreign jurisdictions.
A portion of certain functional and other expenses that are managed company-wide that are allocated to the Antioxidant and Consumer Products businesses have not or will not transfer directly under the respective sale agreements. As such, in historic periods these costs are shown as part of continuing operations in the corporate segment and not included under earnings (loss) from discontinued operations, net of tax. These costs are as follows:
(In millions)	2013			2012			2011
Antioxidant	$	6		$	13		$	15
Consumer Products		14			13			15
Amortization expense(a)		(8	)		(14	)		(16	)
Net increase in Corporate Segment	$	12		$	12		$	14
(a)
Our Corporate segment included amortization expense which related directly to the Antioxidant and Consumer Products businesses which is now included in earnings (loss) from discontinued operations, net of tax.
Other Dispositions
Tetrabrom Joint Venture Divestiture
On November 28, 2011, we sold our 50% interest in Tetrabrom Technologies Ltd. for net consideration of $38 million. The consideration will be paid in equal annual installments over a three-year period. The first and second payments, net of tax, were paid in April 2012 and April 2013. A pre-tax gain of $27 million was recorded on the sale in the fourth quarter of 2011.

RESTRUCTURING_AND_ASSET_IMPAIR

RESTRUCTURING AND ASSET IMPAIRMENT ACTIVITIES	12 Months Ended
	Dec. 31, 2013
RESTRUCTURING AND ASSET IMPAIRMENT ACTIVITIES	'
RESTRUCTURING AND ASSET IMPAIRMENT ACTIVITIES	'
	3) RESTRUCTURING AND ASSET IMPAIRMENT ACTIVITIES
	Restructuring
	In February 2013, our Board approved a restructuring plan providing for, among other things, actions to reduce stranded costs related to divestitures. This plan is expected to preserve pre-divestiture operating margins following our portfolio changes. On October 9, 2013, the Board approved additional restructuring actions to consolidate our business' organizational structure in an effort to streamline the organization and gain efficiencies and additional cost savings. In December 2013, we substantially completed employee communications and the consultation process regarding the closure of our Droitwich, UK facility and consolidation of those operations into our Perth Amboy, NJ facility, in order to improve our competitiveness in the current economic environment. We recorded a pre-tax charge of $44 million in the year ended December 31, 2013, which included $27 million for severance and related costs, $15 million for professional fees, $1 million for accelerated depreciation of property, plant and equipment, and $1 million for accelerated asset retirement obligations. We expect to incur approximately $7 million to $10 million in 2014 primarily for accelerated depreciation and decommissioning costs.
	In April 2012, our Board approved a restructuring plan providing for, among other things, the closure of our Antioxidant business manufacturing facility in Pedrengo, Italy. The Board also approved actions to improve the operating effectiveness of certain global corporate functions. This plan was intended to achieve significant gains in efficiency and costs. The total cost of the restructuring plan was estimated to be approximately $40 million of which approximately $6 million consisted of non-cash charges. During 2012, we recorded pre-tax charges of $33 million which included $4 million for accelerated depreciation of property, plant and equipment included in depreciation and amortization, $2 million for accelerated asset retirement obligations included in cost of goods sold ("COGS"), $12 million for severance and professional fees related to corporate initiatives, $5 million for severance and other obligations related to the Pedrengo closure and $10 million reflecting the write-off of a receivable for which collection is no longer probable as a result of the restructuring actions. We recorded an additional pre-tax charge of $1 million in 2013, primarily for accelerated depreciation and relocation costs related to the Pedrengo closure. All charges related to the Pedrengo closure have been included in loss from discontinued operations, net of tax, as this plant formed part of our Antioxidants business. The Pedrengo plant ceased operations on March 31, 2013 and asset retirement work has been completed. We have retained this property under the terms of the sale of the Antioxidants business and anticipate selling it after all remediation work is completed.
	In November 2011, our Board approved a restructuring plan intended to make Chemtura AgroSolutions more cost efficient by centralizing certain functions regionally and consolidating laboratory activities in North America. As a result of this plan, we recorded a pre-tax charge of $3 million for severance to facility closures, severance and related costs for the year ended December 31, 2011.
	A summary of the changes in the liabilities established for restructuring programs is as follows:
	(In millions)	Severance and			Other Facility			Total
		Related Costs			Closure Costs
	Balance at January 1, 2011	$	1		$	—		$	1
	Facility closure, severance and related costs		3			—			3
	Cash payments		(3	)		—			(3	)
	Balance at December 31, 2011		1			—			1
	Facility closure, severance and related costs:
	Continuing operations		6			5			11
	Discontinued operations		6			—			6
	Cash payments		(5	)		(5	)		(10	)
	Balance at December 31, 2012		8			—			8
	Facility closure, severance and related costs:
	Continuing operations		27			15			42
	Discontinued operations		—			1			1
	Cash payments		(19	)		(14	)		(33	)
	Reclassifications		(2	)		—			(2	)
	Balance at December 31, 2013	$	14			2		$	16
	At December 31, 2013, $15 million of these reserves were included in accrued expenses and $1 million was included in accounts payable in our Consolidated Balance Sheet. At December 31, 2012, the balance of these reserves were included in accrued expenses in our Consolidated Balance Sheet.
	Chapter 11 Reorganization Initiatives
	In January 2010, our Board approved an initiative involving the consolidation and idling of certain assets within the Great Lakes Solutions business operations in El Dorado, Arkansas, which was approved by the Bankruptcy Court on February 23, 2010. In addition, in the first quarter of 2011, our joint venture partner informed us that they would exercise their right to purchase our interest in our Tetrabrom joint venture in the Middle East that supplied a brominated flame retardant to us. The sale of our 50% interest in Tetrabrom Technologies Ltd. was completed in November 2011.
	As a result of our reorganization initiatives, we recorded a pre-tax charge of $3 million in 2011 primarily for asset impairments and accelerated depreciation.
	Asset Impairments
	In accordance with ASC Topic 350, Intangibles—Goodwill and Other ("ASC 350") and ASC Topic 360, Property, Plant and Equipment ("ASC 360"), we recorded pre-tax charges totaling $7 million in 2013 and $47 million in 2012 to earnings (loss) from discontinued operations, net of tax and $4 million in 2011 to impairment charges in our Consolidated Statements of Operations.
	During the first two quarters of 2013, we completed an assessment of the possible sale of the Consumer Products business. As of March 31, 2013 and June 30, 2013, we considered it more-likely-than-not that the initiative would become effective during 2013. In performing the impairment analysis, we probability weighted the possible outcomes of the initiative as of March 31, 2013 and June 30, 2013. Based on this analysis, the expected undiscounted cash flows were sufficient to recover the carrying values of assets of the Consumer Products business. As a result, we concluded that no impairment existed at March 31, 2013 or June 30, 2013.
	In September 2013, when we met the criteria to record assets held for sale, we again performed an impairment analysis of the Consumer Products Business. We probability weighted the fair value less cost to sell under different fair value models, as a proxy for an agreed upon purchase price, and found the fair value less cost to sell was sufficient to recover the carrying value of the net assets to be sold as of September 30, 2013. As a result, we concluded that no impairment existed at September 30, 2013.
	On December 31, 2013, we completed a stock sale of our investment in dedicated legal entities of our Consumer Products business. In connection with the sale we entered into a supply contact with KIK to supply products from our Adrian, MI facility. Under the terms of the supply contract, KIK has the option, exercisable for a period of six-months following the closing date, to purchase the net assets of the Adrian facility at a price that is below the carrying value of the net assets. Accordingly, we concluded that the net assets of the Adrian facility met the criteria to be classified as assets held for sale and based on the expected selling price we recorded an impairment charge in December 2013 of $7 million to write-down the property, plant and equipment to its estimated fair value which is included in earnings from discontinued operations, net of tax in our Consolidated Statement of Operations.
	During the third quarter of 2012, we completed an assessment of an initiative to monetize portfolio assets relating to our Antioxidant business. As of September 30, 2012, we considered it more-likely-than-not that the initiative would become effective before the end of 2012. In performing the impairment analysis, we probability weighted the possible outcomes of the initiative as of September 30, 2012. Based on this analysis, the expected undiscounted cash flows were insufficient to recover the carrying values of assets of the component of the segment to which the initiative relates. We estimated the fair value using various income and market approaches to calculate the impairment charge. We recorded an asset impairment charge included in loss from discontinued operations, net of tax on our Consolidated Statement of Operations of $35 million, of which $26 million related to property, plant and equipment, net and $9 million related to intangible assets, net included in non-current assets of discontinued operations on our Consolidated Balance Sheets.
	In November 2012, we entered into an asset purchase agreement to sell our Antioxidant business and determined that discontinued operations treatment applied. Accordingly, we compared the carrying value of the net assets to be sold to their estimated fair value based on the proceeds expected to be received per the asset purchase agreement less the estimated costs to sell. As a result, in the fourth quarter of 2012 we recorded an additional asset impairment charge of $11 million included in loss from discontinued operations, net of tax on our Consolidated Statement of Operations to write-down the long-lived assets of the Antioxidant business to their estimated fair value, of which $9 million relates to property, plant and equipment and $2 million related to intangible assets that are classified as non-current assets of discontinued operations on the Consolidated Balance Sheets.
	For the year ended December 31, 2011, we recorded an impairment charge of $3 million related to intangible assets of the Chemtura AgroSolutions reporting unit with no future use. Additionally, there was a $1 million impairment charge related to property, plant and equipment of the El Dorado, Arkansas facility reorganization initiative.

INVENTORIES

INVENTORIES	12 Months Ended
	Dec. 31, 2013
INVENTORIES	'
INVENTORIES	'
	4) INVENTORIES
	(In millions)	2013		2012
	Finished goods	$	288	$	280
	Work in process		34		27
	Raw materials and supplies		93		91
		$	415	$	398
	Included in the above net inventory balances are inventory obsolescence reserves of approximately $21 million and $14 million at December 31, 2013 and 2012, respectively.

PROPERTY_PLANT_AND_EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	12 Months Ended
	Dec. 31, 2013
PROPERTY, PLANT AND EQUIPMENT	'
PROPERTY, PLANT AND EQUIPMENT	'
	5) PROPERTY, PLANT AND EQUIPMENT
	(In millions)	2013		2012
	Land and improvements	$	74	$	67
	Buildings and improvements		216		190
	Machinery and equipment		1,239		1,152
	Information systems and equipment		173		183
	Furniture, fixtures and other		29		28
	Construction in progress		94		108
			1,825		1,728
	Less: accumulated depreciation		1,101		1,073
		$	724	$	655
	Depreciation expense from continuing operations amounted to $82 million, $80 million and $81 million for 2013, 2012 and 2011, respectively. Depreciation expense from continuing operations includes accelerated depreciation of certain fixed assets associated with our restructuring programs of $1 million for 2013 and $2 million for 2011.

GOODWILL_AND_INTANGIBLE_ASSETS

GOODWILL AND INTANGIBLE ASSETS	12 Months Ended
	Dec. 31, 2013
GOODWILL AND INTANGIBLE ASSETS	'
GOODWILL AND INTANGIBLE ASSETS	'
	6) GOODWILL AND INTANGIBLE ASSETS
	Goodwill
	Goodwill by reportable segment is as follows:
		Industrial Performance Products
	(In millions)	Gross Goodwill		Accumulated Impairments			Net Goodwill
	Balance at December 31, 2011	$	264	$	(90	)	$	174
	Foreign currency translation		3		—			3
	Balance at December 31, 2012		267		(90	)		177
	Foreign currency translation		2		—			2
	Balance at December 31, 2013	$	269	$	(90	)	$	179
	We have elected to perform our annual goodwill impairment procedures for all of our reporting units in accordance with ASC Subtopic 350-20, Intangibles—Goodwill and Other—Goodwill ("ASC 350-20") as of July 31, or sooner, if events occur or circumstances change that would more likely than not reduce the fair value of a reporting unit below the carrying value. We estimate the fair value of our reporting units utilizing income and market approaches through the application of discounted cash flow and market comparable methods (Level 3 inputs as described in Note 15—Financial Instruments and Fair Value Measurements). The assessment is required to be performed in two steps: step one to test for a potential impairment of goodwill and, if a potential impairment is identified, step two to measure the impairment loss through a full fair valuing of the assets and liabilities of the reporting unit utilizing the acquisition method of accounting. We concluded that no goodwill impairment existed in any of our reporting units based on the annual reviews as of July 31, 2013 and 2012.
	We continually monitor and evaluate business and competitive conditions that affect our operations and reflects the impact of these factors in our financial projections. If permanent or sustained changes in business or, competitive conditions occur, they can lead to revised projections that could potentially give rise to impairment charges.
	Intangible Assets
	Our intangible assets (excluding goodwill) are comprised of the following:
		2013							2012
	(In millions)	Gross		Accumulated			Net		Gross		Accumulated			Net
		Value		Amortization			Intangibles		Value		Amortization			Intangibles
	Patents	$	91	$	(52	)	$	39	$	85	$	(48	)	$	37
	Trademarks		68		(34	)		34		68		(31	)		37
	Customer relationships		42		(18	)		24		41		(15	)		26
	Production rights		46		(37	)		9		46		(32	)		14
	Other		81		(45	)		36		74		(42	)		32
	Total	$	328	$	(186	)	$	142	$	314	$	(168	)	$	146
	The increase in gross intangible assets since December 31, 2012 is due to additions of $13 million and foreign currency translation of $3 million offset by the write-off of $2 million related to fully amortized intangibles (offset within accumulated amortization).
	Amortization expense from continuing operations related to intangible assets amounted to $19 million in 2013, $20 million in 2012 and $22 million in 2011. Estimated amortization expense of intangible assets for the next five fiscal years is as follows: $18 million (2014), $16 million (2015), $11 million (2016) $11 million (2017) and $11 million (2018).

DEBT

DEBT	12 Months Ended
	Dec. 31, 2013
DEBT	'
DEBT	'
	7) DEBT
	Our debt is comprised of the following:
	(In millions)	2013			2012
	5.75% Senior Notes due 2021, with an effective interest rate of 5.83% in 2013	$	450		$	—
	7.875% Senior Notes due 2018, net of unamortized discount of $1 million in 2013 and $3 million in 2012 with an effective interest rate of 8.90% in 2013 and 8.19% in 2012		100			452
	Term Loan due 2016, net of unamortized discount of $2 million in 2013 and 2012 with an effective interest rate of 5.39% in 2013 and 5.70% in 2012		316			418
	Other borrowings		32			6
	Total Debt		898			876
	Less: Short-term borrowings		(2	)		(3	)
	Less; Current portion of other long-term debt		(5	)		—
	Less: Current portion of Term Loan		(110	)		(2	)
	Total Long-Term Debt	$	781		$	871
	Tender Offer & New Bond Offering
	On June 10, 2013, we launched a cash tender offer and consent solicitation with respect to any and all of our outstanding $455 million aggregate principal amount of 7.875% Senior Notes due 2018 (the "2018 Senior Notes") pursuant to our Offer to Purchase and Consent Solicitation Statement (the "Offer to Purchase"). The requisite consent solicitation was required to adopt proposed amendments to the indenture governing the 2018 Senior Notes (the "2018 Indenture") that would eliminate substantially all of the restrictive covenants, certain events of default and related provisions contained in the 2018 Indenture. Subject to the terms and conditions set forth in the Offer to Purchase, holders who validly tendered their notes on or prior to June 21, 2013 (the "Consent Date") received total consideration of $1,117.50 per $1,000 principal amount of the 2018 Senior Notes accepted for purchase, which included a consent payment of $30 per $1,000 principal amount of the notes. As of July 5, 2013, holders of $348 million or approximately 76.56% of the 2018 Senior Notes, had tendered such 2018 Senior Notes and consented to the proposed amendments to the 2018 Indenture.
	On July 8, 2013, we amended the terms of the Offer to Purchase to extend the expiration date to July 19, 2013 to meet the terms of the Financing Condition (as defined in the Offer to Purchase). Holders who validly tendered their 2018 Senior Notes after the Consent Date but on or prior to July 19, 2013, received the tender offer consideration of $1,087.50 per $1,000 principal
	amount of the 2018 Senior Notes accepted for purchase but were not entitled to the consent payment. As of July 19, 2013, additional holders of $6 million or approximately 1.33% of the 2018 Senior Notes, had tendered such 2018 Senior Notes and Solicitation and consented to the proposed amendments to the 2018 Indenture.
	On July 18, 2013, we undertook a registered public offering of $450 million of 5.75% Senior Notes due 2021 (the "2021 Senior Notes"), for the purposes of funding the purchase under the terms of the Offer to Purchase all of the 2018 Senior Notes tendered, expenses related to the offering and a prepayment of our senior secured term loan facility due 2016 (the "Term Loan"). On July 23, 2013, the 2021 Senior Notes offering closed and the majority of the proceeds were used to complete the purchase of the 2018 Senior Notes tendered in response to the Offer to Purchase. With the purchase of the tendered 2018 Senior Notes complete, the amendments to the 2018 Indenture that eliminated substantially all of the restrictive covenants, certain events of default and related provisions became effective.
	In our third quarter of 2013, we recorded a loss on the early extinguishment of debt of $50 million. The loss included $42 million for the difference between the principal amount of the 2018 Senior Notes tendered and the sum of the tender offer consideration and consent payments. The loss also included $8 million for the write-off of unamortized capitalized financing costs and original issuance discount with respect to the 2018 Senior Notes purchased under the tender.
	On July 23, 2013, we used the balance of the proceeds from the offering of the 2021 Senior Notes, after completing the purchase of the 2018 Senior Notes tendered and paying transaction costs, of approximately $45 million and approximately $5 million of cash on hand to prepay $50 million of principal of our Term Loan. On July 31, 2013, we prepaid an additional $50 million of Term Loan principal with cash on hand.
	Financing Facilities
	2018 Senior Notes
	In August 2010, we completed a $455 million private placement offering under Securities and Exchange Commission ("SEC") Rule 144A for the 2018 Senior Notes at an issue price of 99.269% in reliance on an exemption pursuant to Section 4(2) of the Securities Act of 1933. The 2018 Senior Notes were exchanged in June 2011 for identical registered 2018 Senior Notes. In July 2013, we purchased $354 million of the $455 million outstanding balance with proceeds from the 2021 Senior Notes offering.
	At any time prior to September 1, 2014, we may redeem some or all of the remaining 2018 Senior Notes at a redemption price equal to 100% of the principal amount thereof plus a make-whole premium (as defined in the indenture) and accrued and unpaid interest up to, but excluding, the redemption date. We may also redeem some or all of the remaining 2018 Senior Notes at any time on or after September 1, 2014, with the redemption prices being, prior to September 1, 2015, 103.938% of the principal amount, on or after September 1, 2015 and prior to September 1, 2016, 101.969% of the principal amount and thereafter 100% plus any accrued and unpaid interest to the redemption date.
	When issued in 2010, our 2018 Senior Notes contain covenants that limited our ability to enter into certain transactions, such as incurring additional indebtedness, creating liens, paying dividends, and entering into dispositions and joint ventures. With the purchase of the tendered 2018 Senior Notes under the Offer to Purchase complete, the amendments to the 2018 Indenture that eliminated substantially all of the restrictive covenants, certain events of default and related provisions became effective.
	Our 2018 Senior Notes are now subject to only limited events of default including failure to pay principal or interest.
	2021 Senior Notes
	At any time prior to July 15, 2016, we are permitted to redeem some or all of the 2021 Senior Notes at a redemption price equal to 100% of the principal amount thereof plus a make-whole premium (as defined in the indenture governing the 2021 Senior Notes (the "2021 Indenture")) and accrued and unpaid interest up to, but excluding, the redemption date. At any time after July 15, 2016, we are permitted to redeem some or all of the 2021 Senior Notes at any time, with the redemption prices being, prior to July 15, 2017, 104.313% of the principal amount; on or after July 15, 2017 and prior to July 15, 2018, 102.875% of the principal amount; on or after July 15, 2018 and prior to July 15, 2019, 101.438% of the principal amount; and thereafter 100% of the principal amount, in each case plus any accrued and unpaid interest to the redemption date. In addition, prior to July 15, 2016, we may redeem up to 35% of the 2021 Senior Notes from the proceeds of certain equity offerings at a redemption price of 105.75% plus accrued but unpaid interest to the redemption date. If we experience certain kinds of changes in control, as defined in the 2021 Indenture, we may be required to offer to repurchase all of the 2021 Senior Notes at a redemption price
	(subject to limitations as described in the 2021 Indenture) equal to 101% of the aggregate principal amount plus accrued and unpaid interest.
	Our 2021 Senior Notes contain covenants that limit our ability to enter into certain transactions, such as incurring secured debt and subsidiary debt and entering into sale and lease-back transactions.
	Our 2021 Senior Notes are subject to certain events of default, including, among others, breach of other agreements in the 2021 Indenture; any guarantee of a significant subsidiary ceasing to be in full force and effect; a default by us or our restricted subsidiaries under any bonds, debentures, notes or other evidences of indebtedness of a certain amount, resulting in its acceleration; and certain events of bankruptcy or insolvency.
	Term Loan
	In August 2010, we entered into the Term Loan with Bank of America, N.A., as administrative agent, and other lenders party thereto for an aggregate principal amount of $295 million with an original issue discount of 1%. The Term Loan permitted us to increase the size of the facility with an accordion feature by up to $125 million. On October 31, 2012, we exercised the accordion feature of our Term Loan and borrowed the additional $125 million for the purpose of funding potential investment opportunities and for general corporate purposes. Accordingly, we recognized a $1 million charge for the year ended December 31, 2012 for loss on early extinguishment of debt resulting from the write-off of deferred financing costs and miscellaneous fees. An additional $1 million in arranger fees were written-off to interest expense for the year end December 31, 2012. During 2013, we repaid $102 million of the Term Loan with proceeds from the 2021 Senior Notes offering and cash on hand. In January 2014, we repaid an additional $110 million of the Term Loan with proceeds from the sale of the Consumer Products business. In light of this transaction, we classified the $110 million as short-term borrowings in our Consolidated Balance Sheet as of December 31, 2013.
	Borrowings under the Term Loan (due in 2016), prior to an amendment in October 2013, bore interest at a rate per annum equal to, at our election, (i) 3.0% plus the Base Rate (defined as the higher of (a) the Federal Funds rate plus 0.5%; (b) Bank of America's published prime rate; and (c) the Eurodollar Rate plus 1%) or (ii) 4.0% plus the Eurodollar Rate (defined as the higher of (a) 1.5% and (b) the current LIBOR adjusted for reserve requirements).
	In October 2013, we entered into Amendment No. 2 to the Term Loan which, among other things, (i) reduces the interest rate and LIBOR floor on the term loans outstanding under the Term Loan agreement (the "term loans"), (ii) provides for a 1% prepayment premium if the term loans are refinanced with certain specified refinancing debt within 6 months, (iii) introduces scheduled quarterly amortization of the term loans in the amount of 1% annually, and (iv) permits additional flexibility under certain of our operating covenants (including but not limited to additional flexibility for debt, investments, restricted payments and dispositions) in the Term Loan agreement. The amendment became effective on October 30, 2013.
	Borrowings under the amended Term Loan bear interest at a rate per annum equal to, at our election, (i) 1.75% plus the Base Rate (defined as the higher of (a) the Federal Funds rate plus 0.5%; (b) Bank of America's published prime rate; and (c) the Eurodollar Rate plus 1%) or (ii) 2.75% plus the Eurodollar Rate (defined as the higher of (a) 0.75% and (b) the current LIBOR adjusted for reserve requirements).
	The Term Loan is secured by a first priority lien on substantially all of our U.S. tangible and intangible assets (excluding accounts receivable, inventory, deposit accounts and certain other related assets), including, without limitation, real property, equipment and intellectual property, together with a pledge of the equity interests of our first tier subsidiaries and the guarantors of the Term Loan, and a second priority lien on substantially all of our U.S. accounts receivable and inventory.
	We may, at our option, prepay the outstanding aggregate principal amount on the Term Loan advances in whole or ratably in part along with accrued and unpaid interest on the date of the prepayment, subject to a 1% prepayment premium if the Term Loan advances are refinanced with certain specified refinancing debt within 6 months.
	Our obligations as borrower under the Term Loan are guaranteed by certain of our U.S. subsidiaries.
	The Term Loan contains covenants that limit, among other things, our ability to enter into certain transactions, such as creating liens, incurring additional indebtedness or repaying certain indebtedness, making investments, paying dividends, and entering into acquisitions, dispositions and joint ventures.
	Additionally, the Term Loan requires that we meet certain financial maintenance covenants including a maximum Secured Leverage Ratio (net of unrestricted cash, as defined in the agreement) of 2.5:1.0 and a minimum Consolidated Interest
	Coverage Ratio (as defined in the agreement) of 3.0:1.0. Additionally, the Term Loan contains a covenant related to the repayment of excess cash flow (as defined in the agreement). As of December 31, 2013, we were in compliance with the covenant requirements of the Term Loan.
	The Term Loan is subject to certain events of default, applicable to Chemtura, the guarantors and their respective subsidiaries, including, nonpayment of principal, interest, fees or other amounts, violation of covenants, material inaccuracy of representations and warranties (including the existence of a material adverse event as defined in the agreement), cross-default to material indebtedness, certain events of bankruptcy and insolvency, material judgments, certain ERISA events, a change in control, and actual or asserted invalidity of liens or guarantees or any collateral document, in certain cases subject to the threshold amounts and grace periods set forth in the Term Loan agreement.
	ABL Facility
	In November 2010, we entered into a five-year senior secured revolving credit facility available through 2015 (the "ABL Facility") with Bank of America, N.A., as administrative agent and the other lenders party thereto for an amount up to $275 million, subject to availability under a borrowing base, and included a $125 million letter of credit sub-facility.
	The revolving loans under the ABL Facility, prior to a December 2013 amendment, bore interest at a rate per annum which, at our option, was either: (a) a base rate (the highest of (i) Bank of America, N.A.'s "prime rate," (ii) the Federal Funds Effective Rate plus 0.5% and (iii) the one-month LIBOR plus 1.00%) plus a margin of between 2.25% and 1.75% based on the average excess availability under the ABL Facility for the preceding quarter; or (b) the current reserve adjusted LIBOR plus a margin of between 3.25% and 2.75% based on the average excess availability under the ABL Facility for the preceding quarter.
	In December 2013, we amended and restated the ABL Facility. The new five-year senior secured revolving credit facility available through 2018 provides for $175 million available to our domestic subsidiaries (the "US ABL Facility") and €60 million available to Chemtura Sales Europe B.V., a Netherlands subsidiary (the "Foreign ABL Facility", and together with the US ABL Facility, the "2018 ABL Facility"), subject in each case to availability under a borrowing base. The 2018 ABL Facility provides a $125 million letter of credit sub-facility.
	The revolving loans under the 2018 ABL Facility will bear interest at a rate per annum which, at our option, can be either: (a) a base rate (which varies depending on the currency in which the loans are borrowed) plus a margin of between 0.50% and 1.00% for loans denominated in U.S. dollars or between 1.50% and 2.00% for loans denominated in other currencies, in each case based on the average excess availability under the 2018 ABL Facility for the preceding quarter; or (b) the current reserve adjusted Eurocurrency Rate plus a margin of between 1.50% and 2.00% based on the average excess availability under the 2018 ABL Facility for the preceding quarter.
	Our obligations (and the obligations of the other borrowing subsidiaries) under the US ABL Facility will continue to be guaranteed on a secured basis by all of the existing domestic subsidiaries that were borrowers or guarantors prior to the amendment of the 2015 ABL Facility, and by certain of our future direct and indirect domestic subsidiaries (collectively, the "US Loan Parties"). The obligations under the Foreign ABL Facility are guaranteed on a secured basis by Chemtura Europe GmbH, a Swiss subsidiary, and are guaranteed and secured on a junior priority basis by the US Loan Parties.
	The obligations and guarantees under the US ABL Facility will continue to be secured by (i) a first-priority security interest in the US Loan Parties' existing and future inventory and accounts receivable, together with general intangibles relating to inventory and accounts receivable, contract rights under agreements relating to inventory and accounts receivable, documents relating to inventory, supporting obligations and letter-of-credit rights relating to inventory and accounts receivable, instruments evidencing payment for inventory and accounts receivable; money, cash, cash equivalents, securities and other property held by the Administrative Agent or any lender under the US ABL Facility; deposit accounts, credits and balances with any financial institution with which any US Loan Party maintains deposits and which contain proceeds of, or collections on, inventory and accounts receivable; books, records and other property related to or referring to any of the foregoing and proceeds of any of the foregoing (the "US ABL Priority Collateral"); and (ii) a second-priority security interest in substantially all of the US Loan Parties' other assets (the "Term Loan Priority Collateral"), including (x) 100% of the capital stock of US Loan Parties' direct domestic subsidiaries held by the US Loan Parties and 100% of the non-voting capital stock of the US Loan Parties' direct foreign subsidiaries held by the US Loan Parties, and (y) 65% of the voting capital stock of the US Loan Parties' direct foreign subsidiaries (to the extent held by the US Loan Parties), in each case subject to certain exceptions set forth in the 2018 ABL Facility Agreement and the related loan documentation. The obligations and guarantees under the Foreign ABL Facility are secured by (i) a first priority security interest on certain of Chemtura Sales Europe B.V., a Netherlands accounts receivable and receivables collection accounts and certain of Chemtura Europe GmbH's inventory; (ii) a second-priority security interest in the US ABL Priority Collateral; and (iii) a third-priority security interest in the Term Loan
	Priority Collateral; in each case subject to certain exceptions set forth in the 2018 ABL Facility and the related loan documentation.
	Mandatory prepayments of the loans under the US ABL Facility (and cash collateralization of outstanding letters of credit) shall be required (i) to the extent the usage of the US ABL Facility exceeds the lesser of (x) the borrowing base for the US ABL Facility and (y) the then effective commitments under the US ABL Facility, and mandatory prepayments of the loans under the Foreign ABL Facility shall be required (i) to the extent the usage of the Foreign ABL Facility exceeds the lesser of (x) the borrowing base for the Foreign ABL Facility and (y) the then effective commitments under the Foreign ABL Facility. Mandatory prepayments of the loans under the 2018 ABL Facility (and cash collateralization of outstanding letters of credit) shall also be required, subject to exceptions, thresholds and reinvestment rights, with the proceeds of certain sales or casualty events of assets on which the 2018 ABL Facility have a first priority security interest (but, solely during a cash dominion period).
	The 2018 ABL Facility Agreement contains certain affirmative and negative covenants (applicable to us, the other borrowing subsidiaries, the guarantors and their respective subsidiaries other than unrestricted subsidiaries), including, without limitation, covenants requiring financial reporting and notices of certain events, and covenants imposing limitations on incurrence of indebtedness and guaranties; liens; loans and investments; asset dispositions; dividends, redemptions, and repurchases of stock and prepayments, redemptions and repurchases of certain indebtedness; mergers, consolidations, acquisitions, joint ventures or creation of subsidiaries; material changes in business; transactions with affiliates; restrictions on distributions from restricted subsidiaries and granting of negative pledges; changes in accounting and reporting; sale leasebacks; and speculative transactions, and a springing financial covenant requiring a minimum trailing four quarter fixed charge coverage ratio of 1.0 to 1.0 at all times during (A) any period from the date when the amount available for borrowings under the 2018 ABL Facility falls below the greater of (i) $25 million and (ii) 10% of the aggregate commitments to the date such available amount has been equal to or greater than the greater of (i) $25 million and (ii) 10% of the aggregate commitments for 30 consecutive days, or (B) any period from the date when the amount available for borrowings under the US ABL Facility falls below the greater of (i) $18 million and (ii) 10% of the aggregate commitments under the US ABL Facility to the date such available amount has been equal to or greater than the greater of (i) $18 million and (ii) 10% of the aggregate commitments under the US ABL Facility for 30 consecutive days.
	The 2018 ABL Facility Agreement contains certain events of default (applicable to us, the other borrowers, the guarantors and their respective restricted subsidiaries), including nonpayment of principal, interest, fees or other amounts, violation of covenants, material inaccuracy of representations and warranties, cross-default to material indebtedness, certain events of bankruptcy and insolvency, material judgments, certain ERISA events, a change in control, and actual or asserted invalidity of liens or guarantees or any collateral document, in certain cases subject to the threshold amounts and grace periods set forth in the 2018 ABL Facility Agreement.
	At December 31, 2013 and 2012, we had no borrowings under the ABL Facility and the 2018 ABL Facility, but we had $14 million at December 31, 2013 and 2012 of outstanding letters of credit (primarily related to insurance obligations, environmental obligations and banking credit facilities) which utilizes available capacity under the facility. At December 31, 2013 and 2012, we had approximately $237 million and $199 million, respectively, of undrawn availability under the ABL Facility and the 2018 ABL Facility.
	Other Facilities
	In December 2012, we entered into a CNY 250 million (approximately $40 million) 5 year secured credit facility available through December 2017 (the "China Bank Facility") with Agricultural Bank of China, Nantong Branch ("ABC Bank"). The China Bank Facility is being used for funding construction of our manufacturing facility in Nantong, China. The China Bank Facility is secured by land, property and machinery of our subsidiary Chemtura Advanced Materials (Nantong) Co., Ltd. The loans under the China Bank Facility bear interest at a rate determined from time to time by ABC Bank base on the prevailing People Bank of China Lending Rate. At December 31, 2013, we had borrowings of $17 million under the China Bank Facility. Repayments of principal will be made in semi-annual installments from December 2014 through December 2017.
	In March 2013, we entered into a promissory note in the principal sum of $7 million with a term of six years bearing interest at a rate of 5.29% per annum to finance the cost of certain information technology software licenses. The principal of note is to be repaid in equal monthly installments over its term.
	Maturities
	At December 31, 2013, the scheduled maturities of debt are as follows: 2014—$118 million; 2015—$11 million; 2016—$213 million; 2017—$2 million; 2018—$103 million and thereafter $451 million.

LEASES

LEASES	12 Months Ended
	Dec. 31, 2013
LEASES	'
LEASES	'
	8) LEASES
	At December 31, 2013, minimum rental commitments, primarily for buildings, land and equipment under non-cancelable operating leases, net of sublease income, amounted to $10 million (2014), $8 million (2015), $6 million (2016), $5 million (2017), $4 million (2018), $14 million (2019 and thereafter) and $47 million in the aggregate. Sublease income is not significant in future periods. Rental expenses under operating leases, net of sublease income were $23 million (2013), $24 million (2012) and $21 million (2011). Sublease income was less than $1 million in 2013, 2012 and 2011.
	Future minimum lease payments under capital leases at December 31, 2013 were not significant.
	Real estate taxes, insurance and maintenance expenses are generally our obligations and, accordingly, were not included as part of rental payments. It is expected that in the normal course of business, leases that expire will be renewed or replaced by similar leases.

INCOME_TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2013
INCOME TAXES	'
INCOME TAXES	'
	9) INCOME TAXES
	The components of (loss) earnings from continuing operations before income taxes and the income tax expense (benefit) are as follows:
	(In millions)	2013			2012			2011
	Pre-tax (Loss) Earnings from Continuing Operations:
	Domestic	$	(105	)	$	26		$	(5	)
	Foreign		101			103			90
		$	(4	)	$	129		$	85
	Income Tax Expense (Benefit)
	Domestic
	Current	$	—		$	—		$	1
	Deferred		(1	)		—			3
			(1	)		—			4
	Foreign
	Current		17			23			22
	Deferred		2			3			(9	)
			19			26			13
	Total
	Current		17			23			23
	Deferred		1			3			(6	)
		$	18		$	26		$	17
	The expense (benefit) for income taxes from continuing operations differs from the Federal statutory rate for the following reasons:
	(In millions)	2013			2012			2011
	Income tax (benefit) expense at the U.S. statutory rate	$	(1	)	$	45		$	30
	Foreign rate differential		(17	)		(4	)		(21	)
	Valuation allowances		21			(25	)		(11	)
	U.S. tax on foreign earnings		26			28			28
	Nondeductible reorganizational expenses		—			1			3
	Nondeductible expenses, other		7			2			1
	Nondeductible stock compensation		1			1			1
	Depletion		(3	)		(3	)		(2	)
	Income tax credits		(6	)		(18	)		(14	)
	Taxes attributable to prior periods		(11	)		(1	)		2
	Other, net		1			—			—
	Income tax expense	$	18		$	26		$	17
	Deferred taxes are recorded based on differences between the book and tax basis of assets and liabilities using currently enacted tax rates and regulations. The components of the deferred tax assets and liabilities are as follows:
	(In millions)	2013			2012
	Deferred tax assets:
	Pension and other post-retirement liabilities	$	61		$	151
	Net operating loss carryforwards		387			389
	Other accruals		15			23
	Tax credit carryforwards		128			99
	Accruals for environmental remediation		29			25
	Intangibles		5			11
	Inventories and other		20			21
	Financial instruments		1			2
	Total deferred tax assets		646			721
	Valuation allowance		(529	)		(628	)
	Net deferred tax assets after valuation allowance		117			93
	Deferred tax liabilities:
	Unremitted foreign earnings of subsidiaries		(36	)		(18	)
	Property, plant and equipment		(72	)		(64	)
	Other		(11	)		(11	)
	Total deferred tax liabilities		(119	)		(93	)
	Net deferred tax liability after valuation allowance	$	(2	)	$	—
	Net current and non-current deferred taxes from each tax jurisdiction are included in the following accounts:
	(In millions)	2013			2012
	Net current deferred taxes
	Other current assets	$	10		$	5
	Other current liabilities		(3	)		(15	)
	Net non-current deferred taxes
	Other assets		25			27
	Other liabilities		(34	)		(17	)
	We had valuation allowances related to U.S. operations of $506 million, $605 million and $652 million at December 31, 2013, 2012 and 2011, respectively. We had valuation allowances related to foreign operations of $23 million, $23 million and $43 million at December 31, 2013, 2012 and 2011, respectively. A valuation allowance has been provided for deferred tax assets
where it is more likely than not these assets will expire before we are able to realize their benefit. Of the $99 million reduction in the total valuation allowance during 2013, $57 million was recorded to the income tax expense in our Consolidated Statements of Operations and $42 million was recorded to other comprehensive loss in our Consolidated Balance Sheet. During 2013, due to the sale of our Antioxidants business, the value of the pension deferred asset and the associated valuation allowance both decreased by $33 million. Of the $67 million reduction in the total valuation allowance during 2012, $57 million was recorded to the income tax expense in our Consolidated Statements of Operations and $10 million was recorded to other comprehensive loss in our Consolidated Balance Sheet. This valuation allowance will be maintained until it is more likely than not that remaining deferred assets will be realized. When this occurs, our income tax expense will be reduced by a decrease in our valuation allowance, which could have a significant impact on our future earnings.
The components of our gross net operating loss ("NOL") are as follows:
(In millions)	2013			2012
Federal NOL	$	974		$	972
State NOL	$	1,034		$	1,165
Foreign NOL	$	141		$	109
State and foreign NOL and credits expire 2014-2032, federal credits expire 2014-2032 and federal NOL expire 2024-2032. As a result of our emergence from Chapter 11 Bankruptcy in 2010, we will be subject to annual federal NOL limitations under Internal Revenue Code ("IRC") Section 382 in the future. Our federal NOL annual limitation will be in the range of $59 million to $77 million starting in 2013 and beyond. For 2014, the cumulative federal NOL available for use is approximately $372 million, subject to adjustment upon audit, if any. At December 31, 2013, we had federal and state tax credit carryforwards of $125 million and $3 million, respectively. At December 31, 2012, we had federal and state tax credit carryforwards of $96 million and $3 million, respectively.
We anticipate that we will repatriate the undistributed earnings of certain foreign subsidiaries. For the year ended December 31, 2013, we increased by $18 million, the amount of the net deferred tax liability we provide for the U.S. tax consequences of these repatriations. In 2013, this increase has been offset by an equal increase to our foreign tax credits, and as such, had no effect on the tax expense recognized in our Consolidated Statements of Operations. We consider undistributed earnings of all other foreign subsidiaries to be indefinitely invested in their operations. At December 31, 2013, such undistributed earnings deemed to be indefinitely reinvested in foreign operations amounted to $756 million.
We also have not recognized a deferred tax liability for the difference between the book basis and tax basis of investments in the common stock of foreign subsidiaries. Such differences relate primarily to the unremitted earnings of both Witco's and Great Lakes' foreign subsidiaries prior to their mergers with us. The basis difference in subsidiaries of Witco, acquired on September 1, 1999, is approximately $218 million and the basis difference in subsidiaries of Great Lakes, acquired on July 1, 2005, is approximately $49 million. Estimating the tax liability that would arise if these earnings were repatriated is not practicable at this time.
During the year ended December 31, 2013, we recorded an increase to our liability for unrecognized tax benefits of approximately $3 million. This increase was primarily related to the effects of currency exchange fluctuations. During the year ended December 31, 2012, we recorded a decrease to our liability for unrecognized tax benefits of approximately $5 million. This decrease was primarily related to settlements of tax audits in various foreign jurisdictions. In accordance with ASC 740, we recognize interest and penalties related to unrecognized tax benefits as a component of income tax expense.
The beginning and ending amount of unrecognized tax benefits reconciles as follows:
(In millions)	2013			2012			2011
Balance at January 1	$	41		$	46		$	41
Gross (decreases) increases for tax positions taken during current year		(1	)		—			1
Gross increases for tax positions taken during a prior period		1			3			13
Gross decreases for tax positions taken during a prior period		—			(1	)		(5	)
Decreases from the expiration of the statute of limitations		—			—			(1	)
Settlements / payments		—			(10	)		(1	)
Foreign currency impact		3			3			(2	)
Balance at December 31	$	44		$	41		$	46
We recognized interest expense of $1 million, related to unrecognized tax benefits within tax expense in our Consolidated Statements of Operations in 2013, 2012 and 2011. We also recognized, in our Consolidated Balance Sheets at December 31, 2013 and 2012, a total amount of $14 million and $13 million of interest, respectively, related to unrecognized tax benefits. We file income tax returns in the U.S., various U.S. states and certain foreign jurisdictions. We have completed our federal examination through December 31, 2009. The tax years 2010-2011 are currently under examination.
Foreign and United States jurisdictions have statutes of limitations generally ranging from 3 to 5 years. We have a number of state, local and foreign examinations currently in process. Major foreign exams in process include Canada, France and Italy.
We believe it is reasonably possible that our unrecognized tax benefits may decrease by approximately $8 million within the next year. This reduction may occur due to the statute of limitations expirations or conclusion of examinations by tax authorities. We further expect that the amount of unrecognized tax benefits will continue to change as a result of ongoing operations, the outcomes of audits, and the expiration of the statute of limitations. This change is not expected to have a significant impact on our results of operations or financial condition.

CAPITAL_STOCK_AND_EARNINGS_LOS

CAPITAL STOCK AND EARNINGS (LOSS) PER COMMON SHARE	12 Months Ended
	Dec. 31, 2013
CAPITAL STOCK AND EARNINGS (LOSS) PER COMMON SHARE	'
CAPITAL STOCK AND EARNINGS (LOSS) PER COMMON SHARE	'
	10) CAPITAL STOCK AND EARNINGS (LOSS) PER COMMON SHARE
	Capital Stock
	Common Shares
	Pursuant to the Plan, all shares, including shares held in treasury, of our common stock outstanding prior to the Effective Date were canceled. On November 8, 2010, the NYSE approved for listing 111 million shares of common shares in the capital of the reorganized company authorized pursuant to the Plan, as, comprising: (i) approximately 95.5 million shares of common stock to be issued under the Plan; (ii) approximately 4.5 million shares of common stock reserved for future issuances under the Plan as disputed claims are settled; and (iii) 11 million shares of common stock reserved for issuance under our equity compensation plans.
	As of December 31, 2012, all reserved shares of the new common stock were issued to either settle disputed claims or to holders of previously issued Chemtura stock ("Holders of Interests").
	We are authorized to issue 500 million shares of $0.01 par value common stock. There were 100.5 million shares issued, of which 4.0 million were held in treasury at December 31, 2013 and there were 100.4 million shares issued, of which 2.4 million were held in treasury at December 31, 2012. We are authorized to issue 0.3 million shares of $0.01 par value preferred stock, none of which are outstanding.
	Treasury Shares
	On May 9, 2013, the Board authorized an increase in our share repurchase program from $100 million to up to $141 million and extended the program to March 31, 2014. On November 12, 2013, the Board authorized a further increase in the share repurchase program by $50 million (up to $191 million in the aggregate when combined with the May 9, 2013 authorization). The Board also authorized an additional $100 million under the share repurchase program upon the closing of the previously announced sale of the Consumer Products business (up to $291 million in the aggregate when combined with the May 9, 2013 and November 12, 2013 authorizations). The Board also extended the authorizations under the share repurchase program through and including November 9, 2014. The shares are expected to be repurchased from time to time through open market purchases. The program, which does not obligate us to repurchase any particular amount of common stock, may be modified or suspended at any time at the Board's discretion. The manner, price, number and timing of such repurchases, if any, will be subject to a variety of factors, including market conditions and the applicable rules and regulations of the Securities and Exchange Commission ("SEC"). During the year ended December 31, 2013, we purchased 2.4 million shares for $54 million. As of December 31, 2013, we had purchased 5.8 million shares for $95 million since inception of our share repurchase program.
	Earnings (Loss) per Common Share
	A portion of the 100 million (which excludes shares reserved for equity compensation plans) newly authorized common shares were immediately distributed, and the remainder was reserved for distribution to holders of certain disputed claims that, although unresolved as of the Effective Date, later become allowed. To the extent that any of the reserved shares remained undistributed upon resolution of the disputed claims, such shares would not be returned to us but rather were distributed pro rata to claimants with allowed claims or to holders of our previously outstanding common stock to increase their recovery under the Plan. Therefore, pursuant to the Plan, all 100 million shares ultimately were distributed. Accordingly, all conditions
	of distribution had been met for these reserved shares as of the Effective Date, and such shares are considered issued and are included in our calculation of weighted average shares outstanding.
	The computation of basic earnings (loss) per common share is based on the weighted average number of common shares outstanding. The computation of diluted earnings (loss) per common share is based on the weighted average number of common and common share equivalents outstanding. For the year ended December 31, 2013, the computation of diluted earnings (loss) per share equals the basic earnings (loss) per common share calculation since common stock equivalents were antidilutive due to losses from continuing operations. Common stock equivalents amounted to 1.3 million for the year ended December 31, 2013.
	The following is a reconciliation of the shares used in the computation of earnings (loss) per share:
		Year ended
	(In millions)	2013		2012		2011
	Weighted average shares outstanding—Basic		97.7		98.2		100.1
	Dilutive effect of common share equivalents		—		0.6		0.2
	Weighted average shares outstanding—Diluted		97.7		98.8		100.3

ACCUMULATED_OTHER_COMPREHENSIV

ACCUMULATED OTHER COMPREHENSIVE LOSS	12 Months Ended
	Dec. 31, 2013
ACCUMULATED OTHER COMPREHENSIVE LOSS	'
ACCUMULATED OTHER COMPREHENSIVE LOSS	'
	11) ACCUMULATED OTHER COMPREHENSIVE LOSS
	The components of accumulated other comprehensive loss ("AOCL"), net of tax at December 31, 2013 and December 31, 2012, are as follows:
	(in millions)	Foreign			Unrecognized			Total
		Currency			Pension and
		Translation			Other Post-
		Adjustments			Retirement
					Benefit Costs
	As of December 31, 2012	$	47		$	(475	)	$	(428	)
	Other comprehensive (loss) income before reclassifications		(9	)		81			72
	Amounts reclassified from AOCL		(51	)		127			76
	Net current period other comprehensive (loss) income		(60	)		208			148
	As of December 31, 2013	$	(13	)	$	(267	)	$	(280	)
	The following table summarizes the reclassifications from AOCL to the Condensed Consolidated Statement of Operations for the period ending December 31, 2013:
	(in millions)	Amount Reclassified			Affected line item in the consolidated
		from AOCL			statement of operations
	Foreign currency translation items:
	Liquidation of consolidated entities	$	13		Other income, net
	Sale of discontinued operations(b)		38		Loss on sale of discontinued operations, net of tax
	Net of tax		51
	Defined benefit pension plan items:
	Amortization of prior-service costs(a)		5		See Note (a)
	Amortization of actuarial losses(a)		(21	)	See Note (a)
	Sale of discontinued operations(b)		(127	)	Loss on sale of discontinued operations, net of tax
	Total before tax		(143	)
	Tax on continuing operations		1		Income Tax Expense
	Tax on discontinued operations		15		Loss on sale of discontinued operations, net of tax
	Total tax		16
	Net of tax		(127	)
	Total reclassifications	$	(76	)
	(a)
	These items are included in the computation of net periodic benefit pension cost (see Note 13—Pension and Other Post-Retirement Plans for additional information).
	(b)
	Sale of the Antioxidant and Consumer Products businesses (see Note 2—Acquisitions and Divestitures)

STOCK_INCENTIVE_PLANS

STOCK INCENTIVE PLANS	12 Months Ended
	Dec. 31, 2013
STOCK INCENTIVE PLANS	'
STOCK INCENTIVE PLANS	'
	12) STOCK INCENTIVE PLANS
	We utilize various employee stock-based compensation plans. Awards under these plans are granted to eligible officers, management employees and non-employee directors. Awards may be made in the form of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock and/or restricted stock units ("RSUs"). Under the plans, we issue additional shares of common stock upon the exercise of stock options or the vesting of RSUs. Stock issuances can be from treasury shares or newly issued shares.
	Description of the Plans
	In 2010, we adopted the Chemtura Corporation 2010 Long-Term Incentive Plan (the "2010 LTIP") which was approved by the Bankruptcy Court and became effective upon our emergence from Chapter 11. The 2010 LTIP provides for grants of nonqualified stock options ("NQO's"), incentive stock options ("ISO's"), stock appreciation rights, dividend equivalent rights, stock units, bonus stock, performance awards, share awards, restricted stock, time-based RSU's and performance-based RSUs. The 2010 LTIP provides for the issuance of a maximum of 11 million shares. Stock options may be granted under the 2010 LTIP at prices equal to the fair market value of the underlying common shares on the date of the grant. All outstanding stock options will expire not more than ten years from the date of the grant.
	During the years ended December 31, 2013 and 2012, we had 4.9 million and 5.3 million shares available for grant, respectively.
	Total stock-based compensation expense, including amounts for RSUs and stock options, was $14 million, $24 million and $26 million for the years ended December 31, 2013, 2012 and 2011, respectively.
	In 2013, stock-based compensation expense of $12 million, $1 million and $1 million was reported in SG&A, COGS and earnings from discontinued operations, net of tax, respectively. In 2012, stock-based compensation expense of $19 million, $3 million and $2 million was reported in SG&A, COGS and loss from discontinued operations, net of tax, respectively. In 2011, stock-based compensation expense of $21 million, $3 million, and $2 million was reported in SG&A, COGS and earnings from discontinued operations, net of tax, respectively.
	In 2013, approximately 23% of the stock-based compensation expense was allocated to our operating segments. In 2012 and 2011, approximately 24% of the stock-based compensation expense was allocated to our operating segments. All other stock-based compensation expense has been allocated to Corporate.
	Stock Options
	In March 2013, the compensation committee of our Board (the "Compensation Committee") approved the grant of 0.4 million NQOs under the 2013 long-term incentive awards (the "2013 Awards"). These options vest ratably over a three-year period.
	In March 2012, the Compensation Committee approved the grant of 0.8 million NQOs under the 2012 long-term incentive awards (the "2012 Awards"). These options vest ratably over a three-year period.
	In March 2011, under the 2010 emergence incentive plan (the "2010 EIP"), we granted 0.8 million NQOs. One third vested immediately, one third vested on March 31, 2012 and one third vested on March 31, 2013.
	In March 2011, the Compensation Committee approved the grant of 1.4 million NQOs under the 2011 long-term awards (the "2011 Awards"). These options will vest ratably over a three-year period.
	We use the Black-Scholes option-pricing model to determine the fair value of NQOs. We have elected to recognize compensation cost for NQOs equally over the requisite service period for each separately vesting tranche, as if multiple awards were granted. Using this method, the weighted average fair value of stock options granted during the years ended December 31, 2013, December 31, 2012 and December 31, 2011 was $9.92, $8.15 and $8.39, respectively. The Black-Scholes option-pricing model requires the use of various assumptions.
	The following table presents the weighted average assumptions used:
		Year Ended
		December 31,
		2013			2012			2011
	Dividend yield		0	%		0	%		0	%
	Expected volatility		51	%		56.7	%		53.8	%
	Risk-free interest rate		1	%		1.2	%		2.5	%
	Expected life (in years)		6			6			6
	The weighted average expected life of six years for the 2013, 2012 and 2011 grants reflects the simplified method, which defines the expected life as the average of the contractual term of the options and the weighted average vesting period for all option tranches. We continue to use the simplified method because there is insufficient data to develop a justifiable expected term. Expected volatility for the 2013, 2012 and 2011 awards of NQOs is based primarily on a combination of the historical volatility prior to our entering into Chapter 11 and historical volatility since emergence from Chapter 11.
	A summary of our stock option activities for 2013, 2012 and 2011 is summarized as follows:
		Price Per Share						Weighted
								Average
								Remaining			Aggregate
								Contractual			Intrinsic
					Shares			Life			Value
		Average			(in millions)						(in millions)
	Outstanding at 1/1/11	$	15.5			0.8
	Granted		16.03			2.2
	Lapsed		15.91			(0.2	)
	Outstanding at 12/31/11		15.9			2.8			9.1		$	—
	Granted		15.39			0.8
	Exercised		15.77			(0.3	)					1
	Lapsed		15.76			(0.2	)
	Outstanding at 12/31/12		15.79			3.1			8.3			17
	Granted		20.5			0.4
	Exercised		15.83			(0.5	)					4
	Lapsed		16.78			(0.2	)
	Outstanding at 12/31/13	$	16.46			2.8			7.4			32
	Exercisable at 12/31/11	$	15.68			0.7
	Exercisable at 12/31/12	$	15.81			1.3
	Exercisable at 12/31/13	$	15.83			1.7			6.9		$	20
	Total remaining unrecognized compensation cost associated with unvested stock options at December 31, 2013 was $3 million, which will be recognized over the weighted average period of approximately 2 years.
	Restricted Stock Awards
	In March 2013, the Compensation Committee approved the grant of 0.2 million time-based RSUs under the 2013 Awards. These RSUs vest ratably over a three-year period.
	In March 2013, the Compensation Committee approved the grant of 0.2 million performance shares under the 2013 Awards. The share grant is subject to a performance multiplier of up to 2 times the targeted award. The performance measurement period is the three calendar year period ending December 31, 2015, the performance share metric used will be our relative total shareholder return against the companies comprising the Russell 3000 Index, and the performance shares will be settled on March 1, 2016. We used the Monte-Carlo simulation model to determine the fair value of the performance shares. Using this method, the average per share fair value of these awards was $27.27.
	In March 2012, the Compensation Committee approved the grant of 0.6 million time-based RSUs under the 2012 Awards. These RSUs vest ratably over a three-year period.
	In March 2012, the Compensation Committee approved the grant of 0.3 million performance shares under the 2012 Awards. The share grant is subject to a performance multiplier of up to 2 times the targeted award. The performance measurement period is the three calendar year period ending December 31, 2014, the performance share metric used will be our relative total shareholder return against the companies comprising the Russell 3000 Index, and the performance shares will be settled on March 1, 2015. We used the Monte-Carlo simulation model to determine the fair value of the performance shares. Using this method, the average per share fair value of these awards was $25.38.
	In March 2011, under the 2010 EIP, we granted 0.4 million time-based RSUs with a fair market value of the quoted closing price of our stock on that date. One third vested immediately, one third vested on March 31, 2012 and one third vests on March 31, 2013.
	In March 2011, the Compensation Committee approved the grant of 0.4 million time-based RSUs under the 2011 Awards. These RSUs vest ratably over a three-year period.
	In March 2011, we established the initial allocations under the 2010 EAP, which was previously approved by the Bankruptcy Court and provided designated participants with the opportunity to share in a pool of up to 1 million fully vested shares of common stock. The portion of the 2010 EAP pool to be distributed was determined by Chemtura's consolidated EBITDA during the 2011 fiscal year. In March 2012, the compensation committee approved the allocation of specified percentage
	interests in the 2010 EAP pool among designated participants, including our named executive officers. Under the formula approved by the Bankruptcy Court, our 2011 consolidated EBITDA resulted in a payout of 57% of the total 2010 EAP pool of 1 million, or 0.6 million, which were distributed to the participants in March 2012.
	In February 2011, the Compensation Committee approved the grant of 0.1 million time-based RSU's to non-employee directors with a fair market value of the quoted closing price of our stock on that date. These RSU's vested ratably over a two-year period.
	RSUs award activity for 2013, 2012 and 2011 is as follows:
		Shares			Weighted			Aggregate
		(in millions)			Average			Fair Value
					Grant Date			(in millions)
					Fair Value
	Unvested RSU awards, January 1, 2011		0.3		$	15.5
	Canceled		(0.1	)		15.97
Granted		1			16
Vested		(0.3	)		15.74		$	5
Unvested RSU awards, December 31, 2011		0.9			15.91			10
Cancelled		(0.1	)		18.04
Granted		1.5			17.72
Vested		(1.0	)		15.93			17
Unvested RSU awards, December 31, 2012		1.3			17.85			27
Cancelled		(0.2	)		20.21
Granted		0.4			23.18
Vested		(0.5	)		16.07			8
Unvested RSU awards, December 31, 2013		1		$	20.53		$	30
Total remaining unrecognized compensation expense associated with unvested RSUs at December 31, 2013 was $10 million, which will be recognized over the weighted average period of approximately 2 years.
Employee Stock Purchase Plan
In May 2012, our shareholders approved the Chemtura Corporation 2012 Employee Stock Purchase Plan (the "ESPP"). This plan permits eligible employees to annually elect to have up to 10% of their compensation withheld and applied to the purchase of shares of Chemtura's common stock. Purchases are made at the end of quarterly offering periods and are based on the lower of the fair market value of the shares on the first and last trading days during the offering period. A total of 1 million shares are authorized to be issued under the ESPP, including up to 0.1 million shares per offering period and 0.3 million shares per plan year. As of December 31, 2013, approximately 0.9 million shares are available for future issuance under this plan.
Tax Benefits of Stock-Based Compensation Plans
ASC 718 Stock Compensation requires the benefits of tax deductions in excess of grant-date fair value be presented in the cash flows from financing section of our Consolidated Statements of Cash Flows. We did not obtain any cash tax benefit associated with shares exercised during the year ended December 31, 2013 and 2012 as we utilized net operating losses. Cash proceeds received from option exercises during 2013 and 2012 was $8 million and $5 million, respectively.

PENSION_AND_OTHER_POSTRETIREME

PENSION AND OTHER POST-RETIREMENT PLANS	12 Months Ended
	Dec. 31, 2013
PENSION AND OTHER POST-RETIREMENT PLANS	'
PENSION AND OTHER POST-RETIREMENT PLANS	'
	13) PENSION AND OTHER POST-RETIREMENT PLANS
	We have several defined benefit and defined contribution pension plans covering substantially all of our domestic employees and certain international employees. Benefits under the defined benefit plans are primarily based on the employees' years of service and compensation during employment. Effective January 1, 2006, we eliminated future earnings benefits to participants of our domestic defined benefit plans for non-bargained employees. All active non-bargained employees would subsequently earn benefits under defined contribution plans for all service incurred on or after January 1, 2006. Our funding policy for the defined benefit plans is based on contributions at the minimum annual amounts required by law plus such amounts as we may deem appropriate. Contributions for the defined contribution plans are determined as a percentage of the covered employee's salary. Plan assets consist of publicly traded securities and mutual funds and investments in commingled funds administered by independent investment advisors.
	International employees are covered by various pension benefit arrangements, some of which are considered to be defined benefit plans for financial reporting purposes. Assets of these plans are comprised primarily of equity investments and fixed-income investments. Benefits under these plans are primarily based upon levels of compensation. Funding policies are based on legal requirements, tax considerations and local practices.
	We also provide health and life insurance benefits for substantially all of our active domestic employees and certain retired and international employees. These plans are generally not prefunded and are paid by us as incurred.
	In November 2009, the Bankruptcy Court entered an order (the "2009 OPEB Order") approving, in part, our motion (the "2009 OPEB Motion") requesting authorization to modify certain post-retirement welfare benefits (the "OPEB Benefits") under our post-retirement welfare benefit plans (the "OPEB Plans"), including the OPEB Benefits of certain Uniroyal salaried retirees (the "Uniroyal Salaried Retirees"). On April 5, 2010, the Bankruptcy Court entered an order denying the Uniroyal Salaried Retirees' motion to reconsider the 2009 OPEB Order based, among other things, on the Uniroyal Salaried Retirees' failure to file a timely objection to the 2009 OPEB Motion. On April 8, 2010, the Uniroyal Salaried Retirees appealed the Bankruptcy Court's April 5, 2010 order and on April 14, 2010, sought a stay pending their appeal (the "Stay") of the 2009 OPEB Order as to our right to modify the OPEB Benefits. On April 21, 2010, the Bankruptcy Court ordered us not to modify the Uniroyal Salaried Retirees' OPEB Benefits, pending a hearing and decision as to the Stay. After consulting with the official committees of unsecured creditors and equity security holders, we requested that the Bankruptcy Court have a hearing to decide, as a matter of law, whether we have the right to modify the OPEB Benefits of the Uniroyal Salaried Retirees as requested in the 2009 OPEB Motion. In November 2011, we reached an agreement in principle with a steering committee of the Uniroyal Salaried Retirees resolving all disputes concerning the 2009 OPEB Motion. On February 21, 2012, we filed a motion with the Bankruptcy Court seeking approval of a settlement stipulation with the steering committee of the Uniroyal Salaried Retirees based upon the prior agreement in principle and authorizing us to implement changes to the OPEB Benefits of all Uniroyal Salaried Retirees based upon the settlement stipulation and as a partial grant of the relief requested in the 2009 OPEB Motion. The Bankruptcy Court approved the motion at a hearing held on March 29, 2012. The changes were communicated to the participants in May 2012. The impact of the change was an $8 million increase to the projected benefit obligation, which we recorded in the second quarter of 2012 as an increase to the pension and post-retirement healthcare liabilities, with an offset reflected within AOCL on our Consolidated Balance Sheet at December 31, 2012.
	In May 2011, one of our UK subsidiaries entered into definitive agreements with the trustees of the Great Lakes U.K. Limited Pension Plan ("the UK Pension Plan") over the terms of a "recovery plan" which provided for a series of additional cash contributions to be made to reduce the underfunding over time. The agreements provided, among other things, for our UK subsidiary to make cash contributions of £60 million (approximately $95 million) in just over a three year period, with the initial contribution of £30 million ($49 million) made in the second quarter of 2011, the second contribution of £15 million ($24 million) made in the second quarter of 2012 and the third contribution of £8 million ($11 million) made in the second quarter of 2013. The final contribution of £8 million ($11 million) is expected to be made in the second quarter of 2014. The agreements also provided for the granting of both a security interest and a guarantee to support certain of the liabilities under the UK Pension Plan.
	There was also an evaluation being undertaken as to whether additional benefit obligations exist in connection with the equalization of certain benefits under the UK Pension Plan that occurred in the early 1990s. Based on the results of the evaluation in 2011, $8 million of expense was recorded in the fourth quarter of 2011, which was subject to adjustment as further information is gathered as part of the evaluation. Additional information has been gathered and evaluated during the second quarter of 2013 and resulted in a reduction of the estimated liability from that originally estimated. Accordingly we recorded $2 million of income to SG&A in the second quarter of 2013. When we reach agreement with the trustees of the UK Pension Plan as to what additional benefit obligations exist, our UK subsidiary is required to make additional cash contributions to the UK Pension Plan.
	Benefit Obligations
		Defined Benefit Pension Plans
		Qualified						International and						Post-Retirement
		Domestic Plans						Non-Qualified						Health Care
								Plans						Plans
	(In millions)	2013			2012			2013			2012			2013			2012
	Change in projected benefit obligation:
	Projected benefit obligation at beginning of year	$	1,040		$	971		$	499		$	420		$	124		$	116
	Service cost		—			1			3			3			—			1
	Interest cost		30			43			19			21			4			5
	Plan participants' contributions		—			—			1			—			—			—
	Actuarial (gains) losses		(69	)		86			11			58			(20	)		5
	Benefits paid		(51	)		(61	)		(19	)		(19	)		(10	)		(12	)
	Plan amendments		—			—			—			—			—			8
	Business divestitures(a)		(327	)		—			—			—			—			—
	Settlements		—			—			(6	)		(1	)		—			—
	Foreign currency exchange rate changes		—			—			11			17			(2	)		1
	Projected benefit obligation at end of year	$	623		$	1,040		$	519		$	499		$	96		$	124
	Accumulated benefit obligation at end of year	$	622		$	1,039		$	506		$	490
	Weighted-average year-end assumptions used to determine benefit obligations:
	Discount rate		4.6	%		3.8	%		4.18	%		4.03	%		4.35	%		3.56	%
	Rate of compensation increase		3	%		3	%		2.85	%		2.77	%		N/A			N/A
	Health care cost trend rate														6.27	%		6.47	%
	(a)
	Business divestitures includes the transfer of $315 million of projected benefit obligations with the sale of our Antioxidants business in April 2013 and $12 million with the sale of our Consumer Products business in December 2013.
	A 6.27% weighted-average rate of increase in the health care cost trend rate was assumed for the accumulated post-retirement benefit obligation as of December 31, 2013. The rate was assumed to decrease gradually to a weighted average rate of 5.0% over approximately the next 6 to 8 years. Assumed health care cost trend rates have a significant effect on the post-retirement benefit obligation reported for the health care plans. A one percentage point increase in assumed health care cost trend rates would increase the accumulated post-retirement benefit obligation by $4 million for health care benefits as of December 31, 2013. A one percentage point decrease in assumed health care cost trend rates would decrease the accumulated post-retirement benefit obligation by $4 million for health care benefits as of December 31, 2013.
	Plan Assets
		Defined Benefit Pension Plans
		Qualified						International and						Post-Retirement
		Domestic Plans						Non-Qualified						Health Care
								Plans						Plans
	(In millions)	2013			2012			2013			2012			2013			2012
	Change in plan assets:
	Fair value of plan assets at beginning of year	$	814		$	737		$	370		$	306		$	—		$	—
	Actual return on plan assets		51			98			30			29			—			—
	Employer contributions		20			40			27			39			10			12
	Plan participants' contributions		—			—			1			—			—			—
	Benefits paid		(51	)		(61	)		(19	)		(19	)		(10	)		(12	)
	Business divestitures(a)		(239	)		—			—			—			—			—
	Settlements		—			—			(6	)		—			—			—
	Foreign currency exchange rate changes		—			—			5			15			—			—
	Fair value of plan assets at end of year	$	595		$	814		$	408		$	370		$	—		$	—
	(a)
	Business divestitures includes the transfer of $233 million of plan assets with the sale of our Antioxidants business in April 2013 and $6 million of plan assets with the sale of our Consumer Products business in December 2013.
	Our pension plan assets are managed by outside investment managers. For our U.S. qualified pension plans, the Employee Investment Committee ("EIC") appointed SEI Investments Management Corporation ("SEI") as an investment manager effective February 1, 2012. The assets of the plans were transitioned from previous investment managers to SEI at the end of March 2012. SEI has assisted the EIC in developing a suitable asset allocation, selecting appropriate investment managers, monitoring and evaluating the performance of such managers. For our Canadian non-qualified pension plans, the EIC appointed Northern Trust as the investment manager effective January 2013 and transitioned the plan assets from the previous investment managers in February 2013. For our UK pension plans, the EIC appointed Mercer Limited as the investment manager effective in July and August 2013 and transitioned the plan assets from previous investment managers in August and November 2013. Assets are monitored regularly to ensure they are within the range of parameters as set forth by the EIC. Our investment strategy with respect to pension assets is to achieve the expected rate of return within an acceptable or appropriate level of risk. Our investment strategy is designed to promote diversification, to moderate volatility and to attempt to balance the expected return with risk levels. The target allocations for qualified domestic plans are 32% equity securities, 58% fixed income securities and 10% to all other types of investments. The weighted average target allocations for international pension plans are 39% equity securities, 27% fixed income securities and 34% to all other types of investments.
	The fair values of our defined benefit pension plan assets at December 31, 2013 and 2012, by asset category are as follows:
		Fair Value Measurements at December 31, 2013
		Defined Benefit Pension Plans
		Qualified Domestic Plans												International and Non-Qualified Plans
	(In millions)	Total			Quoted Prices			Significant			Significant			Total			Quoted Prices			Significant			Significant
					in Active			Observable			Unobservable						in Active			Observable			Unobservable
					Markets for			Inputs			Inputs						Markets for			Inputs			Inputs
					Identical			(Level 2)			(Level 3)						Identical			(Level 2)			(Level 3)
					Assets												Assets
					(Level 1)												(Level 1)
	Equity securities:
Pooled equity(a)	$	141		$	141		$	—		$	—		$	146		$	12		$	134		$	—
Fixed income securities:
U.S. government bonds(b)		71			—			71			—			—			—			—			—
International government bonds(b)		—			—			—			—			2			—			2			—
U.S. corporate bonds(c)		—			—			—			—			—			—			—			—
Pooled fixed income funds(d)		287			287			—			—			247			—			243			4
Alternative collective funds(e)		91			—			—			91			—			—			—			—
Other instruments(f)		1			1			—			—			11			—			—			11
Cash & cash equivalents		4			4			—			—			2			2			—			—
	$	595		$	433		$	71		$	91		$	408		$	14		$	379		$	15
	Fair Value Measurements at December 31, 2012
	Defined Benefit Pension Plans
	Qualified Domestic Plans												International and Non-Qualified Plans
(in millions)	Total			Quoted Prices			Significant			Significant			Total			Quoted Prices			Significant			Significant
				in Active			Observable			Unobservable						in Active			Observable			Unobservable
				Markets for			Inputs			Inputs						Markets for			Inputs			Inputs
				Identical			(Level 2)			(Level 3)						Identical			(Level 2)			(Level 3)
				Assets												Assets
				(Level 1)												(Level 1)
Equity securities:
Pooled equity(a)	$	288		$	288		$	—		$	—		$	168		$	25		$	143		$	—
Fixed income securities:
U.S. government bonds(b)		74			—			74			—			—			—			—			—
International government bonds(b)		—			—			—			—			62			—			62			—
U.S. corporate bonds(c)		—			—			—			—			1			—			1			—
Pooled fixed income funds(e)		331			331			—			—			131			—			131			—
Alternative collective funds(e)		120			—			—			120			—			—			—			—
Other instruments(f)		1			1			—			—			7			—			—			7
Cash & cash equivalents		—			—			—			—			1			1			—			—
	$	814		$	620		$	74		$	120		$	370		$	26		$	337		$	7
(a)
Pooled equity funds include mutual and collective funds that invest primarily in marketable equity securities of various sized companies in a diverse set of industries in various regions of the world. Shares of publicly traded mutual funds are valued at the closing price reported on the U.S. and international exchanges where the underlying securities are actively traded. Units of collective funds are valued at the per unit value determined by the fund manager, which is based on market price of the underlying securities.
(b)
U.S. and international government bonds include U.S. treasury, municipal and agency obligations and international government debt. Such instruments are valued at quoted market prices for those instruments or on institutional bid valuations. The decrease in the value of the international bonds is primarily due to changing the investment manager of our UK plans and shifting assets into pooled fixed income funds in 2013.
(c)
U.S. and international corporate bonds are from a diverse set of industries and regions. Such instruments are valued using similar securities in active markets and observable data or broker or dealer quotations.
(d)
Pooled fixed income funds are fixed income funds that invest primarily in corporate and government bonds. Such instruments are valued using similar securities in active markets and observable data or broker or dealer quotations. The increase in the value of the pooled fixed income funds of our international plans includes the transfer of assets in from international bonds as noted in (b).
(e)
Alternative collective funds include funds that invest mainly in asset backed securities, real estate funds, hedge funds and other alternative investments. The underlying funds are valued based on the net asset values of the investments as determined by the respective individual fund administrators on a daily, weekly or monthly basis depending on the fund. Such valuations are reviewed by the portfolio managers who determine the value of collective funds based on these inputs. Certain of these funds have lock up periods and all of them have notification periods. Due to the process used to value these funds and the restricted trading, we have categorized these funds as level 3.
(f)
Other instruments include primarily annuities and real estate funds instruments for which there are significant unobservable inputs and therefore have been classified as level 3.
	Alternative			Other			Total Level 3
	Collective Funds			Instruments			Investments
Balance at December 31, 2012	$	120		$	7		$	127
Transfers to/(from) Level 3(a)		(39	)		8			(31	)
Realized gains		1			—			1
Unrealized gains		9			1			10
Disbursements		—			(1	)		(1	)
Balance at December 31, 2013	$	91		$	15		$	106
(a)
Transfers from the alternative collective funds in 2013 are due to the U.S. plan transferring assets from these funds into other SEI level 1 and level 2 funds.
Funded Status
The funded status at the end of the year, and the related amounts recognized on the statement of financial condition, are as follows:
	Defined Benefit Pension Plans
	Qualified						International and						Post-Retirement
	Domestic Plans						Non-Qualified						Health Care
							Plans						Plans
(In millions)	2013			2012			2013			2012			2013			2012
Funded status, end of year:
Fair value of plan assets	$	595		$	814		$	408		$	370		$	—		$	—
Benefit obligations		623			1,040			519			499			96			124
Net amount recognized	$	(28	)	$	(226	)	$	(111	)	$	(129	)	$	(96	)	$	(124	)
Amounts recognized in the Consolidated Balance Sheets at the end of year consist of:
Noncurrent assets	$	—		$	—		$	30		$	13		$	—		$	—
Current liability		—			—			(9	)		(8	)		(9	)		(11	)
Noncurrent liability		(28	)		(139	)		(132	)		(134	)		(87	)		(113	)
Liabilities of discontinued operations(a)		—			(87	)		—			—			—			—
Net amount recognized	$	(28	)	$	(226	)	$	(111	)	$	(129	)	$	(96	)	$	(124	)
Amounts recognized in accumulated other comprehensive loss consist of:
Net actuarial loss/(gain)	$	219		$	427		$	120		$	121		$	31		$	54
Prior service cost/(credit)		—			1			—			1			(40	)		(45	)
	$	219		$	428		$	120		$	122		$	(9	)	$	9
(a)
Liabilities of discontinued operations at December 31, 2012 included estimated net pension liabilities of $80 million related to our Antioxidants business and $7 million related to our Consumer Products business. The actuarial valuation of those net pension liabilities were completed upon closing of the transactions and resulted in the transfer of $82 million upon closing the sale of our Antioxidants business in April 2013 and $6 million upon closing the sale of Consumer Products in December 2013. See Note 2—Acquisitions and Divestitures for additional information related to these transactions.
The estimated amounts that will be amortized from AOCL into net periodic benefit cost (credit) in 2014 are as follows:
(In millions)	Qualified			International			Post-Retirement
	Domestic			and			Health Care
	Plans			Non-Qualified			Plans
				Plans
Actuarial loss	$	10		$	5		$	2
Prior service credit		—			—			(5	)
Total amortization cost (credit)	$	10		$	5		$	(3	)
As of December 31, 2013 and 2012, the current liabilities positions are included in accrued expenses in our Consolidated Balance Sheets and the non-current liabilities positions are shown as pension and post-retirement health care liabilities.
Our funding assumptions for our domestic pension plans assume no significant change with regards to demographics, legislation, plan provisions, or actuarial assumptions or methods to determine the estimated funding requirements. We contributed approximately $57 million and $91 million to our pension and post retirement plans in 2013 and 2012, respectively. The 2013 contribution includes $11 million for one of our UK pension plans as required by the "recovery plan" agreed to with the trustees of that plan and a $10 million discretionary contribution to one of our domestic qualified plans. The 2012 contribution included $24 million for one of our UK pension plans as required by the "recovery plan" agreed to with the trustees of that plan. There were no discretionary contributions to our domestic qualified plan in 2012 or to our international plans during 2013 and 2012.
The projected benefit obligation and fair value of plan assets for pension and post-retirement plans with a projected benefit obligation in excess of plan assets at December 31, 2013 and 2012 were as follows:
(In millions)	2013			2012
Projected benefit obligation in excess of plan assets at end of year:
Projected benefit obligation	$	876		$	1,378
Fair value of plan assets		612			887
The projected benefit obligation, accumulated benefit obligation and fair value of plan assets for pension and post-retirement plans with an accumulated benefit obligation in excess of plan assets at December 31, 2013 and 2012 were as follows:
(In millions)	2013			2012
Accumulated benefit obligation in excess of plan assets at end of year:
Projected benefit obligation	$	778		$	1,225
Accumulated benefit obligation		777			1,223
Fair value of plan assets		611			859
Expected Cash Flows
Information about the expected cash flows for the domestic qualified defined benefit plans, international and non-qualified defined benefit plans and post-retirement health care plans are as follows:
	Defined Benefit
	Pension Plans
(in millions)	Qualified			International			Post-Retirement
	Domestic			and			Health Care
	Plans			Non-Qualified			Plans
				Plans
Expected Employer Contributions:(a)
2014	$	—		$	17		$	9
Expected Benefit Payments(b):
2014		46			23			9
2015		46			23			9
2016		45			24			8
2017		45			25			8
2018		45			26			8
2019 - 2023		214			134			32
(a)
The expected employer contributions reflect the minimum required by law or contractual obligation. We may elect to make additional discretionary contributions as deemed appropriate consistent with past practice.
(b)
The expected benefit payments are based on the same assumptions used to measure our benefit obligation at the end of the year and include benefits attributable to estimated future employee service.
Net Periodic Cost
	Defined Benefit Pension Plans
	Qualified									International and									Post-Retirement
	Domestic Plans(a)									Non-Qualified Plans									Health Care Plans
(In millions)	2013			2012			2011			2013			2012			2011			2013			2012			2011
Components of net periodic benefit cost (credit):
Service cost	$	—		$	1		$	1		$	3		$	3		$	3		$	—		$	1		$	1
Interest cost		30			43			46			20			21			22			4			5			5
Expected return on plan assets		(45	)		(54	)		(56	)		(23	)		(22	)		(18	)		—			—			—
Amortization of prior service cost		—			—			—			—			—			—			(5	)		(6	)		(6	)
Recognized actuarial losses		14			14			12			5			2			2			2			3			2
Curtailment loss recognized		—			—			—			1			—			—			—			—			—
Settlement loss recognized(b)		32			—			—			—			—			—			—			—			—
Net periodic benefit cost	$	31		$	4		$	3		$	6		$	4		$	9		$	1		$	3		$	2
(a)
The net periodic benefit cost, excluding the settlement loss recognized, for the years ended December 31, 2013, 2012 and 2011 include pension expense related to the earnings (loss) from discontinued operations of $1 million, $2 million and $2 million, respectively.
(b)
The settlement loss recognized in 2013 includes a loss of $40 million related to the divestiture of our Antioxidants business in April 2013 (included in loss on sale of discontinued operations), partly offset by a $2 million gain related to the divestiture of our Consumer Products business (included in loss on sale of discontinued operations) and a $6 million gain related to an adjustment for a legacy pension plan ($2 million included in SG&A and $4 million in loss from discontinued operations).
	2013			2012			2011			2013			2012			2011			2013			2012			2011
Weighted-average assumptions used to determine net cost:
Discount rate		3.8	%		4.6	%		5.1	%		3.89	%		4.64	%		5.14	%		3.71	%		4.15	%		5.14	%
Expected return on plan assets		7.5	%		7.5	%		7.75	%		6.53	%		6.71	%		6.8	%
Rate of compensation increase		3	%		4	%		4	%		2.77	%		3.22	%		3.34	%
The expected return on pension plan assets is based on our investment strategy, historical experience, and our expectations for long term rates of return. We determine the long-term rate of return assumptions for the domestic and international pension plans based on its investment allocation between various asset classes. The expected rate of return on plan assets is derived by
applying the expected returns on various asset classes to our target asset allocation. The expected returns are based on the expected performance of the various asset classes and are further supported by historical investment returns. We utilized a weighted average expected long-term rate of 7.50% on all domestic assets and a weighted average rate of 6.53% for the international plan assets for the year ended December 31, 2013.
Assumed health care cost trend rates have a significant effect on the service and interest cost components reported for the health care plans. A one percentage point increase in assumed health care cost trend rates increases the service and interest cost components of net periodic post-retirement health care benefit cost by less than $1 million for 2013. A one percentage point decrease in assumed health care cost trend rates decreases the service and interest cost components of net periodic post-retirement health care benefit cost by less than $1 million for 2013.
Our cost of the defined contribution plans was $11 million for 2013, 2012 and 2011.

DERIVATIVE_INSTRUMENTS_AND_HED

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES	12 Months Ended
	Dec. 31, 2013
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES	'
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES	'
	14) DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES
	Our activities expose our earnings, cash flows and financial condition to a variety of market risks, including the effects of changes in foreign currency exchange rates, interest rates and energy prices. We maintain a risk management strategy that may utilize derivative instruments to mitigate risk against foreign currency movements and to manage energy price volatility. We do not enter into derivative instruments for trading or speculative purposes.
	We have exposure to changes in foreign currency exchange rates resulting from transactions entered into by us and our foreign subsidiaries in currencies other than their functional currency (primarily trade payables and receivables). We are also exposed to currency risk on intercompany transactions (including intercompany loans). We manage these currency risks on a consolidated basis, which allows us to net our exposure.
	In September 2013, we entered into a €25 million notional put option and €25 million notional value forward contract to reduce the risk of currency exposure related to the Euro in one of our consolidated subsidiaries. These contracts matured in October 2013. Additionally, during the first half of 2013, we entered into a zero cost collar contract and two additional forward contracts to reduce the risk of currency exposure related to the Euro in one of our consolidated subsidiaries. These contracts matured at various times during the second quarter of 2013. We utilized fair value accounting methods for these contracts and recorded net realized gains of $2 million reflecting the changes in fair market value of these contracts in other income, net in 2013.
	In April 2012, we purchased two forward contracts with a notional amount totaling $25 million to reduce the risk of currency exposure related to the remaining two annual installments of proceeds from the sale of our 50% interest in Tetrabrom Technologies Ltd. in 2011. We utilize fair value accounting methods for these contracts. During the quarter ended June 30, 2013, one of these contracts settled and we recorded a realized gain of less than $1 million in other income, net. We have recorded an unrealized gain of less than $1 million reflecting the changes in the fair market value on the remaining contract in other income, net in 2013. The resulting net liability of the changes in fair market value of the remaining contract of less than $1 million has been accounted for in other current assets in our Consolidated Balance Sheet.
	In June 2012, we purchased and settled a forward contract with a notional amount totaling $8 million to reduce the risk of currency exposure related to the payment of an intercompany payable denominated in Mexican Pesos. We used fair value accounting methods for these contracts and have recorded a gain of less than $1 million reflecting the changes in the fair market value of these contracts in other income, net in 2012.
	The net effect of the realized and unrealized gains and losses recognized in other income (expense), net on foreign exchange transactions including these forward contracts resulted in a pre-tax loss of $7 million, $6 million and $2 million in 2013, 2012 and 2011, respectively.

FINANCIAL_INSTRUMENTS_AND_FAIR

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS	12 Months Ended
	Dec. 31, 2013
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS	'
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS	'
	15) FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS
	Financial Instruments
	The carrying amounts for cash and cash equivalents, accounts receivable, other current assets, accounts payable and other current liabilities, approximate their fair value because of the short-term maturities of these instruments. The fair value of debt is based primarily on quoted market values.
	The following table presents the carrying amounts and estimated fair values of material financial instruments used by us in the normal course of our business:
		2013				2012
	(In millions)	Carrying		Fair		Carrying		Fair
		Amount		Value		Amount		Value
	Total debt	$	898	$	916	$	876	$	920
	Fair Value Measurements
	We apply provisions of ASC 820 with respect to our financial assets and liabilities that are measured at fair value within the financial statements on a recurring basis. ASC 820 specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our market assumptions. The fair value hierarchy specified by ASC 820 is as follows:
	•
	Level 1—Quoted prices in active markets for identical assets and liabilities.
	•
	Level 2—Quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market date.
	•
	Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities.
	Level 1 fair value measurements in 2013 and 2012 included securities purchased in connection with the deferral of compensation, our match and investment earnings related to the supplemental savings plan. These securities are considered our general assets until distributed to the participant and are included in other assets in our Consolidated Balance Sheets. A corresponding liability is included in other liabilities at December 31, 2013 and 2012 in our Consolidated Balance Sheets. Quoted market prices were used to determine fair values of these Level 1 investments which are held in a trust with a third-party brokerage firm. The fair value of the asset and corresponding liability was $3 million and $2 million at December 31, 2013 and 2012, respectively.
	Level 2 fair value measurements are used to value our financial instruments subject to foreign exchange risk (see Note 14—Derivative Instruments and Hedging Activities). For the year ended December 31, 2013, there were no transfers into or out of Level 1 and Level 2.
	Level 3 fair value measurements are utilized in our impairment reviews of Goodwill (see Note 6—Goodwill and Intangible Assets).
	During the second quarter of 2013, we obtained an investment in non-public preferred equity securities with a face value of $9 million. We have estimated the fair value to be $4 million, utilizing Level 3 measurements, where the fair value estimate is determined internally based on business and market sector fundamentals. We have reported the fair value of this investment in Other Non-Current Assets and reported the difference between the face value and fair value in loss on sale of discontinued operations.
	Level 1, 2 and 3 fair value measurements are utilized for defined benefit plan assets in determining the funded status of our pension and post-retirement benefit plan liabilities on an annual basis (at December 31) (see Note 13—Pension and Other Post-Retirement Plans).

ASSET_RETIREMENT_OBLIGATIONS

ASSET RETIREMENT OBLIGATIONS	12 Months Ended
	Dec. 31, 2013
ASSET RETIREMENT OBLIGATIONS	'
ASSET RETIREMENT OBLIGATIONS	'
	16) ASSET RETIREMENT OBLIGATIONS
	We apply the provisions of ASC Topic 410, Asset Retirements and Environmental Obligations ("ASC 410"), which requires us to make estimates regarding future events in order to record a liability for asset retirement obligations in the period in which a legal obligation is created. Such liabilities are recorded at fair value, with an offsetting increase to the carrying value of the related long-lived assets. The fair value is estimated by discounting projected cash flows over the estimated life of the assets using our credit adjusted risk-free rate applicable at the time the obligation is initially recorded. In future periods, the liability is accreted to its present value and the capitalized cost is depreciated over the useful life of the related asset. We also adjust the liability for changes resulting from revisions to the timing of future cash flows or the amount of the original estimate. Upon retirement of the long-lived asset, we either settle the obligation for its recorded amount or incur a gain or loss.
	Our asset retirement obligations include estimates for all asset retirement obligations identified for our worldwide facilities. Our asset retirement obligations are primarily the result of legal obligations for the removal of leasehold improvements and restoration of premises to their original condition upon termination of leases at approximately 20 facilities; legal obligations to close approximately 90 brine supply, brine disposal, waste disposal, and hazardous waste injection wells and the related pipelines at the end of their useful lives; and decommissioning and decontamination obligations that are legally required to be fulfilled upon closure of approximately 25 of our manufacturing facilities.
	The following is a summary of the change in the carrying amount of the asset retirement obligations during 2013 and 2012, the net book value of assets related to the asset retirement obligations at December 31, 2013 and 2012 and the related depreciation expense recorded in 2013 and 2012:
	(In millions)	2013			2012
	Asset retirement obligation balance at beginning of year	$	20		$	21
	Loss on sale of discontinued operations(a)		(2	)		—
	Accretion expense/(benefit)—cost of goods sold(b)		3			(1	)
	Accretion expense—loss from discontinued operations(c)		—			2
	Payments		(5	)		(2	)
	Asset retirement obligation balance at end of year	$	16		$	20
	Net book value of asset retirement obligation assets at end of year	$	—		$	—
	Depreciation expense	$	—		$	—
	(a)
	Represents the transfer of liabilities of legal entities sold with the sale of our Consumer Products business.
	(b)
	The accretion expense from continuing operations in 2013 reflects the increase due to additional cleanup required at our Upton Road, Canada facility and the acceleration of obligations related to our facility in Droitwich, UK due to a planned shutdown in 2014. The net accretion benefit from continuing operations in 2012 includes the reversal of certain retirement obligations due to a reduction in the underlying cost estimate.
	(c)
	The accretion expense from discontinued operations for 2012 primarily reflects the acceleration of obligations related to the Antioxidant business facility in Pedrengo, Italy due to the shutdown in 2013.
	At December 31, 2013, $3 million of the asset retirement obligation balance was included in accrued expenses, $12 million was included in other liabilities and $1 million was included in liabilities held for sale in our Consolidated Balance Sheet. At December 31, 2012, $6 million of the asset retirement obligation balance was included in accrued expenses, $11 million was included in other liabilities and $3 million was included in current liabilities of discontinued operations in our Consolidated Balance Sheet.

EMERGENCE_FROM_CHAPTER_11

EMERGENCE FROM CHAPTER 11	12 Months Ended
	Dec. 31, 2013
EMERGENCE FROM CHAPTER 11	'
EMERGENCE FROM CHAPTER 11	'
	17) EMERGENCE FROM CHAPTER 11
	On March 18, 2009, Chemtura and 26 of our U.S. affiliates (collectively the "U.S. Debtors", or the "Debtors" when used in relation to matters before August 8, 2010) filed voluntary petitions for relief under Chapter 11 of Title 11 of the United States Code ("Chapter 11") in the Bankruptcy Court for the Southern District of New York (the "Bankruptcy Court").
	On August 8, 2010, our Canadian subsidiary, Chemtura Canada Co/Cie ("Chemtura Canada"), filed a voluntary petition for relief under Chapter 11. On August 11, 2010, Chemtura Canada commenced ancillary recognition proceedings under Part IV of the Companies' Creditors Arrangement Act (the "CCAA") in the Ontario Superior Court of Justice (the "Canadian Court" and such proceedings, the "Canadian Case"). The U.S. Debtors along with Chemtura Canada after it filed for Chapter 11 (collectively the "Debtors") requested the Bankruptcy Court to enter an order jointly administering Chemtura Canada's Chapter 11 case with the previously filed Chapter 11 cases and appoint Chemtura Canada as the "foreign representative" for the purposes of the Canadian Case. Such orders were granted on August 9, 2010. On August 11, 2010, the Canadian Court entered an order recognizing the Chapter 11 cases as "foreign proceedings" under the CCAA.
	On November 3, 2010, the Bankruptcy Court entered an order confirming the Debtors' plan of reorganization (the "Plan"). On November 10, 2010, (the "Effective Date"), the Debtors substantially consummated their reorganization through a series of transactions contemplated by the Plan and the Plan became effective. At the Effective Date, we determined that we did not meet the requirements under ASC Section 852-10-45 to adopt fresh start accounting because the reorganized value of our assets exceeded the carrying value of our liabilities. Fresh start accounting would have required us to record assets and liabilities at fair value at the Effective Date.
	The Plan provided for payment in full including interest in certain circumstances on all allowed claims and the establishment of several reserves for disputed claims as of the Effective Date. On May 4, 2012, the Bankruptcy Court entered an order disallowing and expunging the last disputed claims in the Chapter 11 cases. All disputed claims that were ultimately allowed by the Bankruptcy Court have been satisfied by payment from the disputed claims reserve established under the Plan. Under the Plan, on the Effective Date, holders of common stock issued before the Debtors filed for Chapter 11 ("Holders of Interests") received a distribution of new common stock in accordance with the Plan together with the potential right to receive supplemental distributions in certain circumstances. Since the Effective Date, four supplemental distributions were made to Holders of Interests, with the fourth and final supplemental distribution, which included all amounts remaining in the disputed claims reserves, having been made in July 2012.
	On January 31, 2013, the Bankruptcy Court granted Chemtura's motion to enforce the discharge injunction under the Plan against certain tort claimants. On February 7, 2013, the Bankruptcy Court entered a written order consistent with its ruling. On February 20, 2013, the claimants appealed the Bankruptcy Court's February 7, 2013 order. On February 10, 2014, the United States District Court for the Southern District of New York affirmed the Bankruptcy Court's order enforcing the discharge injunction under the Plan.
	As of December 31, 2013, the Bankruptcy Court has entered orders granting final decrees closing all of the Debtors' Chapter 11 cases except the Chapter 11 case of Chemtura Corporation.
	The reorganization items, net recorded in our Consolidated Statements of Operations relating to our Chapter 11 cases compromise the following:
	(In millions)	2013		2012		2011
	Professional fees and other	$	1	$	4		16
	Severance and closure costs(a)		—		—		1
	Claim settlements, net(b)		—		1		2
	Total reorganization items, net	$	1	$	5		19
	(a)
	Represents charges for cost savings initiatives for which Bankruptcy Court approval was obtained.
	(b)
	Represents the difference between the settlement amount of certain pre-petition obligations (which for obligations settled in new common stock is based on the fair value of our stock at the issuance date) and the corresponding carrying value of the recorded liabilities.

LEGAL_PROCEEDINGS_AND_CONTINGE

LEGAL PROCEEDINGS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2013
LEGAL PROCEEDINGS AND CONTINGENCIES	'
LEGAL PROCEEDINGS AND CONTINGENCIES	'
	18) LEGAL PROCEEDINGS AND CONTINGENCIES
	We are involved in claims, litigation, administrative proceedings and investigations of various types in a number of jurisdictions. A number of such matters involve, or may involve, claims for a material amount of damages and relate to or allege, among other things, environmental liabilities, including clean-up costs associated with hazardous waste disposal sites, natural resource damages, property damage and personal injury.
	Discharge of Litigation and Claims Under Chapter 11 Plan
	As a result of the Chapter 11 cases and pursuant to the Plan approved by the Bankruptcy Court, substantially all pre-petition litigation and claims against us and our subsidiaries that were Debtors in the Chapter 11 cases have been discharged and permanently enjoined from further prosecution.
	Claims and legal actions asserted against non-Debtors or relating to events occurring after the Effective Date, certain regulatory and administrative proceedings and certain contractual and other claims assumed with the authorization of the Bankruptcy Court, were not discharged in the Chapter 11 cases and are further described below.
	Litigation and Claims Not Discharged Under Chapter 11 Plan
	UK Pension Plan
	Chemtura Manufacturing UK Limited ("CMUK") is the principal employer of the Great Lakes UK Limited Pension Plan (the "UK Pension Plan"), an occupational pension scheme that was established in the UK to provide pensions and other benefits for
	its employees. Under the UK Pension Plan, certain employees and former employees are entitled to pension benefits, most of which are defined benefits in nature, based on pensionable salary. The UK Pension Plan has approximately 580 pensioners and 690 members entitled to deferred benefits under the defined benefit section. The estimated funding deficit of the UK Pension Plan as of December 31, 2008, as measured in accordance with Section 75 of the Pension Act of 1995 (UK), was approximately £95 million.
	In 2011, Chemtura Manufacturing UK Limited ("CMUK") entered into definitive agreements with the Trustees for the Great Lakes UK Limited Pension Plan (the "UK Pension Plan") which provide, among other things, for CMUK to make cash contributions of £60 million (approximately $95 million) in just over a three year period, with the initial contribution of £30 million ($49 million) made in the second quarter of 2011, the second contribution of £15 million ($24 million) made in the second quarter of 2012 and the third contribution of £8 million ($11 million) made in the second quarter of 2013. The final contribution of £8 million ($11 million) is expected to be made in the second quarter of 2014. The agreements also provided for the granting of both a security interest and a guarantee to support certain of the liabilities under the UK Pension Plan.
	There is also an evaluation being undertaken as to whether additional benefit obligations exist in connection with the equalization of certain benefits under the UK Pension Plan that occurred in the early 1990s. Based on the results of the evaluation in 2011, $8 million of expense was recorded in the fourth quarter of 2011, which may be subject to adjustment as further information is gathered as part of the evaluation. Additional information has been gathered and evaluated during the second quarter of 2013 and resulted in a reduction of the estimated liability from that originally estimated. Accordingly we recorded $2 million of income to SG&A in the second quarter of 2013. When we reach agreement with the trustees of the UK Pension Plan as to what additional benefit obligations exist, our UK subsidiary is required to make additional cash contributions to the UK Pension Plan.
	Environmental Liabilities
	As part of the Chapter 11 cases, under the Plan, the Debtors retained responsibility for environmental cleanup liabilities relating to currently owned or operated sites (i.e. sites that were part of the Debtors' estates) and, with certain exceptions, discharged or settled liabilities relating to formerly owned or operated sites (i.e., sites that were no longer part of the Debtors' estates) and third-party sites (i.e., sites that were never part of the Debtors' estates).
	We are involved in environmental matters of various types in a number of jurisdictions. A number of such matters involve claims for material amounts of damages and relate to or allege environmental liabilities, including clean-up costs associated with hazardous waste disposal sites and natural resource damages.
	The Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended ("CERCLA"), and comparable state statutes impose strict liability upon various classes of persons with respect to the costs associated with the investigation and remediation of waste disposal sites. Such persons are typically referred to as "Potentially Responsible Parties" or PRPs. Chemtura and several of our subsidiaries have been identified by federal, state or local governmental agencies or by other PRPs, as a PRP at various locations in the United States. Because in certain circumstances these laws have been construed to authorize the imposition of joint and several liability, the Environmental Protection Agency ("EPA") and comparable state agencies could seek to recover all costs involving a waste disposal site from any one of the PRPs for such site, including Chemtura, despite the involvement of other PRPs. In many cases, we are one of a large number of PRPs with respect to a site. In a few instances, we are the sole or one of only a handful of PRPs performing investigation and remediation. Where other financially responsible PRPs are involved, we expect that any ultimate liability resulting from such matters will be apportioned between us and such other parties. In addition, we are involved with environmental remediation and compliance activities at some of our current and former sites in the United States and abroad.
	Each quarter, we evaluate and review estimates for future remediation and other costs to determine appropriate environmental reserve amounts. For each site where the cost of remediation is probable and reasonably estimable, we determine the specific measures that are believed to be required to remediate the site, the estimated total cost to carry out the remediation plan, the portion of the total remediation costs to be borne by us and the anticipated time frame over which payments toward the remediation plan will occur. At sites where we expect to incur ongoing operation and maintenance expenditures, we accrue on an undiscounted basis for a period of generally 10 years those costs which we believe are probable and reasonably estimable.
	On September 17, 2012, our subsidiary Great Lakes Chemical Corporation received an enforcement notice from the United States Department of Justice acting on behalf of the Environmental Protection Agency ("EPA") which has alleged violations of a National Pollution Discharge Elimination System Permit issued under the Clean Water Act in conjunction with its facility in El Dorado, Arkansas. The EPA sought injunctive relief and civil penalties. We negotiated a consent decree with the EPA,
	including a penalty of less than $1 million, to resolve the alleged violations, which was paid on September 6, 2013 in full satisfaction of the decree.
	The total amount accrued for environmental liabilities as of December 31, 2013 and December 31, 2012, was $93 million and $84 million, respectively. At December 31, 2013 and December 31, 2012, $18 million and $15 million, respectively, of these environmental liabilities were reflected as accrued expenses and $75 million and $69 million, respectively, were reflected as other liabilities in our Consolidated Balance Sheets. We estimate that ongoing environmental liabilities could range up to $107 million at December 31, 2013. Our accruals for environmental liabilities include estimates for determinable clean-up costs. We recorded a pre-tax charge of $29 million in 2013, $7 million in 2012, and $6 million in 2011, to increase our environmental liabilities and made payments of $15 million in 2013, $12 million in 2012 and $37 million in 2011 (which included $27 million related to pre-petition liabilities) for clean-up costs, which reduced our environmental liabilities. At certain sites, we have contractual agreements with certain other parties to share remediation costs. As of December 31, 2013, no receivables are outstanding related to these agreements. At a number of these sites, the extent of contamination has not yet been fully investigated or the final scope of remediation is not yet determinable. We intend to assert all meritorious legal defenses and will pursue other equitable factors that are available with respect to these matters. However, the final cost of clean-up at these sites could exceed our present estimates, and could have, individually or in the aggregate, a material adverse effect on our financial condition, results of operations or cash flows. Our estimates for environmental remediation liabilities may change in the future should additional sites be identified, further remediation measures be required or undertaken, current laws and regulations be modified or additional environmental laws and regulations be enacted, and as negotiations with respect to certain sites.
	Other
	We are routinely subject to other civil claims, litigation and arbitration, and regulatory investigations, arising in the ordinary course of our business, as well as in respect of our divested businesses. Some of these claims and litigations relate to product liability claims, including claims related to our current and historic products and asbestos-related claims concerning premises and historic products of our corporate affiliates and predecessors. As discussed in Note 17, Emergence from Chapter 11, we were involved in an appeal of an order that we obtained from the Bankruptcy Court granting our motion to enforce the discharge injunction under the Plan against certain tort claimants. On February 10, 2014, the United States District Court for the Southern District of New York affirmed the Bankruptcy Court's order enforcing the discharge injunction under the Plan against certain tort claimants.
	However, we cannot be certain that an adverse outcome of one or more of these claims, to the extent not discharged in the Chapter 11 cases, would not have a material adverse effect on our financial condition, results of operations or cash flows.
	Guarantees
	In addition to the letters of credit of $14 million outstanding at December 31, 2013 and 2012, we have guarantees that have been provided to various financial institutions. At December 31, 2013 and 2012, we had $12 million in guarantees. The letters of credit and guarantees were primarily related to liabilities for insurance obligations, environmental obligations, banking and credit facilities, vendor deposits and European value added tax ("VAT") obligations.
	We have applied the disclosure provisions of ASC Topic 460, Guarantees ("ASC 460"), to our agreements that contain guarantee or indemnification clauses. We are a party to an agreement pursuant to which we may be obligated to indemnify a third party with respect to certain loan obligations of a joint venture company in which we had an equity interest. These obligations arose to provide initial financing for a joint venture start-up, fund an acquisition and/or provide project capital. Such obligations mature through May 2016. In the event that any of the joint venture companies were to default on these loan obligations, we would indemnify the other party up to its proportionate share of the obligation based upon its ownership interest in the joint venture. At December 31, 2013, the maximum potential future principal and interest payments due under these guarantees were $2 million. At December 31, 2012, the maximum potential future principal and interest payments due under these guarantees were $3 million. In accordance with ASC 460, we have accrued less than $1 million in reserves, which represents the fair value of these guarantees at December 31, 2013 and 2012. The reserve has been included in long-term liabilities on our Consolidated Balance Sheet at December 31, 2013 and 2012 with an offset to other assets.
	In addition, we have financing agreements with banks in Brazil for certain customers under which we receive funds from the banks at invoice date, and in turn, the customer agrees to pay the banks on the due date. We provide a full recourse guarantee to the banks in the event of customer non-payment.
	At December 31, 2013, unconditional purchase obligations primarily for commitments to purchase raw materials and tolling arrangements with outside vendors, amounted to $3 million (2014), $1 million (2015), $1 million (2016) and $5 million in the aggregate.
	In the ordinary course of business, we enter into contractual arrangements under which we may agree to indemnify a third party to such arrangement from any losses incurred relating to the services they perform on our behalf or for losses arising from certain events as defined within the particular contract, which may include, for example, litigation, claims or environmental matters relating to our past performance. For any losses that we believe are probable and estimable, we have accrued for such amounts in our Consolidated Balance Sheets.

BUSINESS_SEGMENTS

BUSINESS SEGMENTS	12 Months Ended
	Dec. 31, 2013
BUSINESS SEGMENTS	'
BUSINESS SEGMENTS	'
	19) BUSINESS SEGMENTS
	We evaluate a segment's performance based on several factors, of which the primary factor is operating income (loss). In computing operating income (loss) by segment, the following items have not been deducted: (1) general corporate expense; (2) amortization; (3) facility closures, severance and related costs; (4) gain (loss) on sale of business; (5) changes in estimates related to expected allowable claims; and (6) impairment charges. Pursuant to ASC Topic 280, Segment Reporting ("ASC 280"), these items have been excluded from our presentation of segment operating income (loss) because they are not reported to the chief operating decision maker for purposes of allocating resources among reporting segments or assessing segment performance.
	Industrial Performance Products
	Industrial Performance Products are engineered solutions for our customers' specialty chemical needs. Industrial Performance Products include petroleum additives that provide detergency, friction modification and corrosion protection in automotive lubricants, greases, refrigeration and turbine lubricants as well as synthetic lubricant base-stocks and greases; castable urethane prepolymers engineered to provide superior abrasion resistance and durability in many industrial and recreational applications; and polyurethane dispersions and urethane prepolymers used in various types of coatings such as clear floor finishes, high-gloss paints and textiles treatments. These products are sold directly to manufacturers and through distribution channels.
	Industrial Engineered Products
	Industrial Engineered Products are chemical additives designed to improve the performance of polymers in their end-use applications. Industrial Engineered Products include brominated performance products, flame retardants, fumigants and organometallics. The products are sold across the entire value chain ranging from direct sales to monomer producers, polymer manufacturers, compounders and fabricators, manufacturers of electronic components, fine chemical manufacturers, utilities, pharmaceutical manufacturers and oilfield service companies to industry distributors.
	Chemtura AgroSolutions
	Chemtura AgroSolutions develops, supplies, registers and sells agricultural chemicals formulated for specific crops in various geographic regions for the purpose of enhancing quality and improving yields. The business focuses on specific target markets in six major product lines: seed treatments, fungicides, miticides, insecticides, growth regulators and herbicides. These products are sold mainly to distributors and retailers in the agricultural sector.
	Corporate and Other Charges
	Corporate includes costs and expenses that are of a general corporate nature or managed on a corporate basis. These costs (net of allocations to the business segments) primarily represent corporate stewardship and administration activities together with costs associated with legacy activities and intangible asset amortization. Functional costs are allocated between the business segments and general corporate expense. Certain functional and other expenses that are managed company-wide that were allocated to the Antioxidant and Consumer Products businesses do not transfer directly under the sale agreements. As such, in historic periods these costs are shown as part of continuing operations in the corporate segment and not included under earnings (loss) from discontinued operations, net of tax. These costs approximate $20 million, $26 million and $30 million for 2013, 2012 and 2011, respectively. Additionally, our Corporate segment excludes $8 million, $14 million and $16 million for 2013, 2012 and 2011, respectively, of amortization expense related directly to our Antioxidant business and Consumer Product segment which has been included in earnings (loss) from discontinued operations, net of tax in our Consolidated Statement of Operations. Facility closures, severance and related costs are primarily for severance costs related to our cost savings initiatives. The gain on sale of business relates to the sale of our 50% interest in Tetrabrom Technologies Ltd. in 2011. Impairment charges primarily relate to the impairment of intangibles assets and property, plant and equipment that were no
	longer supportable in 2011. Change in estimates related to expected allowable claims relates to adjustments to resolve disputed claims.
	Corporate assets are principally cash and cash equivalents, intangible assets (including goodwill) and other assets (including deferred tax assets) maintained for general corporate purposes.
	Discontinued Operations
	Antioxidant Business
	In November 2012, we announced the sale of our Antioxidant business, which closed on April 30, 2013. As a result of entering into this transaction, the assets and liabilities included in the Antioxidant Sale have been presented as assets and liabilities of discontinued operations for comparative periods and earnings and direct costs associated with the Antioxidant business have been presented as earnings (loss) from discontinued operations, net of tax for current and comparative periods. The Antioxidant business was formerly included in the Industrial Performance Product segment.
	Consumer Products
	On October 10, 2013, we announced the sale of our investment in legal entities dedicated to the Consumer Products business, which closed on December 31, 2013. As a result of entering into this transaction, the underlying assets and liabilities of our investments in the legal entities sold have been presented as assets and liabilities of discontinued operations for comparative periods and earnings and direct costs associated with Consumer Products business have been presented as earnings (loss) from discontinued operations, net of tax in our Consolidated Statements of Operations for current and comparative periods.
	A summary of business data for our reportable segments for the years 2013, 2012 and 2011 is as follows:
	Information by Business Segment
	(In millions)
	Net Sales	2013			2012			2011
	Petroleum additives	$	689		$	600		$	634
	Urethanes		290			291			305
	Industrial Performance Products		979			891			939
	Bromine based & related products		639			730			688
	Organometallics		164			166			181
	Industrial Engineered Products		803			896			869
	Chemtura AgroSolutions		449			409			376
	Net Sales	$	2,231		$	2,196		$	2,184
	Operating Income	2013			2012			2011
	Industrial Performance Products	$	109		$	102		$	116
	Industrial Engineered Products		55			140			130
	Chemtura AgroSolutions		88			65			30
	Segment Operating Income		252			307			276
	General corporate expense		(97	)		(100	)		(105	)
	Amortization		(15	)		(16	)		(22	)
	Facility closures, severance and related costs		(42	)		(11	)		(3	)
	Gain on sale of business		—			—			27
	Impairment charges		—			—			(4	)
	Changes in estimates related to expected allowable claims		—			(1	)		(3	)
	Total Operating Income		98			179			166
	Interest expense		(60	)		(64	)		(63	)
	Loss on early extinguishment of debt		(50	)		(1	)		—
	Other income, net		9			20			1
	Reorganization items, net		(1	)		(5	)		(19	)
	(Loss) earnings from continuing operations before income taxes	$	(4	)	$	129		$	85
	Depreciation and Amortization	2013			2012			2011
	Industrial Performance Products	$	28		$	25		$	26
	Industrial Engineered Products		43			43			42
	Chemtura AgroSolutions		12			13			10
			83			81			78
	Corporate		18			19			25
	Total continuing operations		101			100			103
	Discontinued operations		22			39			37
		$	123		$	139		$	140
	Equity Income (Loss)	2013			2012			2011
	Industrial Performance Products	$	—		$	1		$	(1	)
	Industrial Engineered Products		(1	)		(2	)		2
	Chemtura AgroSolutions		1			(3	)		(2	)
	Total continuing operations		—			(4	)		(1	)
	Discontinued operations		2			7			4
		$	2		$	3		$	3
	Segment Assets	2013			2012			2011
Industrial Performance Products	$	591		$	514		$	491
Industrial Engineered Products		743			693			624
Chemtura AgroSolutions		285			319			326
		1,619			1,526			1,441
Discontinued operations		—			654			718
Corporate		1,085			850			696
	$	2,704		$	3,030		$	2,855
Capital Expenditures	2013			2012			2011
Industrial Performance Products	$	73		$	52		$	35
Industrial Engineered Products		73			69			98
Chemtura AgroSolutions		7			5			6
		153			126			139
Corporate		6			10			3
Total continuing operations		159			136			142
Discontinued operations		11			13			12
	$	170		$	149		$	154
Equity Method Investments	2013			2012			2011
Industrial Performance Products	$	7		$	10		$	8
Industrial Engineered Products		—			4			6
Chemtura AgroSolutions		6			24			28
	$	13		$	38		$	42
Information by Geographic Area
(In millions)
Net sales (based on location of customer)	2013			2012			2011
United States	$	944		$	878		$	840
Canada		42			39			40
Latin America		194			159			139
Europe/Africa		624			676			682
Asia/Pacific		427			444			483
	$	2,231		$	2,196		$	2,184
Property, Plant and Equipment	2013			2012			2011
United States	$	335		$	341		$	343
Canada		62			69			68
Latin America		14			15			15
Europe/Africa		217			188			158
Asia/Pacific		96			42			18
	$	724		$	655		$	602

GUARANTOR_CONDENSED_CONSOLIDAT

GUARANTOR CONDENSED CONSOLIDATING FINANCIAL DATA	12 Months Ended
	Dec. 31, 2013
GUARANTOR CONDENSED CONSOLIDATING FINANCIAL DATA	'
GUARANTOR CONDENSED CONSOLIDATING FINANCIAL DATA	'
	20) GUARANTOR CONDENSED CONSOLIDATING FINANCIAL DATA
	Our obligations under the 2018 Senior Notes and 2021 Senior Notes are fully and unconditionally guaranteed on a senior unsecured basis, jointly and severally, by each current and future domestic restricted subsidiary, other than excluded subsidiaries that guarantee any indebtedness of Chemtura or our restricted subsidiaries. Our subsidiaries that do not guarantee the 2018 Senior Notes and 2021 Senior Notes are referred to as the "Non-Guarantor Subsidiaries." The Guarantor Condensed Consolidating Financial Data presented below presents the statements of operations, statements of comprehensive income, balance sheets and statements of cash flow data for: (i) Chemtura Corporation (the "Parent Company"), the Guarantor Subsidiaries and the Non-Guarantor Subsidiaries on a consolidated basis (which is derived from Chemtura historical reported financial information); (ii) the Parent Company, alone (accounting for our Guarantor Subsidiaries and the Non-Guarantor Subsidiaries on an equity basis under which the investments are recorded by each entity owning a portion of another entity at cost, adjusted for the applicable share of the subsidiary's cumulative results of operations, capital contributions and distributions, and other equity changes); (iii) the Guarantor Subsidiaries alone; and (iv) the Non-Guarantor Subsidiaries alone.
	Condensed Consolidating Statement of Operations
	Year ended December 31, 2013
	(In millions)
		Consolidated			Eliminations			Parent			Guarantor			Non-Guarantor
								Company			Subsidiaries			Subsidiaries
	Net sales	$	2,231		$	(1,813	)	$	1,443		$	449		$	2,152
	Cost of goods sold		1,721			(1,813	)		1,235			389			1,910
	Selling, general and administrative		229			—			109			15			105
	Depreciation and amortization		101			—			29			35			37
	Research and development		40			—			15			8			17
	Facility closures, severance and related costs		42			—			21			1			20
	Operating income		98			—			34			1			63
	Interest expense		(60	)		—			(69	)		—			9
	Loss on early extinguishment of debt		(50	)		—			(50	)		—			—
	Other income (expense), net		9			—			(20	)		—			29
	Reorganization items, net		(1	)		—			(1	)		—			—
	Equity in net earnings of subsidiaries		—			(85	)		85			—			—
	(Loss) earnings from continuing operations before income taxes		(4	)		(85	)		(21	)		1			101
	Income tax expense		(18	)		—			—			—			(18	)
	(Loss) earnings from continuing operations		(22	)		(85	)		(21	)		1			83
	Earnings (loss) from discontinued operations, net of tax		25			—			(3	)		23			5
	(Loss) gain on sale of discontinued operations, net of tax		(180	)		—			(153	)		14			(41	)
	Net (loss) earnings attributable to Chemtura	$	(177	)	$	(85	)	$	(177	)	$	38		$	47
	Condensed Consolidating Statement of Comprehensive (Loss) Income
	As of December 31, 2013
	(In millions)
		Consolidated			Eliminations			Parent			Guarantor			Non-Guarantor
								Company			Subsidiaries			Subsidiaries
	Net (loss) earnings	$	(177	)	$	(85	)	$	(177	)	$	38		$	47
	Other comprehensive (loss) income, net of tax:
	Foreign currency translation adjustments		(60	)		—			(18	)		2			(44	)
	Unrecognized pension and other post-retirement benefit costs		208			—			202			—			6
	Comprehensive (loss) income attributable to Chemtura	$	(29	)	$	(85	)	$	7		$	40		$	9
	Condensed Consolidating Balance Sheet
	As of December 31, 2013
	(In millions)
		Consolidated			Eliminations			Parent			Guarantor			Non-Guarantor
								Company			Subsidiaries			Subsidiaries
	ASSETS
	Current assets	$	1,487		$	—		$	559		$	122		$	806
	Intercompany receivables		—			(7,671	)		2,681			2,349			2,641
	Investment in subsidiaries		—			(7,277	)		1,530			1,135			4,612
	Property, plant and equipment		724			—			121			214			389
	Goodwill		179			—			93			3			83
	Other assets		314			—			149			44			121
	Total assets	$	2,704		$	(14,948	)	$	5,133		$	3,867		$	8,652
	LIABILITIES AND STOCKHOLDERS' EQUITY
	Current liabilities	$	486		$	—		$	244		$	41		$	201
	Intercompany payables		—			(7,671	)		2,944			2,583			2,144
	Long-term debt		781			—			764			—			17
	Other long-term liabilities		438			—			182			52			204
	Total liabilities		1,705			(7,671	)		4,134			2,676			2,566
	Stockholders' equity		999			(7,277	)		999			1,191			6,086
	Total liabilities and stockholders' equity	$	2,704		$	(14,948	)	$	5,133		$	3,867		$	8,652
	Condensed Consolidating Statement of Cash Flows
	Year ended December 31, 2013
	(In millions)
		Consolidated			Eliminations			Parent			Guarantor			Non-Guarantor
								Company			Subsidiaries			Subsidiaries
	Increase (decrease) to cash
	CASH FLOWS FROM OPERATING ACTIVITIES
Net (loss) earnings	$	(177	)	$	(85	)	$	(177	)	$	38		$	47
Adjustments to reconcile net (loss) earnings to net cash provided by (used in) operations:
(Loss) gain on sale of discontinued operations		180			—			153			(14	)		41
Impairment charges		7			—			—			7			—
Reclass of translation adjustment from liquidated entities		(13	)		—			—			—			(13	)
Loss on early extinguishment of debt		50			—			50			—			—
Depreciation and amortization		123			—			33			45			45
Stock-based compensation expense		14			—			14			—			—
Equity income, net of cash received		(2	)		—			—			—			(2	)
Changes in assets and liabilities, net		(103	)		85			(84	)		(27	)		(77	)
Net cash provided by (used in) operations		79			—			(11	)		49			41
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from divestments, net		357			—			255			(2	)		104
Payments for acquisitions, net of cash acquired		(3	)		—			—			—			(3	)
Capital expenditures		(170	)		—			(20	)		(47	)		(103	)
Net cash provided by (used in) investing activities		184			—			235			(49	)		(2	)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from 2021 Senior Notes		450			—			450			—			—
Payments on 2018 Senior Notes, includes premium on tendering of notes		(396	)		—			(396	)		—			—
Payments on Term Loan		(102	)		—			(102	)		—			—
Proceeds from other long-term borrowings		31			—			7			—			24
Payments on other long-term borrowings		(4	)		—			(1	)					(3	)
Payments on short term borrowings, net		(1	)		—			—			—			(1	)
Payments for debt issuance costs		(12	)		—			(12	)		—			—
Common shares acquired		(54	)		—			(54	)		—			—
Proceeds from the exercise of stock options		8			—			8			—			—
Net cash (used in) provided by financing activities		(80	)		—			(100	)		—			20
CASH AND CASH EQUIVALENTS
Effect of exchange rates on cash and cash equivalents		1			—			—			—			1
Change in cash and cash equivalents		184			—			124			—			60
Cash and cash equivalents at beginning of year		365			—		$	193		$	—		$	172
Cash and cash equivalents at end of year	$	549		$	—		$	317		$	—		$	232
Condensed Consolidating Statement of Operations
Year ended December 31, 2012
(In millions)
	Consolidated			Eliminations			Parent			Guarantor			Non-Guarantor
							Company			Subsidiaries			Subsidiaries
Net sales	$	2,196		$	(1,623	)	$	1,477		$	454		$	1,888
Cost of goods sold		1,615			(1,623	)		1,192			383			1,663
Selling, general and administrative		245			—			120			17			108
Depreciation and amortization		100			—			27			44			29
Research and development		41			—			16			7			18
Facility closures, severance and related costs		11			—			8			—			3
Changes in estimates related to expected allowable claims		1			—			1			—			—
Equity loss		4			—			—			—			4
Operating income		179			—			113			3			63
Interest expense		(64	)		—			(69	)		2			3
Loss on early extinguishment of debt		(1	)		—			(1	)		—			—
Other income (expense), net		20			—			(17	)		—			37
Reorganization items, net		(5	)		—			(5	)		—			—
Equity in net earnings of subsidiaries		—			(81	)		81			—			—
Earnings from continuing operations before income taxes		129			(81	)		102			5			103
Income tax expense		(26	)		—			—			—			(26	)
Earnings from continuing operations		103			(81	)		102			5			77
(Loss) earnings from discontinued operations, net of tax		(3	)		—			(1	)		28			(30	)
Net earnings		100			(81	)		101			33			47
Less: net loss attributable to non-controlling interests		1			—			—			—			1
Net earnings attributable to Chemtura	$	101		$	(81	)	$	101		$	33		$	48
Condensed Consolidating Statement of Comprehensive Income
As of December 31, 2012
(In millions)
	Consolidated			Eliminations			Parent			Guarantor			Non-Guarantor
							Company			Subsidiaries			Subsidiaries
Net earnings	$	100		$	(81	)	$	101		$	33		$	47
Other comprehensive (loss) income, net of tax:
Foreign currency translation adjustments		(6	)		—			(11	)		1			4
Unrecognized pension and other post-retirement benefit costs		(76	)		—			(44	)		—			(32	)
Comprehensive income		18			(81	)		46			34			19
Comprehensive loss attributable to non-controlling interests		1			—			—			—			1
Comprehensive income attributable to Chemtura	$	19		$	(81	)	$	46		$	34		$	20
Condensed Consolidating Balance Sheet
As of December 31, 2012
(In millions)
	Consolidated			Eliminations			Parent			Guarantor			Non-Guarantor
							Company			Subsidiaries			Subsidiaries
ASSETS
Current assets	$	1,612		$	—		$	505		$	213		$	894
Intercompany receivables		—			(9,412	)		3,531			3,065			2,816
Investment in subsidiaries		—			(8,831	)		1,738			1,633			5,460
Property, plant and equipment		655			—			127			215			313
Goodwill		177			—			92			3			82
Other assets		586			—			131			233			222
Total assets	$	3,030		$	(18,243	)	$	6,124		$	5,362		$	9,787
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities	$	511		$	—		$	210		$	69		$	232
Intercompany payables		—			(9,412	)		3,676			3,305			2,431
Long-term debt		871			—			870			—			1
Other long-term liabilities		580			—			300			56			224
Total liabilities		1,962			(9,412	)		5,056			3,430			2,888
Stockholders' equity		1,068			(8,831	)		1,068			1,932			6,899
Total liabilities and stockholders' equity	$	3,030		$	(18,243	)	$	6,124		$	5,362		$	9,787
Condensed Consolidating Statement of Cash Flows
Year ended December 31, 2012
(In millions)
Increase (decrease) to cash	Consolidated			Eliminations			Parent			Guarantor			Non-Guarantor
							Company			Subsidiaries			Subsidiaries
CASH FLOWS FROM OPERATING ACTIVITIES
Net earnings	$	100		$	(81	)	$	101		$	33		$	47
Adjustments to reconcile net earnings to net cash provided by operations:
Impairment charges		47			—			12			—			35
Reclass of translation adjustment from liquidated entities		(21	)		—			—			—			(21	)
Loss on early extinguishment of debt		1			—			1			—			—
Depreciation and amortization		139			—			36			51			52
Stock-based compensation expense		24			—			24			—			—
Reorganization items, net		1			—			1			—			—
Changes in estimates related to expected allowable claims		1			—			1			—			—
Equity income		(3	)		—			—			—			(3	)
Changes in assets and liabilities, net		(71	)		81			(106	)		(37	)		(9	)
Net cash provided by operations		218			—			70			47			101
CASH FLOWS FROM INVESTING ACTIVITIES
Net proceeds from divestments		9			—			—			—			9
Capital expenditures		(149	)		—			(21	)		(47	)		(81	)
Net cash used in investing activities		(140	)		—			(21	)		(47	)		(72	)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from Term Loan		125			—			125			—			—
Payments on short term borrowings, net		(3	)		—			—			—			(3	)
Payments for debt issuance and refinancing costs		(2	)		—			(1	)		—			(1	)
Common shares acquired		(20	)		—			(20	)		—			—
Proceeds from exercise of stock options		5			—			5			—			—
Net cash provided by (used in) financing activities		105			—			109			—			(4	)
CASH AND CASH EQUIVALENTS
Effect of exchange rates on cash and cash equivalents		2			—			—			—			2
Change in cash and cash equivalents		185			—			158			—			27
Cash and cash equivalents at beginning of year		180			—			35			—			145
Cash and cash equivalents at end of year	$	365		$	—		$	193		$	—		$	172
Condensed Consolidating Statement of Operations
Year ended December 31, 2011
(In millions)
	Consolidated			Eliminations			Parent			Guarantor			Non-Guarantor
							Company			Subsidiaries			Subsidiaries
Net sales	$	2,184		$	(1,593	)	$	1,462		$	435		$	1,880
Cost of goods sold		1,626			(1,593	)		1,195			367			1,657
Selling, general and administrative		269			—			127			14			128
Depreciation and amortization		103			—			27			43			33
Research and development		36			—			16			5			15
Facility closures, severance and related costs		3			—			1			—			2
Gain on sale of business		(27	)		—			—			—			(27	)
Impairment charges		4			—			1			1			2
Changes in estimates related to expected allowable claims		3			—			3			—			—
Equity loss		1			—			1			—			—
Operating income		166			—			91			5			70
Interest expense		(63	)		—			(72	)		1			8
Other income (expense), net		1			—			(10	)		4			7
Reorganization items, net		(19	)		—			(19	)		—			—
Equity in net earnings (loss) of subsidiaries		—			(114	)		116			(2	)		—
Earnings from continuing operations before income taxes		85			(114	)		106			8			85
Income tax expense		(17	)		—			(4	)		—			(13	)
Earnings from continuing operations		68			(114	)		102			8			72
Earnings from discontinued operations, net of tax		52			—			17			17			18
Net earnings		120			(114	)		119			25			90
Less: net earnings attributable to non-controlling interests		(1	)		—			—			—			(1	)
Net earnings attributable to Chemtura	$	119		$	(114	)	$	119		$	25		$	89
Condensed Consolidating Statement of Comprehensive Income
As of December 31, 2011
(In millions)
	Consolidated			Eliminations			Parent			Guarantor			Non-Guarantor
							Company			Subsidiaries			Subsidiaries
Net earnings	$	120		$	(114	)	$	119		$	25		$	90
Other comprehensive (loss) income, net of tax:
Foreign currency translation adjustments		(35	)		—			11			(2	)		(44	)
Unrecognized pension and other post-retirement benefit costs		(35	)		—			(39	)		1			3
Comprehensive income		50			(114	)		91			24			49
Comprehensive income attributable to non-controlling interests		(1	)		—			—			—			(1	)
Comprehensive income attributable to Chemtura	$	49		$	(114	)	$	91		$	24		$	48
Condensed Consolidating Statement of Cash Flows
Year ended December 31, 2011
(In millions)
Increase (decrease) to cash	Consolidated			Eliminations			Parent			Guarantor			Non-Guarantor
							Company			Subsidiaries			Subsidiaries
CASH FLOWS FROM OPERATING ACTIVITIES
Net earnings	$	120		$	(114	)	$	119		$	25		$	90
Adjustments to reconcile net earnings to net cash provided by operations:
Gain on sale of business		(27	)		—			—			—			(27	)
Impairment charges		4			—			1			1			2
Depreciation and amortization		140			—			36			50			54
Stock-based compensation expense		26			—			26			—			—
Reorganization items, net		2			—			2			—			—
Changes in estimates related to expected allowable claims		3			—			3			—			—
Equity (income) loss		(3	)		—			1			—			(4	)
Changes in assets and liabilities, net		(83	)		114			(157	)		7			(47	)
Net cash provided by operations		182			—			31			83			68
CASH FLOWS FROM INVESTING ACTIVITIES
Net proceeds from divestments		8			—			8			—			—
Payments for acquisitions, net of cash acquired		(35	)		—			—			—			(35	)
Capital expenditures		(154	)		—			(24	)		(83	)		(47	)
Net cash used in investing activities		(181	)		—			(16	)		(83	)		(82	)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from other short term borrowings, net		3			—			—			—			3
Common shares acquired		(22	)		—			(22	)		—			—
Proceeds from exercise of stock options		1			—			1			—			—
Net cash (used in) provided by financing activities		(18	)		—			(21	)		—			3
CASH AND CASH EQUIVALENTS
Effect of exchange rates on cash and cash equivalents		(4	)		—			—			—			(4	)
Change in cash and cash equivalents		(21	)		—			(6	)		—			(15	)
Cash and cash equivalents at beginning of year		201			—			41			—			160
Cash and cash equivalents at end of year	$	180		$	—		$	35		$	—		$	145

SUMMARIZED_UNAUDITED_QUARTERLY

SUMMARIZED UNAUDITED QUARTERLY FINANCIAL DATA	12 Months Ended
	Dec. 31, 2013
SUMMARIZED UNAUDITED QUARTERLY FINANCIAL DATA	'
SUMMARIZED UNAUDITED QUARTERLY FINANCIAL DATA	'
	21) SUMMARIZED UNAUDITED QUARTERLY FINANCIAL DATA
		2013
	(In millions, except per share data)	First			Second			Third			Fourth
	Net sales	$	528		$	590		$	569		$	544
	Gross profit	$	110		$	146		$	121		$	133
	AMOUNTS ATTRIBUTABLE TO CHEMTURA COMMON SHAREHOLDERS:
	(Loss) earnings from continuing operations, net of tax	$	-18	(a)	$	27	(b)	$	-44	(c)	$	13	(d)
	(Loss) earnings from discontinued operations, net of tax		(5	)		26			7			(3	)
	Loss on sale of discontinued operations, net of tax		—			(146	)		(3	)		(31	)
	Net loss	$	(23	)	$	(93	)	$	(40	)	$	(21	)
	BASIC PER SHARE—ATTRIBUTABLE TO CHEMTURA (i):
	(Loss) earnings from continuing operations, net of tax	$	(0.18	)	$	0.27		$	(0.45	)	$	0.13
	(Loss) earnings from discontinued operations, net of tax		(0.05	)		0.26			0.07			(0.03	)
	Loss on sale of discontinued operations, net of tax		—			(1.48	)		(0.03	)		(0.32	)
	Net loss	$	(0.23	)	$	(0.95	)	$	(0.41	)	$	(0.22	)
	DILUTED PER SHARE—ATTRIBUTABLE TO CHEMTURA(i):
	(Loss) earnings from continuing operations, net of tax	$	(0.18	)	$	0.27		$	(0.45	)	$	0.13
	(Loss) earnings from discontinued operations, net of tax		(0.05	)		0.26			0.07			(0.03	)
	Loss on sale of discontinued operations, net of tax		—			(1.46	)		(0.03	)		(0.32	)
	Net loss	$	(0.23	)	$	(0.93	)	$	(0.41	)	$	(0.22	)
	Basic weighted-average shares outstanding		98.2			98.6			97.5			96.6
	Diluted weighted-average shares outstanding		98.2			99.7			97.5			98.1
		2012
		First			Second			Third			Fourth
	Net sales	$	534		$	583		$	546		$	533
	Gross profit	$	148		$	158		$	148		$	127
	AMOUNTS ATTRIBUTABLE TO CHEMTURA COMMON SHAREHOLDERS (i):
	Earnings from continuing operations, net of tax	$	28	(e)	$	34	(f)	$	22	(g)	$	19	(h)
	(Loss) earnings from discontinued operations, net of tax		(6	)		16			(13	)		1
	Net earnings	$	22		$	50		$	9		$	20
	BASIC AND DILUTED PER SHARE—ATTRIBUTABLE TO CHEMTURA (i):
	Earnings from continuing operations, net of tax	$	0.28		$	0.34		$	0.22		$	0.19
	(Loss) earnings from discontinued operations, net of tax		(0.06	)		0.16			(0.13	)		0.01
	Net earnings	$	0.22		$	0.5		$	0.09		$	0.2
	Basic weighted-average shares outstanding		98.3			98.9			97.9			97.9
	Diluted weighted-average shares outstanding		99.1			99.1			98.2			99
	(a)
	The earnings from continuing operations for the first quarter of 2013 included pre-tax charges for facility closures, severance and related costs of $14 million.
	(b)
	The earnings from continuing operations for the second quarter of 2013 included pre-tax charges for facility closures, severance and related costs of $11 million.
	(c)
	The earnings from continuing operations for the third quarter of 2013 included pre-tax charges for loss on early extinguishment of debt of $50 million and facility closures, severance and related costs of $3 million.
	(d)
	The earnings from continuing operations for the fourth quarter of 2013 included pre-tax charges for facility closures, severance and related costs of $14 million.
	(e)
	The earnings from continuing operations for the first quarter of 2012 included pre-tax charges for changes in estimates related to expected allowable claims of $2 million and reorganization items of $2 million.
	(f)
	The earnings from continuing operations for the second quarter of 2012 included pre-tax charges for facility closures, severance and related costs of $6 million.
	(g)
	The earnings from continuing operations for the third quarter of 2012 included pre-tax charges for facility closures, severance and related costs of $2 million.
	(h)
	The earnings from continuing operations for the fourth quarter of 2012 included a pre-tax charges for facility closures, severance and related costs of $3 million.
	(i)
	The sum of the earnings per common share for the four quarters may not equal the total earnings per common share for the full year due to quarterly changes in the average number of shares outstanding.

Schedule_II_Valuation_and_Qual

Schedule II Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2013
Schedule II Valuation and Qualifying Accounts	'
Schedule II Valuation and Qualifying Accounts	'
	Schedule II
	Valuation and Qualifying Accounts
	(In millions of dollars)
		Balance at		Additions		Deductions			Other			Balance at
		beginning		charged to								end of year
		of year		costs and
				expenses
	2013:00:00
	Allowance for doubtful accounts	$	11		2		-1	(a)		-1	(c)		11
	Reserve for customer rebates		14		36		-40	(b)		—			10
	2012:00:00
	Allowance for doubtful accounts	$	15		2		-6	(a)		—			11
	Reserve for customer rebates		14		8		-8	(b)		—			14
	2011:00:00
	Allowance for doubtful accounts	$	20		5		-10	(a)					15
	Reserve for customer rebates		14		28		-28	(b)		—			14
	(a)
	Primarily represents accounts written off as uncollectible (net of recoveries).
	(b)
	Primarily represents payment to the customers.
	(c)
	Primarily represents the translation effect of balances denominated in foreign currencies.

NATURE_OF_OPERATIONS_AND_SUMMA1

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2013
NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
Basis of Presentation	'
	Basis of Presentation
	The accompanying Consolidated Financial Statements include the accounts of Chemtura and our wholly-owned and majority-owned subsidiaries that we control. Other affiliates in which we have a 20% to 50% ownership interest or a non-controlling majority interest are accounted for in accordance with the equity method. Other investments in which we have less than 20% ownership are recorded at cost. All significant intercompany balances and transactions have been eliminated in consolidation.
	Our Consolidated Financial Statements have been prepared in conformity with U.S. generally accepted accounting principles ("GAAP"), which require us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.
	Certain prior year amounts have been reclassified to conform to the current year's presentation. These changes did not have a material impact on previously reported results of operations, cash flows or financial position.
	We operated as a debtor-in-possession ("DIP") under the protection of the United States Bankruptcy Court for the Southern District of New York (the "Bankruptcy Court") from March 18, 2009 (the "Petition Date") through November 10, 2010 (the "Effective Date"). From the Petition Date through the Effective Date, our Consolidated Financial Statements were prepared in accordance with Accounting Standards Codification ("ASC") Section 852-10-45, Reorganizations—Other Presentation Matters ("ASC 852-10-45") which requires that financial statements, for periods during the pendency of our voluntary petitions for relief under Chapter 11 of Title 11 of the United States Code (the "Chapter 11") filings, distinguish transactions and events that are directly associated with the reorganization from the ongoing operations of the business. Accordingly, certain income, expenses, realized gains and losses and expenses for losses that were realized or incurred in the Chapter 11 cases were recorded in Reorganization items, net in our Consolidated Statements of Operations. In connection with our emergence from Chapter 11 on November 10, 2010, we recorded certain "plan effect" adjustments to our Consolidated Financial Statements as of the Effective Date in order to reflect certain expenses of our plan of reorganization (the "Plan"). As of December 31, 2013, the Bankruptcy Court has entered orders granting final decrees closing all of the Debtors' Chapter 11 cases except the Chapter 11 case of Chemtura Corporation. See Note 17—Emergence from Chapter 11 for a further discussion.
Revenue Recognition	'
	Revenue Recognition
	Substantially all of our revenues are derived from the sale of products. Revenue is recognized when risk of loss and title to the product is transferred to the customer. Revenue is recorded net of taxes collected from customers that are remitted to governmental authorities with the collected taxes recorded as current liabilities until remitted to the respective governmental authorities. Our products are sold subject to various shipping terms. Our terms of delivery are included on our sales invoices and order confirmation documents.
Customer Rebates	'
	Customer Rebates
	We accrue for the estimated cost of customer rebates as a reduction of sales. Customer rebates are primarily based on customers achieving defined sales targets over a specified period of time. We estimate the cost of these rebates based on the likelihood of the rebate being achieved and recognize the cost as a deduction from sales when such sales are recognized. Rebate programs are monitored on a regular basis and adjusted as required. Our accruals for customer rebates were $10 million and $14 million at December 31, 2013 and 2012, respectively. Customer rebates are included as a reduction to accounts receivable on our Consolidated Balance Sheet.
Operating Costs and Expenses	'
	Operating Costs and Expenses
	Cost of goods sold ("COGS") includes all costs incurred in manufacturing goods, including raw materials, direct manufacturing costs and manufacturing overhead. COGS also includes warehousing, distribution, engineering, purchasing, customer service, environmental, health and safety functions, and shipping and handling costs for outbound product shipments. Selling, general and administrative ("SG&A") expenses include costs and expenses related to the following functions and activities: selling, advertising, legal, provision for doubtful accounts, corporate facilities and corporate administration. SG&A also includes accounting, information technology, finance and human resources, excluding direct support in manufacturing operations, which is included as COGS. Research and development ("R&D") expenses include basic and applied research and development activities of a technical and non-routine nature. R&D costs are expensed as incurred. COGS, SG&A and R&D expenses exclude depreciation and amortization expenses which are presented on a separate line in our Consolidated Statements of Operations.
Other Income (Expense), Net	'
	Other Income (Expense), Net
	Other income (expense), net includes:
	(In millions)	2013			2012			2011
	Foreign exchange loss	$	(7	)	$	(6	)	$	(2	)
	Interest income		3			5			3
	Release of cumulative foreign currency translation adjustments from liquidation of entities		13			21			—
		$	9		$	20		$	1
Allowance for doubtful accounts	'
	Allowance for Doubtful Accounts
	Included in accounts receivable are allowances for doubtful accounts in the amount of $11 million in 2013 and 2012. The allowance for doubtful accounts reflects a reserve representing our estimate of the amounts that may not be collectible. In addition to reviewing delinquent accounts receivable, we consider many factors in estimating our reserves, including historical data, experience, customer types, credit worthiness, and economic trends. From time to time, we may adjust our assumptions for anticipated changes in any of these or other factors expected to affect collection.
Inventory Valuation	'
	Inventory Valuation
	Inventories are valued at the lower of cost or market. Cost is determined using the first-in, first-out ("FIFO") method.
Property, Plant and Equipment	'
	Property, Plant and Equipment
	Property, plant and equipment are carried at cost, less accumulated depreciation. Depreciation expense is principally computed on the straight-line method using the following ranges of asset lives: land improvements—3 to 20 years; buildings and improvements—2 to 40 years; machinery and equipment—2 to 25 years; information systems and equipment—2 to 10 years; and furniture, fixtures and other—1 to 10 years. See Note 5—Property, Plant and Equipment for further information.
	Renewals and improvements that significantly extend the useful lives of the assets are capitalized. Capitalized leased assets and leasehold improvements are depreciated over the shorter of their useful lives or the remaining lease term. Expenditures for maintenance and repairs are charged to expense as incurred.
Intangible Assets	'
	Intangible Assets
	Patents, trademarks and other intangibles assets are being amortized principally on a straight-line basis using the following ranges for their estimated useful lives: patents—5 to 20 years; trademarks—6 to 40 years; customer relationships—15 to 30 years; production rights—10 years; and other intangibles—5 to 50 years. See Note 6—Goodwill and Intangible Assets for further information.
Recoverability of Long-Lived Assets and Goodwill	'
	Recoverability of Long-Lived Assets and Goodwill
	We evaluate the recoverability of the carrying value of long-lived assets, excluding goodwill, whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Under such circumstances, we assess whether the projected undiscounted cash flows of our long-lived assets are sufficient to recover the existing unamortized cost of our long-lived assets. If the undiscounted projected cash flows are not sufficient, we calculate the impairment amount by discounting the projected cash flows using our weighted-average cost of capital. The amount of the impairment is written off against earnings in the period in which the impairment is determined.
	We evaluate the recoverability of the carrying value of goodwill on an annual basis as of July 31, or when events occur or circumstances change. See Note 6—Goodwill and Intangible Assets for further details.
Income Taxes	'
	Income Taxes
	We account for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences of temporary differences between the carrying amounts and tax bases of assets and liabilities using enacted rates. The effect of a change in tax rates on deferred tax assets is recognized in income in the period that includes the enactment date.
	We recognize the financial statement effects of an uncertain income tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. We accrue for other tax contingencies when it is probable that a liability to a taxing authority has been incurred and the amount of the contingency can be reasonably estimated.
	Provision is made for taxes on undistributed earnings of foreign subsidiaries and related companies to the extent that such earnings are not deemed to be indefinitely reinvested.
Environmental Liabilities	'
	Environmental Liabilities
	Each quarter, we evaluate and review our estimates for future remediation, operation and management costs directly related to environmental remediation, to determine appropriate environmental reserve amounts. For each site where the cost of remediation is probable and reasonably estimable, we determine the specific measures that are believed to be required to remediate the site, the estimated total cost to carry out the remediation plan, the portion of the total remediation costs to be borne by us and the anticipated time frame over which payments to implement the remediation plan will occur. At sites where we expect to incur ongoing operations and maintenance expenditures, we accrue on an undiscounted basis, for a period of generally 10 years, those costs which are probable and reasonably estimable.
Litigation and Contingencies	'
	Litigation and Contingencies
	In accordance with guidance now codified under ASC Topic 450, Contingencies, we record in our Consolidated Financial Statements amounts representing our probable and reasonably estimable liability for claims, litigation and guarantees. As information about current or future litigation or other contingencies becomes available, management assesses whether such information warrants the recording of additional expenses relating to those contingencies. See Note 18—Legal Proceedings and Contingencies for further information.
Stock-Based Compensation	'
	Stock-Based Compensation
	We recognize compensation expense for stock-based awards issued over the requisite service period for each separately vesting tranche, as if multiple awards were granted. Stock-based compensation expense is measured at the date of grant, based on the fair value of the award. Stock-based compensation expense recognized was $14 million, $24 million, and $26 million for the years ended December 31, 2013, 2012 and 2011, respectively.
Translation of Foreign Currencies	'
	Translation of Foreign Currencies
	Balance sheet accounts denominated in foreign currencies are translated at the current rate of exchange as of the balance sheet date, while revenues and expenses are translated at average rates of exchange during the periods presented. The cumulative foreign currency adjustments resulting from such translation are included in accumulated other comprehensive loss. Upon complete or substantial liquidation of any of our subsidiaries, the value of the cumulative translation adjustment of such subsidiaries prior to their liquidation is reported in net earnings.
Cash Flows	'
	Cash Flows
	Cash and cash equivalents include bank term deposits with original maturities of three months or less.
	In 2012, we settled approximately $5 million in cash relating to our Chapter 11 cases. The $5 million paid in 2012, was paid from restricted cash. Additionally, in 2012 we issued approximately $26 million of common stock for the settlement of liabilities in accordance with the Plan.
	Cash payments included interest payments of $57 million in 2013, $58 million in 2012 and $57 million in 2011. Cash payments also included income tax payments, net of refunds of $21 million in 2013, $45 million in 2012 and $16 million in 2011.

NATURE_OF_OPERATIONS_AND_SUMMA2

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2013
NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
Schedule of other income (expense), net	'
	(In millions)	2013			2012			2011
	Foreign exchange loss	$	(7	)	$	(6	)	$	(2	)
	Interest income		3			5			3
	Release of cumulative foreign currency translation adjustments from liquidation of entities		13			21			—
		$	9		$	20		$	1

ACQUISITIONS_AND_DIVESTITURES_

ACQUISITIONS AND DIVESTITURES (Tables)	12 Months Ended
	Dec. 31, 2013
Divestitures	'
Schedule of Earnings (loss) from discontinued operations	'
		Year Ended
	(in millions)	2013			2013			2013			2012			2012			2012			2011			2011			2011
		Consumer			Antioxidant			Total			Consumer			Antioxidant			Total			Consumer			Antioxidant			Total
	Net Sales	$	408		$	123		$	531		$	433		$	387		$	820		$	422		$	419		$	841
	Earnings (loss) from discontinued operations:
	Pre-tax earnings (loss)	$	24		$	4		$	28		$	33		$	(45	)	$	(12	)	$	29		$	31		$	60
	Income tax (expense) benefit		(3	)		—			(3	)		(2	)		11			9			(3	)		(5	)		(8	)
	Earnings (loss), net of taxes		21			4			25			31			(34	)		(3	)		26			26			52
	Net loss (earnings) attributable to non-controlling interests		—			—			—			—			1			1			—			(1	)		(1	)
	Earnings (loss), net of taxes—attributable to Chemtura	$	21		$	4		$	25		$	31		$	(33	)	$	(2	)	$	26		$	25		$	51
	Loss on sale of discontinued operations:
	Pre-tax loss	$	(24	)	$	(164	)	$	(188	)
	Income tax (expense) benefit(a)		(1	)		9			8
	Net loss	$	(25	)	$	(155	)	$	(180	)
	(a)
	Income tax expense on the sale of our Consumer Products business is primarily a cash tax charge for estimated U.S. Federal alternative minimum tax and state taxes. Deferred taxes in our non-U.S. entities are included in the calculation of the pre-tax loss on sale. However, the reversal of deferred tax assets and liabilities of our U.S. entities are included in tax expense, reflecting the election made to treat the sale of stock of the U.S. legal entities in the transaction as a sale of assets. The reversal of these U.S. net deferred tax liabilities increased the value of our consolidated U.S. net deferred tax assets against which we provide a valuation allowance. The result was that there was no net deferred tax expense. The income tax benefit on the sale of our Antioxidant business is primarily related to the domestic tax impacts of the release of AOCL related to pensions that was not offset by a valuation allowance and reduced by tax expense in various foreign jurisdictions.
Schedule of functional and other expenses allocated to businesses that will not transfer directly under the sale agreements, and which is shown as part of continuing operations in the corporate segment	'
	(In millions)	2013			2012			2011
	Antioxidant	$	6		$	13		$	15
	Consumer Products		14			13			15
	Amortization expense(a)		(8	)		(14	)		(16	)
	Net increase in Corporate Segment	$	12		$	12		$	14
	(a)
	Our Corporate segment included amortization expense which related directly to the Antioxidant and Consumer Products businesses which is now included in earnings (loss) from discontinued operations, net of tax.
Consumer Divestiture	'
Divestitures	'
Summary of the assets and liabilities sold or settled and the assets and liabilities of discontinued operations	'
	(In millions)	December 31, 2013			2012
	Cash and cash equivalents	$	13		$	—
	Accounts receivable		55			60
	Inventories		64			70
	Current domestic tax assets reversed upon sale		7			7
	Other current assets, includes foreign deferred tax assets		8			12
	Property, plant and equipment		63			64
	Intangible assets, net		195			202
	Other assets		5			5
	Assets		410			420
	Accounts payable		16			23
	Accrued expenses		14			16
	Income taxes payable		—			4
	Pension and post-retirement health care liabilities		6			7
	Domestic tax liabilities reversed upon sale		44			43
	Other liabilities, includes foreign deferred tax liabilities		32			35
	Liabilities		112			128
	Net Assets	$	298		$	292
Schedule of reconciliation of adjusted cash proceeds to pre-tax loss on sale	'
	(In millions)	December 31, 2013
	Cash consideration	$	300
	Pre-closing working capital and other adjustments		(36	)
	Cash proceeds		264
	Less direct items:
	Net assets sold or settled, excluding domestic tax liabilities reversed upon sale and included in tax effect		335
	Transaction costs and other(1)		10
	Post-closing adjustments, obligations and other, net		(18	)
	Less non-cash items:
	Release of AOCL—Pension		5
	Release of AOCL—cumulative translation adjustment		(44	)
	Pre-tax loss on sale of discontinued operations	$	(24	)
	-1
	Transaction costs include legal fees and other direct costs incurred to sell the business since October 1, 2013.
Antioxidant and UV Stabilizers Divestiture	'
Divestitures	'
Summary of the assets and liabilities sold or settled and the assets and liabilities of discontinued operations	'
	(In millions)	April 30, 2013			2012
	Cash and cash equivalents	$	2		$	2
	Accounts and trade receivable		70			61
	Inventories		76			78
	Other current assets		2			4
	Property, plant and equipment		48			44
	Intangible assets, net		14			14
	Other assets		32			31
	Assets		244			234
	Accounts payable		39			29
	Accrued expenses		2			4
	Income taxes payable		—			1
	Pension and post-retirement health care liabilities		81			80
	Other liabilities		11			11
	Liabilities		133			125
	Net Assets	$	111		$	109
Schedule of reconciliation of adjusted cash proceeds to pre-tax loss on sale	'
	(In millions)	December 31, 2013
	Cash consideration	$	97
	Retained working capital and other adjustments		(10	)
	Post-closing adjustments		(2	)
	Cash proceeds		85
	Preferred stock		9
	Less direct items:
	Net assets sold or settled		111
	Transaction costs and other(1)		5
	Post-closing obligations and other, net		8
	Fair value of supply agreements		13
	Less non-cash items:
	Release of AOCL—pension		122
	Release of AOCL—cumulative translation adjustment		6
	Release of non-controlling interest		(7	)
	Pre-tax loss on sale of discontinued operations	$	(164	)
	-1
	Transaction costs include legal fees and other direct costs incurred to sell the business since April 1, 2013.

RESTRUCTURING_AND_ASSET_IMPAIR1

RESTRUCTURING AND ASSET IMPAIRMENT ACTIVITIES (Tables)	12 Months Ended
	Dec. 31, 2013
RESTRUCTURING AND ASSET IMPAIRMENT ACTIVITIES	'
Summary of changes in liabilities established for restructuring programs	'
	(In millions)	Severance and			Other Facility			Total
		Related Costs			Closure Costs
	Balance at January 1, 2011	$	1		$	—		$	1
	Facility closure, severance and related costs		3			—			3
	Cash payments		(3	)		—			(3	)
	Balance at December 31, 2011		1			—			1
	Facility closure, severance and related costs:
	Continuing operations		6			5			11
	Discontinued operations		6			—			6
	Cash payments		(5	)		(5	)		(10	)
	Balance at December 31, 2012		8			—			8
	Facility closure, severance and related costs:
	Continuing operations		27			15			42
	Discontinued operations		—			1			1
	Cash payments		(19	)		(14	)		(33	)
	Reclassifications		(2	)		—			(2	)
	Balance at December 31, 2013	$	14			2		$	16

INVENTORIES_Tables

INVENTORIES (Tables)	12 Months Ended
	Dec. 31, 2013
INVENTORIES	'
Components of inventories	'
	(In millions)	2013		2012
	Finished goods	$	288	$	280
	Work in process		34		27
	Raw materials and supplies		93		91
		$	415	$	398

PROPERTY_PLANT_AND_EQUIPMENT_T

PROPERTY, PLANT AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2013
PROPERTY, PLANT AND EQUIPMENT	'
Schedule of property, plant and equipment	'
	(In millions)	2013		2012
	Land and improvements	$	74	$	67
	Buildings and improvements		216		190
	Machinery and equipment		1,239		1,152
	Information systems and equipment		173		183
	Furniture, fixtures and other		29		28
	Construction in progress		94		108
			1,825		1,728
	Less: accumulated depreciation		1,101		1,073
		$	724	$	655

GOODWILL_AND_INTANGIBLE_ASSETS1

GOODWILL AND INTANGIBLE ASSETS (Tables)	12 Months Ended
	Dec. 31, 2013
GOODWILL AND INTANGIBLE ASSETS	'
Schedule of goodwill by reportable segment	'
		Industrial Performance Products
	(In millions)	Gross Goodwill		Accumulated Impairments			Net Goodwill
	Balance at December 31, 2011	$	264	$	(90	)	$	174
	Foreign currency translation		3		—			3
	Balance at December 31, 2012		267		(90	)		177
	Foreign currency translation		2		—			2
	Balance at December 31, 2013	$	269	$	(90	)	$	179
Schedule of intangible assets (excluding goodwill)	'
		2013							2012
	(In millions)	Gross		Accumulated			Net		Gross		Accumulated			Net
		Value		Amortization			Intangibles		Value		Amortization			Intangibles
	Patents	$	91	$	(52	)	$	39	$	85	$	(48	)	$	37
	Trademarks		68		(34	)		34		68		(31	)		37
	Customer relationships		42		(18	)		24		41		(15	)		26
	Production rights		46		(37	)		9		46		(32	)		14
	Other		81		(45	)		36		74		(42	)		32
	Total	$	328	$	(186	)	$	142	$	314	$	(168	)	$	146

DEBT_Tables

DEBT (Tables)	12 Months Ended
	Dec. 31, 2013
DEBT	'
Schedule of debt	'
	(In millions)	2013			2012
	5.75% Senior Notes due 2021, with an effective interest rate of 5.83% in 2013	$	450		$	—
	7.875% Senior Notes due 2018, net of unamortized discount of $1 million in 2013 and $3 million in 2012 with an effective interest rate of 8.90% in 2013 and 8.19% in 2012		100			452
	Term Loan due 2016, net of unamortized discount of $2 million in 2013 and 2012 with an effective interest rate of 5.39% in 2013 and 5.70% in 2012		316			418
	Other borrowings		32			6
	Total Debt		898			876
	Less: Short-term borrowings		(2	)		(3	)
	Less; Current portion of other long-term debt		(5	)		—
	Less: Current portion of Term Loan		(110	)		(2	)
	Total Long-Term Debt	$	781		$	871

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2013
INCOME TAXES	'
Schedule of (loss) earnings from continuing operations before income taxes and the income tax expense (benefit)	'
	(In millions)	2013			2012			2011
	Pre-tax (Loss) Earnings from Continuing Operations:
	Domestic	$	(105	)	$	26		$	(5	)
	Foreign		101			103			90
		$	(4	)	$	129		$	85
	Income Tax Expense (Benefit)
	Domestic
	Current	$	—		$	—		$	1
	Deferred		(1	)		—			3
			(1	)		—			4
	Foreign
	Current		17			23			22
	Deferred		2			3			(9	)
			19			26			13
	Total
	Current		17			23			23
	Deferred		1			3			(6	)
		$	18		$	26		$	17
Schedule of expense (benefit) for income taxes from continuing operations that differs from federal statutory rate	'
	(In millions)	2013			2012			2011
	Income tax (benefit) expense at the U.S. statutory rate	$	(1	)	$	45		$	30
	Foreign rate differential		(17	)		(4	)		(21	)
	Valuation allowances		21			(25	)		(11	)
	U.S. tax on foreign earnings		26			28			28
	Nondeductible reorganizational expenses		—			1			3
	Nondeductible expenses, other		7			2			1
	Nondeductible stock compensation		1			1			1
	Depletion		(3	)		(3	)		(2	)
	Income tax credits		(6	)		(18	)		(14	)
	Taxes attributable to prior periods		(11	)		(1	)		2
	Other, net		1			—			—
	Income tax expense	$	18		$	26		$	17
Schedule of components of the deferred tax assets and liabilities	'
	(In millions)	2013			2012
	Deferred tax assets:
	Pension and other post-retirement liabilities	$	61		$	151
	Net operating loss carryforwards		387			389
	Other accruals		15			23
	Tax credit carryforwards		128			99
	Accruals for environmental remediation		29			25
	Intangibles		5			11
	Inventories and other		20			21
	Financial instruments		1			2
	Total deferred tax assets		646			721
	Valuation allowance		(529	)		(628	)
	Net deferred tax assets after valuation allowance		117			93
	Deferred tax liabilities:
	Unremitted foreign earnings of subsidiaries		(36	)		(18	)
	Property, plant and equipment		(72	)		(64	)
	Other		(11	)		(11	)
	Total deferred tax liabilities		(119	)		(93	)
	Net deferred tax liability after valuation allowance	$	(2	)	$	—
Schedule of net current and non-current deferred taxes from each tax jurisdiction	'
	(In millions)	2013			2012
	Net current deferred taxes
	Other current assets	$	10		$	5
	Other current liabilities		(3	)		(15	)
	Net non-current deferred taxes
	Other assets		25			27
	Other liabilities		(34	)		(17	)
Schedule of components of gross net operating loss	'
	(In millions)	2013			2012
	Federal NOL	$	974		$	972
	State NOL	$	1,034		$	1,165
	Foreign NOL	$	141		$	109
Schedule of reconciliation of beginning and ending amount of unrecognized tax benefits	'
	(In millions)	2013			2012			2011
	Balance at January 1	$	41		$	46		$	41
	Gross (decreases) increases for tax positions taken during current year		(1	)		—			1
	Gross increases for tax positions taken during a prior period		1			3			13
	Gross decreases for tax positions taken during a prior period		—			(1	)		(5	)
	Decreases from the expiration of the statute of limitations		—			—			(1	)
	Settlements / payments		—			(10	)		(1	)
	Foreign currency impact		3			3			(2	)
	Balance at December 31	$	44		$	41		$	46

CAPITAL_STOCK_AND_EARNINGS_LOS1

CAPITAL STOCK AND EARNINGS (LOSS) PER COMMON SHARE (Tables)	12 Months Ended
	Dec. 31, 2013
CAPITAL STOCK AND EARNINGS (LOSS) PER COMMON SHARE	'
Schedule of reconciliation of the shares used in computation of earnings (loss) per share	'
		Year ended
	(In millions)	2013		2012		2011
	Weighted average shares outstanding—Basic		97.7		98.2		100.1
	Dilutive effect of common share equivalents		—		0.6		0.2
	Weighted average shares outstanding—Diluted		97.7		98.8		100.3

ACCUMULATED_OTHER_COMPREHENSIV1

ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)	12 Months Ended
	Dec. 31, 2013
ACCUMULATED OTHER COMPREHENSIVE LOSS	'
Schedule of components of accumulated other comprehensive loss ("AOCL"), net of tax	'
	(in millions)	Foreign			Unrecognized			Total
		Currency			Pension and
		Translation			Other Post-
		Adjustments			Retirement
					Benefit Costs
	As of December 31, 2012	$	47		$	(475	)	$	(428	)
	Other comprehensive (loss) income before reclassifications		(9	)		81			72
	Amounts reclassified from AOCL		(51	)		127			76
	Net current period other comprehensive (loss) income		(60	)		208			148
	As of December 31, 2013	$	(13	)	$	(267	)	$	(280	)
Summary of reclassifications from AOCL to the Condensed Consolidated Statement of Operations	'
	(in millions)	Amount Reclassified			Affected line item in the consolidated
		from AOCL			statement of operations
	Foreign currency translation items:
	Liquidation of consolidated entities	$	13		Other income, net
	Sale of discontinued operations(b)		38		Loss on sale of discontinued operations, net of tax
	Net of tax		51
	Defined benefit pension plan items:
	Amortization of prior-service costs(a)		5		See Note (a)
	Amortization of actuarial losses(a)		(21	)	See Note (a)
	Sale of discontinued operations(b)		(127	)	Loss on sale of discontinued operations, net of tax
	Total before tax		(143	)
	Tax on continuing operations		1		Income Tax Expense
	Tax on discontinued operations		15		Loss on sale of discontinued operations, net of tax
	Total tax		16
	Net of tax		(127	)
	Total reclassifications	$	(76	)
	(a)
	These items are included in the computation of net periodic benefit pension cost (see Note 13—Pension and Other Post-Retirement Plans for additional information).
	(b)
	Sale of the Antioxidant and Consumer Products businesses (see Note 2—Acquisitions and Divestitures)

STOCK_INCENTIVE_PLANS_Tables

STOCK INCENTIVE PLANS (Tables)	12 Months Ended
	Dec. 31, 2013
STOCK INCENTIVE PLANS	'
Schedule of weighted average assumptions	'
		Year Ended
		December 31,
		2013			2012			2011
	Dividend yield		0	%		0	%		0	%
	Expected volatility		51	%		56.7	%		53.8	%
	Risk-free interest rate		1	%		1.2	%		2.5	%
	Expected life (in years)		6			6			6
Summary of stock option activities	'
		Price Per Share						Weighted
								Average
								Remaining			Aggregate
								Contractual			Intrinsic
					Shares			Life			Value
		Average			(in millions)						(in millions)
	Outstanding at 1/1/11	$	15.5			0.8
	Granted		16.03			2.2
	Lapsed		15.91			(0.2	)
	Outstanding at 12/31/11		15.9			2.8			9.1		$	—
	Granted		15.39			0.8
	Exercised		15.77			(0.3	)					1
	Lapsed		15.76			(0.2	)
	Outstanding at 12/31/12		15.79			3.1			8.3			17
	Granted		20.5			0.4
	Exercised		15.83			(0.5	)					4
	Lapsed		16.78			(0.2	)
	Outstanding at 12/31/13	$	16.46			2.8			7.4			32
	Exercisable at 12/31/11	$	15.68			0.7
	Exercisable at 12/31/12	$	15.81			1.3
	Exercisable at 12/31/13	$	15.83			1.7			6.9		$	20
Schedule of RSUs award activity	'
		Shares			Weighted			Aggregate
		(in millions)			Average			Fair Value
					Grant Date			(in millions)
					Fair Value
	Unvested RSU awards, January 1, 2011		0.3		$	15.5
	Canceled		(0.1	)		15.97
	Granted		1			16
	Vested		(0.3	)		15.74		$	5
	Unvested RSU awards, December 31, 2011		0.9			15.91			10
	Cancelled		(0.1	)		18.04
	Granted		1.5			17.72
	Vested		(1.0	)		15.93			17
	Unvested RSU awards, December 31, 2012		1.3			17.85			27
	Cancelled		(0.2	)		20.21
	Granted		0.4			23.18
	Vested		(0.5	)		16.07			8
	Unvested RSU awards, December 31, 2013		1		$	20.53		$	30

PENSION_AND_OTHER_POSTRETIREME1

PENSION AND OTHER POST-RETIREMENT PLANS (Tables)	12 Months Ended
	Dec. 31, 2013
PENSION AND OTHER POST-RETIREMENT PLANS	'
Schedule of benefit obligation and weighted-average assumptions used	'
		Defined Benefit Pension Plans
		Qualified						International and						Post-Retirement
		Domestic Plans						Non-Qualified						Health Care
								Plans						Plans
	(In millions)	2013			2012			2013			2012			2013			2012
	Change in projected benefit obligation:
	Projected benefit obligation at beginning of year	$	1,040		$	971		$	499		$	420		$	124		$	116
	Service cost		—			1			3			3			—			1
	Interest cost		30			43			19			21			4			5
	Plan participants' contributions		—			—			1			—			—			—
	Actuarial (gains) losses		(69	)		86			11			58			(20	)		5
	Benefits paid		(51	)		(61	)		(19	)		(19	)		(10	)		(12	)
	Plan amendments		—			—			—			—			—			8
	Business divestitures(a)		(327	)		—			—			—			—			—
	Settlements		—			—			(6	)		(1	)		—			—
	Foreign currency exchange rate changes		—			—			11			17			(2	)		1
	Projected benefit obligation at end of year	$	623		$	1,040		$	519		$	499		$	96		$	124
	Accumulated benefit obligation at end of year	$	622		$	1,039		$	506		$	490
	Weighted-average year-end assumptions used to determine benefit obligations:
	Discount rate		4.6	%		3.8	%		4.18	%		4.03	%		4.35	%		3.56	%
	Rate of compensation increase		3	%		3	%		2.85	%		2.77	%		N/A			N/A
	Health care cost trend rate														6.27	%		6.47	%
	(a)
	Business divestitures includes the transfer of $315 million of projected benefit obligations with the sale of our Antioxidants business in April 2013 and $12 million with the sale of our Consumer Products business in December 2013.
Schedule of changes in fair value of plan assets	'
		Defined Benefit Pension Plans
		Qualified						International and						Post-Retirement
		Domestic Plans						Non-Qualified						Health Care
								Plans						Plans
	(In millions)	2013			2012			2013			2012			2013			2012
	Change in plan assets:
	Fair value of plan assets at beginning of year	$	814		$	737		$	370		$	306		$	—		$	—
	Actual return on plan assets		51			98			30			29			—			—
	Employer contributions		20			40			27			39			10			12
	Plan participants' contributions		—			—			1			—			—			—
	Benefits paid		(51	)		(61	)		(19	)		(19	)		(10	)		(12	)
	Business divestitures(a)		(239	)		—			—			—			—			—
	Settlements		—			—			(6	)		—			—			—
	Foreign currency exchange rate changes		—			—			5			15			—			—
	Fair value of plan assets at end of year	$	595		$	814		$	408		$	370		$	—		$	—
	(a)
	Business divestitures includes the transfer of $233 million of plan assets with the sale of our Antioxidants business in April 2013 and $6 million of plan assets with the sale of our Consumer Products business in December 2013.
Schedule of fair values of defined benefit pension plan assets, by asset category	'
		Fair Value Measurements at December 31, 2013
		Defined Benefit Pension Plans
		Qualified Domestic Plans												International and Non-Qualified Plans
	(In millions)	Total			Quoted Prices			Significant			Significant			Total			Quoted Prices			Significant			Significant
					in Active			Observable			Unobservable						in Active			Observable			Unobservable
					Markets for			Inputs			Inputs						Markets for			Inputs			Inputs
					Identical			(Level 2)			(Level 3)						Identical			(Level 2)			(Level 3)
					Assets												Assets
					(Level 1)												(Level 1)
	Equity securities:
	Pooled equity(a)	$	141		$	141		$	—		$	—		$	146		$	12		$	134		$	—
	Fixed income securities:
	U.S. government bonds(b)		71			—			71			—			—			—			—			—
	International government bonds(b)		—			—			—			—			2			—			2			—
	U.S. corporate bonds(c)		—			—			—			—			—			—			—			—
	Pooled fixed income funds(d)		287			287			—			—			247			—			243			4
	Alternative collective funds(e)		91			—			—			91			—			—			—			—
	Other instruments(f)		1			1			—			—			11			—			—			11
	Cash & cash equivalents		4			4			—			—			2			2			—			—
		$	595		$	433		$	71		$	91		$	408		$	14		$	379		$	15
		Fair Value Measurements at December 31, 2012
		Defined Benefit Pension Plans
		Qualified Domestic Plans												International and Non-Qualified Plans
	(in millions)	Total			Quoted Prices			Significant			Significant			Total			Quoted Prices			Significant			Significant
					in Active			Observable			Unobservable						in Active			Observable			Unobservable
					Markets for			Inputs			Inputs						Markets for			Inputs			Inputs
					Identical			(Level 2)			(Level 3)						Identical			(Level 2)			(Level 3)
					Assets												Assets
					(Level 1)												(Level 1)
	Equity securities:
	Pooled equity(a)	$	288		$	288		$	—		$	—		$	168		$	25		$	143		$	—
	Fixed income securities:
	U.S. government bonds(b)		74			—			74			—			—			—			—			—
	International government bonds(b)		—			—			—			—			62			—			62			—
	U.S. corporate bonds(c)		—			—			—			—			1			—			1			—
	Pooled fixed income funds(e)		331			331			—			—			131			—			131			—
	Alternative collective funds(e)		120			—			—			120			—			—			—			—
	Other instruments(f)		1			1			—			—			7			—			—			7
	Cash & cash equivalents		—			—			—			—			1			1			—			—
		$	814		$	620		$	74		$	120		$	370		$	26		$	337		$	7
	(a)
	Pooled equity funds include mutual and collective funds that invest primarily in marketable equity securities of various sized companies in a diverse set of industries in various regions of the world. Shares of publicly traded mutual funds are valued at the closing price reported on the U.S. and international exchanges where the underlying securities are actively traded. Units of collective funds are valued at the per unit value determined by the fund manager, which is based on market price of the underlying securities.
	(b)
	U.S. and international government bonds include U.S. treasury, municipal and agency obligations and international government debt. Such instruments are valued at quoted market prices for those instruments or on institutional bid valuations. The decrease in the value of the international bonds is primarily due to changing the investment manager of our UK plans and shifting assets into pooled fixed income funds in 2013.
	(c)
	U.S. and international corporate bonds are from a diverse set of industries and regions. Such instruments are valued using similar securities in active markets and observable data or broker or dealer quotations.
	(d)
	Pooled fixed income funds are fixed income funds that invest primarily in corporate and government bonds. Such instruments are valued using similar securities in active markets and observable data or broker or dealer quotations. The increase in the value of the pooled fixed income funds of our international plans includes the transfer of assets in from international bonds as noted in (b).
	(e)
	Alternative collective funds include funds that invest mainly in asset backed securities, real estate funds, hedge funds and other alternative investments. The underlying funds are valued based on the net asset values of the investments as determined by the respective individual fund administrators on a daily, weekly or monthly basis depending on the fund. Such valuations are reviewed by the portfolio managers who determine the value of collective funds based on these inputs. Certain of these funds have lock up periods and all of them have notification periods. Due to the process used to value these funds and the restricted trading, we have categorized these funds as level 3.
	(f)
	Other instruments include primarily annuities and real estate funds instruments for which there are significant unobservable inputs and therefore have been classified as level 3.
		Alternative			Other			Total Level 3
		Collective Funds			Instruments			Investments
	Balance at December 31, 2012	$	120		$	7		$	127
	Transfers to/(from) Level 3(a)		(39	)		8			(31	)
	Realized gains		1			—			1
	Unrealized gains		9			1			10
	Disbursements		—			(1	)		(1	)
	Balance at December 31, 2013	$	91		$	15		$	106
	(a)
	Transfers from the alternative collective funds in 2013 are due to the U.S. plan transferring assets from these funds into other SEI level 1 and level 2 funds.
Schedule of investments transferred into pooled equity and fixed income funds due to the change in asset management	'
		Alternative			Other			Total Level 3
		Collective Funds			Instruments			Investments
	Balance at December 31, 2012	$	120		$	7		$	127
	Transfers to/(from) Level 3(a)		(39	)		8			(31	)
	Realized gains		1			—			1
	Unrealized gains		9			1			10
	Disbursements		—			(1	)		(1	)
	Balance at December 31, 2013	$	91		$	15		$	106
	(a)
	Transfers from the alternative collective funds in 2013 are due to the U.S. plan transferring assets from these funds into other SEI level 1 and level 2 funds.
Schedule of funded status and related amounts recognized on statement of financial condition	'
		Defined Benefit Pension Plans
		Qualified						International and						Post-Retirement
		Domestic Plans						Non-Qualified						Health Care
								Plans						Plans
	(In millions)	2013			2012			2013			2012			2013			2012
	Funded status, end of year:
	Fair value of plan assets	$	595		$	814		$	408		$	370		$	—		$	—
	Benefit obligations		623			1,040			519			499			96			124
	Net amount recognized	$	(28	)	$	(226	)	$	(111	)	$	(129	)	$	(96	)	$	(124	)
	Amounts recognized in the Consolidated Balance Sheets at the end of year consist of:
	Noncurrent assets	$	—		$	—		$	30		$	13		$	—		$	—
	Current liability		—			—			(9	)		(8	)		(9	)		(11	)
	Noncurrent liability		(28	)		(139	)		(132	)		(134	)		(87	)		(113	)
	Liabilities of discontinued operations(a)		—			(87	)		—			—			—			—
	Net amount recognized	$	(28	)	$	(226	)	$	(111	)	$	(129	)	$	(96	)	$	(124	)
	Amounts recognized in accumulated other comprehensive loss consist of:
	Net actuarial loss/(gain)	$	219		$	427		$	120		$	121		$	31		$	54
	Prior service cost/(credit)		—			1			—			1			(40	)		(45	)
		$	219		$	428		$	120		$	122		$	(9	)	$	9
	(a)
	Liabilities of discontinued operations at December 31, 2012 included estimated net pension liabilities of $80 million related to our Antioxidants business and $7 million related to our Consumer Products business. The actuarial valuation of those net pension liabilities were completed upon closing of the transactions and resulted in the transfer of $82 million upon closing the sale of our Antioxidants business in April 2013 and $6 million upon closing the sale of Consumer Products in December 2013. See Note 2—Acquisitions and Divestitures for additional information related to these transactions.
Schedule of estimated amounts that will be amortized from AOCL into net periodic benefit cost (credit) in next fiscal year	'
	(In millions)	Qualified			International			Post-Retirement
		Domestic			and			Health Care
		Plans			Non-Qualified			Plans
					Plans
	Actuarial loss	$	10		$	5		$	2
	Prior service credit		—			—			(5	)
	Total amortization cost (credit)	$	10		$	5		$	(3	)
Schedule of projected benefit obligation in excess of plan assets	'
	(In millions)	2013			2012
	Projected benefit obligation in excess of plan assets at end of year:
	Projected benefit obligation	$	876		$	1,378
	Fair value of plan assets		612			887
Schedule of accumulated benefit obligation in excess of plan assets	'
	(In millions)	2013			2012
	Accumulated benefit obligation in excess of plan assets at end of year:
	Projected benefit obligation	$	778		$	1,225
	Accumulated benefit obligation		777			1,223
	Fair value of plan assets		611			859
Schedule of expected employer contributions and expected benefit payments	'
		Defined Benefit
		Pension Plans
	(in millions)	Qualified			International			Post-Retirement
		Domestic			and			Health Care
		Plans			Non-Qualified			Plans
					Plans
	Expected Employer Contributions:(a)
	2014	$	—		$	17		$	9
	Expected Benefit Payments(b):
	2014		46			23			9
	2015		46			23			9
	2016		45			24			8
	2017		45			25			8
	2018		45			26			8
	2019 - 2023		214			134			32
	(a)
	The expected employer contributions reflect the minimum required by law or contractual obligation. We may elect to make additional discretionary contributions as deemed appropriate consistent with past practice.
	(b)
	The expected benefit payments are based on the same assumptions used to measure our benefit obligation at the end of the year and include benefits attributable to estimated future employee service.
Schedule of components of net periodic benefit cost (credit) and weighted-average assumptions used to determine net cost	'
		Defined Benefit Pension Plans
		Qualified									International and									Post-Retirement
		Domestic Plans(a)									Non-Qualified Plans									Health Care Plans
	(In millions)	2013			2012			2011			2013			2012			2011			2013			2012			2011
	Components of net periodic benefit cost (credit):
	Service cost	$	—		$	1		$	1		$	3		$	3		$	3		$	—		$	1		$	1
	Interest cost		30			43			46			20			21			22			4			5			5
	Expected return on plan assets		(45	)		(54	)		(56	)		(23	)		(22	)		(18	)		—			—			—
	Amortization of prior service cost		—			—			—			—			—			—			(5	)		(6	)		(6	)
	Recognized actuarial losses		14			14			12			5			2			2			2			3			2
	Curtailment loss recognized		—			—			—			1			—			—			—			—			—
	Settlement loss recognized(b)		32			—			—			—			—			—			—			—			—
	Net periodic benefit cost	$	31		$	4		$	3		$	6		$	4		$	9		$	1		$	3		$	2
	(a)
	The net periodic benefit cost, excluding the settlement loss recognized, for the years ended December 31, 2013, 2012 and 2011 include pension expense related to the earnings (loss) from discontinued operations of $1 million, $2 million and $2 million, respectively.
	(b)
	The settlement loss recognized in 2013 includes a loss of $40 million related to the divestiture of our Antioxidants business in April 2013 (included in loss on sale of discontinued operations), partly offset by a $2 million gain related to the divestiture of our Consumer Products business (included in loss on sale of discontinued operations) and a $6 million gain related to an adjustment for a legacy pension plan ($2 million included in SG&A and $4 million in loss from discontinued operations).
		2013			2012			2011			2013			2012			2011			2013			2012			2011
	Weighted-average assumptions used to determine net cost:
	Discount rate		3.8	%		4.6	%		5.1	%		3.89	%		4.64	%		5.14	%		3.71	%		4.15	%		5.14	%
	Expected return on plan assets		7.5	%		7.5	%		7.75	%		6.53	%		6.71	%		6.8	%
	Rate of compensation increase		3	%		4	%		4	%		2.77	%		3.22	%		3.34	%

FINANCIAL_INSTRUMENTS_AND_FAIR1

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
	Dec. 31, 2013
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS	'
Schedule of the carrying amounts and estimated fair values of material financial instruments	'
		2013				2012
	(In millions)	Carrying		Fair		Carrying		Fair
		Amount		Value		Amount		Value
	Total debt	$	898	$	916	$	876	$	920

ASSET_RETIREMENT_OBLIGATIONS_T

ASSET RETIREMENT OBLIGATIONS (Tables)	12 Months Ended
	Dec. 31, 2013
ASSET RETIREMENT OBLIGATIONS	'
Summary of the change in the carrying amount of the asset retirement obligations and the net book value of assets	'
	(In millions)	2013			2012
	Asset retirement obligation balance at beginning of year	$	20		$	21
	Loss on sale of discontinued operations(a)		(2	)		—
	Accretion expense/(benefit)—cost of goods sold(b)		3			(1	)
	Accretion expense—loss from discontinued operations(c)		—			2
	Payments		(5	)		(2	)
	Asset retirement obligation balance at end of year	$	16		$	20
	Net book value of asset retirement obligation assets at end of year	$	—		$	—
	Depreciation expense	$	—		$	—
	(a)
	Represents the transfer of liabilities of legal entities sold with the sale of our Consumer Products business.
	(b)
	The accretion expense from continuing operations in 2013 reflects the increase due to additional cleanup required at our Upton Road, Canada facility and the acceleration of obligations related to our facility in Droitwich, UK due to a planned shutdown in 2014. The net accretion benefit from continuing operations in 2012 includes the reversal of certain retirement obligations due to a reduction in the underlying cost estimate.
	(c)
	The accretion expense from discontinued operations for 2012 primarily reflects the acceleration of obligations related to the Antioxidant business facility in Pedrengo, Italy due to the shutdown in 2013.

EMERGENCE_FROM_CHAPTER_11_Tabl

EMERGENCE FROM CHAPTER 11 (Tables)	12 Months Ended
	Dec. 31, 2013
EMERGENCE FROM CHAPTER 11	'
Schedule of reorganization items related to Chapter 11 cases	'
	(In millions)	2013		2012		2011
	Professional fees and other	$	1	$	4		16
	Severance and closure costs(a)		—		—		1
	Claim settlements, net(b)		—		1		2
	Total reorganization items, net	$	1	$	5		19
	(a)
	Represents charges for cost savings initiatives for which Bankruptcy Court approval was obtained.
	(b)
	Represents the difference between the settlement amount of certain pre-petition obligations (which for obligations settled in new common stock is based on the fair value of our stock at the issuance date) and the corresponding carrying value of the recorded liabilities.

BUSINESS_SEGMENTS_Tables

BUSINESS SEGMENTS (Tables)	12 Months Ended
	Dec. 31, 2013
BUSINESS SEGMENTS	'
Summary of revenue and operating profit for reportable segments	'
	(In millions)
	Net Sales	2013			2012			2011
	Petroleum additives	$	689		$	600		$	634
	Urethanes		290			291			305
	Industrial Performance Products		979			891			939
	Bromine based & related products		639			730			688
	Organometallics		164			166			181
	Industrial Engineered Products		803			896			869
	Chemtura AgroSolutions		449			409			376
	Net Sales	$	2,231		$	2,196		$	2,184
	Operating Income	2013			2012			2011
	Industrial Performance Products	$	109		$	102		$	116
	Industrial Engineered Products		55			140			130
	Chemtura AgroSolutions		88			65			30
	Segment Operating Income		252			307			276
	General corporate expense		(97	)		(100	)		(105	)
	Amortization		(15	)		(16	)		(22	)
	Facility closures, severance and related costs		(42	)		(11	)		(3	)
	Gain on sale of business		—			—			27
	Impairment charges		—			—			(4	)
	Changes in estimates related to expected allowable claims		—			(1	)		(3	)
	Total Operating Income		98			179			166
	Interest expense		(60	)		(64	)		(63	)
	Loss on early extinguishment of debt		(50	)		(1	)		—
	Other income, net		9			20			1
	Reorganization items, net		(1	)		(5	)		(19	)
	(Loss) earnings from continuing operations before income taxes	$	(4	)	$	129		$	85
	Depreciation and Amortization	2013			2012			2011
	Industrial Performance Products	$	28		$	25		$	26
	Industrial Engineered Products		43			43			42
	Chemtura AgroSolutions		12			13			10
			83			81			78
	Corporate		18			19			25
	Total continuing operations		101			100			103
	Discontinued operations		22			39			37
		$	123		$	139		$	140
	Equity Income (Loss)	2013			2012			2011
	Industrial Performance Products	$	—		$	1		$	(1	)
	Industrial Engineered Products		(1	)		(2	)		2
	Chemtura AgroSolutions		1			(3	)		(2	)
	Total continuing operations		—			(4	)		(1	)
	Discontinued operations		2			7			4
		$	2		$	3		$	3
	Segment Assets	2013			2012			2011
	Industrial Performance Products	$	591		$	514		$	491
	Industrial Engineered Products		743			693			624
	Chemtura AgroSolutions		285			319			326
			1,619			1,526			1,441
	Discontinued operations		—			654			718
	Corporate		1,085			850			696
		$	2,704		$	3,030		$	2,855
	Capital Expenditures	2013			2012			2011
	Industrial Performance Products	$	73		$	52		$	35
	Industrial Engineered Products		73			69			98
	Chemtura AgroSolutions		7			5			6
			153			126			139
	Corporate		6			10			3
	Total continuing operations		159			136			142
	Discontinued operations		11			13			12
		$	170		$	149		$	154
	Equity Method Investments	2013			2012			2011
	Industrial Performance Products	$	7		$	10		$	8
	Industrial Engineered Products		—			4			6
Chemtura AgroSolutions		6			24			28
	$	13		$	38		$	42
Schedule of information by geographic area	'
	(In millions)
	Net sales (based on location of customer)	2013			2012			2011
	United States	$	944		$	878		$	840
	Canada		42			39			40
	Latin America		194			159			139
	Europe/Africa		624			676			682
	Asia/Pacific		427			444			483
		$	2,231		$	2,196		$	2,184
	Property, Plant and Equipment	2013			2012			2011
	United States	$	335		$	341		$	343
	Canada		62			69			68
	Latin America		14			15			15
	Europe/Africa		217			188			158
	Asia/Pacific		96			42			18
		$	724		$	655		$	602

GUARANTOR_CONDENSED_CONSOLIDAT1

GUARANTOR CONDENSED CONSOLIDATING FINANCIAL DATA (Tables)	12 Months Ended
	Dec. 31, 2013
GUARANTOR CONDENSED CONSOLIDATING FINANCIAL DATA	'
Schedule of condensed consolidating statement of operations	'
	Condensed Consolidating Statement of Operations
	Year ended December 31, 2013
	(In millions)
		Consolidated			Eliminations			Parent			Guarantor			Non-Guarantor
								Company			Subsidiaries			Subsidiaries
	Net sales	$	2,231		$	(1,813	)	$	1,443		$	449		$	2,152
	Cost of goods sold		1,721			(1,813	)		1,235			389			1,910
	Selling, general and administrative		229			—			109			15			105
	Depreciation and amortization		101			—			29			35			37
	Research and development		40			—			15			8			17
	Facility closures, severance and related costs		42			—			21			1			20
	Operating income		98			—			34			1			63
	Interest expense		(60	)		—			(69	)		—			9
	Loss on early extinguishment of debt		(50	)		—			(50	)		—			—
	Other income (expense), net		9			—			(20	)		—			29
	Reorganization items, net		(1	)		—			(1	)		—			—
	Equity in net earnings of subsidiaries		—			(85	)		85			—			—
	(Loss) earnings from continuing operations before income taxes		(4	)		(85	)		(21	)		1			101
	Income tax expense		(18	)		—			—			—			(18	)
	(Loss) earnings from continuing operations		(22	)		(85	)		(21	)		1			83
	Earnings (loss) from discontinued operations, net of tax		25			—			(3	)		23			5
	(Loss) gain on sale of discontinued operations, net of tax		(180	)		—			(153	)		14			(41	)
	Net (loss) earnings attributable to Chemtura	$	(177	)	$	(85	)	$	(177	)	$	38		$	47
	Condensed Consolidating Statement of Operations
	Year ended December 31, 2012
	(In millions)
		Consolidated			Eliminations			Parent			Guarantor			Non-Guarantor
								Company			Subsidiaries			Subsidiaries
	Net sales	$	2,196		$	(1,623	)	$	1,477		$	454		$	1,888
	Cost of goods sold		1,615			(1,623	)		1,192			383			1,663
	Selling, general and administrative		245			—			120			17			108
	Depreciation and amortization		100			—			27			44			29
	Research and development		41			—			16			7			18
	Facility closures, severance and related costs		11			—			8			—			3
	Changes in estimates related to expected allowable claims		1			—			1			—			—
	Equity loss		4			—			—			—			4
	Operating income		179			—			113			3			63
	Interest expense		(64	)		—			(69	)		2			3
	Loss on early extinguishment of debt		(1	)		—			(1	)		—			—
	Other income (expense), net		20			—			(17	)		—			37
	Reorganization items, net		(5	)		—			(5	)		—			—
	Equity in net earnings of subsidiaries		—			(81	)		81			—			—
	Earnings from continuing operations before income taxes		129			(81	)		102			5			103
	Income tax expense		(26	)		—			—			—			(26	)
	Earnings from continuing operations		103			(81	)		102			5			77
	(Loss) earnings from discontinued operations, net of tax		(3	)		—			(1	)		28			(30	)
	Net earnings		100			(81	)		101			33			47
	Less: net loss attributable to non-controlling interests		1			—			—			—			1
	Net earnings attributable to Chemtura	$	101		$	(81	)	$	101		$	33		$	48
	Condensed Consolidating Statement of Operations
	Year ended December 31, 2011
	(In millions)
		Consolidated			Eliminations			Parent			Guarantor			Non-Guarantor
								Company			Subsidiaries			Subsidiaries
	Net sales	$	2,184		$	(1,593	)	$	1,462		$	435		$	1,880
	Cost of goods sold		1,626			(1,593	)		1,195			367			1,657
	Selling, general and administrative		269			—			127			14			128
	Depreciation and amortization		103			—			27			43			33
	Research and development		36			—			16			5			15
	Facility closures, severance and related costs		3			—			1			—			2
	Gain on sale of business		(27	)		—			—			—			(27	)
	Impairment charges		4			—			1			1			2
	Changes in estimates related to expected allowable claims		3			—			3			—			—
Equity loss		1			—			1			—			—
Operating income		166			—			91			5			70
Interest expense		(63	)		—			(72	)		1			8
Other income (expense), net		1			—			(10	)		4			7
Reorganization items, net		(19	)		—			(19	)		—			—
Equity in net earnings (loss) of subsidiaries		—			(114	)		116			(2	)		—
Earnings from continuing operations before income taxes		85			(114	)		106			8			85
Income tax expense		(17	)		—			(4	)		—			(13	)
Earnings from continuing operations		68			(114	)		102			8			72
Earnings from discontinued operations, net of tax		52			—			17			17			18
Net earnings		120			(114	)		119			25			90
Less: net earnings attributable to non-controlling interests		(1	)		—			—			—			(1	)
Net earnings attributable to Chemtura	$	119		$	(114	)	$	119		$	25		$	89
Schedule of condensed consolidating statement of comprehensive income	'
	Condensed Consolidating Statement of Comprehensive (Loss) Income
	As of December 31, 2013
	(In millions)
		Consolidated			Eliminations			Parent			Guarantor			Non-Guarantor
								Company			Subsidiaries			Subsidiaries
	Net (loss) earnings	$	(177	)	$	(85	)	$	(177	)	$	38		$	47
	Other comprehensive (loss) income, net of tax:
	Foreign currency translation adjustments		(60	)		—			(18	)		2			(44	)
	Unrecognized pension and other post-retirement benefit costs		208			—			202			—			6
	Comprehensive (loss) income attributable to Chemtura	$	(29	)	$	(85	)	$	7		$	40		$	9
	Condensed Consolidating Statement of Comprehensive Income
	As of December 31, 2012
	(In millions)
		Consolidated			Eliminations			Parent			Guarantor			Non-Guarantor
								Company			Subsidiaries			Subsidiaries
	Net earnings	$	100		$	(81	)	$	101		$	33		$	47
	Other comprehensive (loss) income, net of tax:
	Foreign currency translation adjustments		(6	)		—			(11	)		1			4
	Unrecognized pension and other post-retirement benefit costs		(76	)		—			(44	)		—			(32	)
	Comprehensive income		18			(81	)		46			34			19
	Comprehensive loss attributable to non-controlling interests		1			—			—			—			1
	Comprehensive income attributable to Chemtura	$	19		$	(81	)	$	46		$	34		$	20
	Condensed Consolidating Statement of Comprehensive Income
	As of December 31, 2011
	(In millions)
		Consolidated			Eliminations			Parent			Guarantor			Non-Guarantor
								Company			Subsidiaries			Subsidiaries
	Net earnings	$	120		$	(114	)	$	119		$	25		$	90
	Other comprehensive (loss) income, net of tax:
	Foreign currency translation adjustments		(35	)		—			11			(2	)		(44	)
	Unrecognized pension and other post-retirement benefit costs		(35	)		—			(39	)		1			3
	Comprehensive income		50			(114	)		91			24			49
	Comprehensive income attributable to non-controlling interests		(1	)		—			—			—			(1	)
	Comprehensive income attributable to Chemtura	$	49		$	(114	)	$	91		$	24		$	48
Schedule of condensed consolidating balance sheet	'
	Condensed Consolidating Balance Sheet
	As of December 31, 2013
	(In millions)
		Consolidated			Eliminations			Parent			Guarantor			Non-Guarantor
								Company			Subsidiaries			Subsidiaries
	ASSETS
	Current assets	$	1,487		$	—		$	559		$	122		$	806
	Intercompany receivables		—			(7,671	)		2,681			2,349			2,641
	Investment in subsidiaries		—			(7,277	)		1,530			1,135			4,612
	Property, plant and equipment		724			—			121			214			389
	Goodwill		179			—			93			3			83
	Other assets		314			—			149			44			121
	Total assets	$	2,704		$	(14,948	)	$	5,133		$	3,867		$	8,652
	LIABILITIES AND STOCKHOLDERS' EQUITY
	Current liabilities	$	486		$	—		$	244		$	41		$	201
	Intercompany payables		—			(7,671	)		2,944			2,583			2,144
	Long-term debt		781			—			764			—			17
	Other long-term liabilities		438			—			182			52			204
	Total liabilities		1,705			(7,671	)		4,134			2,676			2,566
	Stockholders' equity		999			(7,277	)		999			1,191			6,086
	Total liabilities and stockholders' equity	$	2,704		$	(14,948	)	$	5,133		$	3,867		$	8,652
	Condensed Consolidating Balance Sheet
	As of December 31, 2012
	(In millions)
		Consolidated			Eliminations			Parent			Guarantor			Non-Guarantor
								Company			Subsidiaries			Subsidiaries
	ASSETS
	Current assets	$	1,612		$	—		$	505		$	213		$	894
	Intercompany receivables		—			(9,412	)		3,531			3,065			2,816
	Investment in subsidiaries		—			(8,831	)		1,738			1,633			5,460
	Property, plant and equipment		655			—			127			215			313
	Goodwill		177			—			92			3			82
	Other assets		586			—			131			233			222
	Total assets	$	3,030		$	(18,243	)	$	6,124		$	5,362		$	9,787
	LIABILITIES AND STOCKHOLDERS' EQUITY
	Current liabilities	$	511		$	—		$	210		$	69		$	232
	Intercompany payables		—			(9,412	)		3,676			3,305			2,431
	Long-term debt		871			—			870			—			1
	Other long-term liabilities		580			—			300			56			224
	Total liabilities		1,962			(9,412	)		5,056			3,430			2,888
	Stockholders' equity		1,068			(8,831	)		1,068			1,932			6,899
	Total liabilities and stockholders' equity	$	3,030		$	(18,243	)	$	6,124		$	5,362		$	9,787
Schedule of condensed consolidating statement of cash flows	'
	Condensed Consolidating Statement of Cash Flows
	Year ended December 31, 2013
	(In millions)
		Consolidated			Eliminations			Parent			Guarantor			Non-Guarantor
								Company			Subsidiaries			Subsidiaries
	Increase (decrease) to cash
	CASH FLOWS FROM OPERATING ACTIVITIES
	Net (loss) earnings	$	(177	)	$	(85	)	$	(177	)	$	38		$	47
	Adjustments to reconcile net (loss) earnings to net cash provided by (used in) operations:
	(Loss) gain on sale of discontinued operations		180			—			153			(14	)		41
	Impairment charges		7			—			—			7			—
	Reclass of translation adjustment from liquidated entities		(13	)		—			—			—			(13	)
	Loss on early extinguishment of debt		50			—			50			—			—
	Depreciation and amortization		123			—			33			45			45
	Stock-based compensation expense		14			—			14			—			—
	Equity income, net of cash received		(2	)		—			—			—			(2	)
	Changes in assets and liabilities, net		(103	)		85			(84	)		(27	)		(77	)
	Net cash provided by (used in) operations		79			—			(11	)		49			41
	CASH FLOWS FROM INVESTING ACTIVITIES
	Proceeds from divestments, net		357			—			255			(2	)		104
	Payments for acquisitions, net of cash acquired		(3	)		—			—			—			(3	)
	Capital expenditures		(170	)		—			(20	)		(47	)		(103	)
	Net cash provided by (used in) investing activities		184			—			235			(49	)		(2	)
	CASH FLOWS FROM FINANCING ACTIVITIES
	Proceeds from 2021 Senior Notes		450			—			450			—			—
	Payments on 2018 Senior Notes, includes premium on tendering of notes		(396	)		—			(396	)		—			—
	Payments on Term Loan		(102	)		—			(102	)		—			—
	Proceeds from other long-term borrowings		31			—			7			—			24
	Payments on other long-term borrowings		(4	)		—			(1	)					(3	)
	Payments on short term borrowings, net		(1	)		—			—			—			(1	)
	Payments for debt issuance costs		(12	)		—			(12	)		—			—
	Common shares acquired		(54	)		—			(54	)		—			—
	Proceeds from the exercise of stock options		8			—			8			—			—
	Net cash (used in) provided by financing activities		(80	)		—			(100	)		—			20
	CASH AND CASH EQUIVALENTS
	Effect of exchange rates on cash and cash equivalents		1			—			—			—			1
	Change in cash and cash equivalents		184			—			124			—			60
	Cash and cash equivalents at beginning of year		365			—		$	193		$	—		$	172
	Cash and cash equivalents at end of year	$	549		$	—		$	317		$	—		$	232
	Condensed Consolidating Statement of Cash Flows
	Year ended December 31, 2012
	(In millions)
	Increase (decrease) to cash	Consolidated			Eliminations			Parent			Guarantor			Non-Guarantor
								Company			Subsidiaries			Subsidiaries
	CASH FLOWS FROM OPERATING ACTIVITIES
	Net earnings	$	100		$	(81	)	$	101		$	33		$	47
	Adjustments to reconcile net earnings to net cash provided by operations:
	Impairment charges		47			—			12			—			35
	Reclass of translation adjustment from liquidated entities		(21	)		—			—			—			(21	)
	Loss on early extinguishment of debt		1			—			1			—			—
	Depreciation and amortization		139			—			36			51			52
	Stock-based compensation expense		24			—			24			—			—
	Reorganization items, net		1			—			1			—			—
	Changes in estimates related to expected allowable claims		1			—			1			—			—
	Equity income		(3	)		—			—			—			(3	)
	Changes in assets and liabilities, net		(71	)		81			(106	)		(37	)		(9	)
	Net cash provided by operations		218			—			70			47			101
	CASH FLOWS FROM INVESTING ACTIVITIES
	Net proceeds from divestments		9			—			—			—			9
	Capital expenditures		(149	)		—			(21	)		(47	)		(81	)
	Net cash used in investing activities		(140	)		—			(21	)		(47	)		(72	)
	CASH FLOWS FROM FINANCING ACTIVITIES
	Proceeds from Term Loan		125			—			125			—			—
Payments on short term borrowings, net		(3	)		—			—			—			(3	)
Payments for debt issuance and refinancing costs		(2	)		—			(1	)		—			(1	)
Common shares acquired		(20	)		—			(20	)		—			—
Proceeds from exercise of stock options		5			—			5			—			—
Net cash provided by (used in) financing activities		105			—			109			—			(4	)
CASH AND CASH EQUIVALENTS
Effect of exchange rates on cash and cash equivalents		2			—			—			—			2
Change in cash and cash equivalents		185			—			158			—			27
Cash and cash equivalents at beginning of year		180			—			35			—			145
Cash and cash equivalents at end of year	$	365		$	—		$	193		$	—		$	172
Condensed Consolidating Statement of Cash Flows
Year ended December 31, 2011
(In millions)
Increase (decrease) to cash	Consolidated			Eliminations			Parent			Guarantor			Non-Guarantor
							Company			Subsidiaries			Subsidiaries
CASH FLOWS FROM OPERATING ACTIVITIES
Net earnings	$	120		$	(114	)	$	119		$	25		$	90
Adjustments to reconcile net earnings to net cash provided by operations:
Gain on sale of business		(27	)		—			—			—			(27	)
Impairment charges		4			—			1			1			2
Depreciation and amortization		140			—			36			50			54
Stock-based compensation expense		26			—			26			—			—
Reorganization items, net		2			—			2			—			—
Changes in estimates related to expected allowable claims		3			—			3			—			—
Equity (income) loss		(3	)		—			1			—			(4	)
Changes in assets and liabilities, net		(83	)		114			(157	)		7			(47	)
Net cash provided by operations		182			—			31			83			68
CASH FLOWS FROM INVESTING ACTIVITIES
Net proceeds from divestments		8			—			8			—			—
Payments for acquisitions, net of cash acquired		(35	)		—			—			—			(35	)
Capital expenditures		(154	)		—			(24	)		(83	)		(47	)
Net cash used in investing activities		(181	)		—			(16	)		(83	)		(82	)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from other short term borrowings, net		3			—			—			—			3
Common shares acquired		(22	)		—			(22	)		—			—
Proceeds from exercise of stock options		1			—			1			—			—
Net cash (used in) provided by financing activities		(18	)		—			(21	)		—			3
CASH AND CASH EQUIVALENTS
Effect of exchange rates on cash and cash equivalents		(4	)		—			—			—			(4	)
Change in cash and cash equivalents		(21	)		—			(6	)		—			(15	)
Cash and cash equivalents at beginning of year		201			—			41			—			160
Cash and cash equivalents at end of year	$	180		$	—		$	35		$	—		$	145

SUMMARIZED_UNAUDITED_QUARTERLY1

SUMMARIZED UNAUDITED QUARTERLY FINANCIAL DATA (Tables)	12 Months Ended
	Dec. 31, 2013
SUMMARIZED UNAUDITED QUARTERLY FINANCIAL DATA	'
Schedule of summarized unaudited quarterly financial data	'
		2013
	(In millions, except per share data)	First			Second			Third			Fourth
	Net sales	$	528		$	590		$	569		$	544
	Gross profit	$	110		$	146		$	121		$	133
	AMOUNTS ATTRIBUTABLE TO CHEMTURA COMMON SHAREHOLDERS:
	(Loss) earnings from continuing operations, net of tax	$	-18	(a)	$	27	(b)	$	-44	(c)	$	13	(d)
	(Loss) earnings from discontinued operations, net of tax		(5	)		26			7			(3	)
	Loss on sale of discontinued operations, net of tax		—			(146	)		(3	)		(31	)
	Net loss	$	(23	)	$	(93	)	$	(40	)	$	(21	)
	BASIC PER SHARE—ATTRIBUTABLE TO CHEMTURA (i):
	(Loss) earnings from continuing operations, net of tax	$	(0.18	)	$	0.27		$	(0.45	)	$	0.13
	(Loss) earnings from discontinued operations, net of tax		(0.05	)		0.26			0.07			(0.03	)
	Loss on sale of discontinued operations, net of tax		—			(1.48	)		(0.03	)		(0.32	)
	Net loss	$	(0.23	)	$	(0.95	)	$	(0.41	)	$	(0.22	)
	DILUTED PER SHARE—ATTRIBUTABLE TO CHEMTURA(i):
	(Loss) earnings from continuing operations, net of tax	$	(0.18	)	$	0.27		$	(0.45	)	$	0.13
	(Loss) earnings from discontinued operations, net of tax		(0.05	)		0.26			0.07			(0.03	)
	Loss on sale of discontinued operations, net of tax		—			(1.46	)		(0.03	)		(0.32	)
	Net loss	$	(0.23	)	$	(0.93	)	$	(0.41	)	$	(0.22	)
	Basic weighted-average shares outstanding		98.2			98.6			97.5			96.6
	Diluted weighted-average shares outstanding		98.2			99.7			97.5			98.1
		2012
		First			Second			Third			Fourth
	Net sales	$	534		$	583		$	546		$	533
	Gross profit	$	148		$	158		$	148		$	127
	AMOUNTS ATTRIBUTABLE TO CHEMTURA COMMON SHAREHOLDERS (i):
	Earnings from continuing operations, net of tax	$	28	(e)	$	34	(f)	$	22	(g)	$	19	(h)
	(Loss) earnings from discontinued operations, net of tax		(6	)		16			(13	)		1
	Net earnings	$	22		$	50		$	9		$	20
	BASIC AND DILUTED PER SHARE—ATTRIBUTABLE TO CHEMTURA (i):
	Earnings from continuing operations, net of tax	$	0.28		$	0.34		$	0.22		$	0.19
	(Loss) earnings from discontinued operations, net of tax		(0.06	)		0.16			(0.13	)		0.01
	Net earnings	$	0.22		$	0.5		$	0.09		$	0.2
	Basic weighted-average shares outstanding		98.3			98.9			97.9			97.9
	Diluted weighted-average shares outstanding		99.1			99.1			98.2			99
	(a)
	The earnings from continuing operations for the first quarter of 2013 included pre-tax charges for facility closures, severance and related costs of $14 million.
	(b)
	The earnings from continuing operations for the second quarter of 2013 included pre-tax charges for facility closures, severance and related costs of $11 million.
	(c)
	The earnings from continuing operations for the third quarter of 2013 included pre-tax charges for loss on early extinguishment of debt of $50 million and facility closures, severance and related costs of $3 million.
	(d)
	The earnings from continuing operations for the fourth quarter of 2013 included pre-tax charges for facility closures, severance and related costs of $14 million.
	(e)
	The earnings from continuing operations for the first quarter of 2012 included pre-tax charges for changes in estimates related to expected allowable claims of $2 million and reorganization items of $2 million.
	(f)
	The earnings from continuing operations for the second quarter of 2012 included pre-tax charges for facility closures, severance and related costs of $6 million.
	(g)
	The earnings from continuing operations for the third quarter of 2012 included pre-tax charges for facility closures, severance and related costs of $2 million.
	(h)
	The earnings from continuing operations for the fourth quarter of 2012 included a pre-tax charges for facility closures, severance and related costs of $3 million.
	(i)
	The sum of the earnings per common share for the four quarters may not equal the total earnings per common share for the full year due to quarterly changes in the average number of shares outstanding.

NATURE_OF_OPERATIONS_AND_SUMMA3

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Customer Rebates	'	'	'
Accruals for customer rebates	$10	$14	'
Other Expense, Net	'	'	'
Foreign exchange loss	-7	-6	-2
Interest income	3	5	3
Release of cumulative foreign currency translation adjustments from liquidation of entities	13	21	'
Other expense, net	9	20	1
Allowance for Doubtful Accounts	'	'	'
Allowances for doubtful accounts	$11	$11	'
Minimum	'	'	'
NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'	'	'
Investment in other affiliates to be accounted using the equity method (as a percent)	20.00%	'	'
Maximum	'	'	'
NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'	'	'
Investment in other affiliates to be accounted using the equity method (as a percent)	50.00%	'	'
Ownership interest in other affiliates to be accounted for at cost (as a percent)	20.00%	'	'

NATURE_OF_OPERATIONS_AND_SUMMA4

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)	12 Months Ended
	Dec. 31, 2013
Land improvements | Minimum	'
Property, plant and equipment	'
Asset lives	'3 years
Land improvements | Maximum	'
Property, plant and equipment	'
Asset lives	'20 years
Buildings and improvements | Minimum	'
Property, plant and equipment	'
Asset lives	'2 years
Buildings and improvements | Maximum	'
Property, plant and equipment	'
Asset lives	'40 years
Machinery and equipment | Minimum	'
Property, plant and equipment	'
Asset lives	'2 years
Machinery and equipment | Maximum	'
Property, plant and equipment	'
Asset lives	'25 years
Information systems equipment | Minimum	'
Property, plant and equipment	'
Asset lives	'2 years
Information systems equipment | Maximum	'
Property, plant and equipment	'
Asset lives	'10 years
Furniture, fixtures and other | Minimum	'
Property, plant and equipment	'
Asset lives	'1 year
Furniture, fixtures and other | Maximum	'
Property, plant and equipment	'
Asset lives	'10 years

NATURE_OF_OPERATIONS_AND_SUMMA5

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3)	12 Months Ended
	Dec. 31, 2013
Patents | Minimum	'
Intangible assets (excluding goodwill)	'
Estimated useful lives	'5 years
Patents | Maximum	'
Intangible assets (excluding goodwill)	'
Estimated useful lives	'20 years
Trademarks | Minimum	'
Intangible assets (excluding goodwill)	'
Estimated useful lives	'6 years
Trademarks | Maximum	'
Intangible assets (excluding goodwill)	'
Estimated useful lives	'40 years
Customer relationships | Minimum	'
Intangible assets (excluding goodwill)	'
Estimated useful lives	'15 years
Customer relationships | Maximum	'
Intangible assets (excluding goodwill)	'
Estimated useful lives	'30 years
Production rights	'
Intangible assets (excluding goodwill)	'
Estimated useful lives	'10 years
Other intangibles | Minimum	'
Intangible assets (excluding goodwill)	'
Estimated useful lives	'5 years
Other intangibles | Maximum	'
Intangible assets (excluding goodwill)	'
Estimated useful lives	'50 years

NATURE_OF_OPERATIONS_AND_SUMMA6

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 4) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Stock-Based Compensation	'	'	'
Stock-based compensation expense	$14	$24	$26
Cash Flows	'	'	'
Maximum term of original maturity to classify bank term deposits as cash equivalents	'3 months	'	'
Cash paid for settlement of liabilities subject to compromise	'	5	'
Value of common stock issued for settlement of liabilities subject to compromise	'	26	'
Interest paid	57	58	57
Income taxes (net of refunds)	$21	$45	$16
Environmental	'	'	'
Environmental Liabilities	'	'	'
Period for accrual of probable and reasonable remediation costs on an undiscounted basis	'10 years	'	'

ACQUISITIONS_AND_DIVESTITURES_1

ACQUISITIONS AND DIVESTITURES (Details)

3 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

12 Months Ended

0 Months Ended

0 Months Ended

In Millions, unless otherwise specified

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Apr. 30, 2013

Dec. 31, 2013

Apr. 30, 2013

Apr. 30, 2013

Dec. 31, 2013

Apr. 30, 2013

Dec. 31, 2013

Oct. 31, 2013

Jan. 26, 2011

Dec. 31, 2013

Dec. 31, 2013

Jan. 31, 2011

Jan. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Sep. 26, 2012

Feb. 02, 2011

15-May-13

15-May-13

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Consumer Divestiture

Antioxidant and UV Stabilizers Divestiture

Antioxidant and UV Stabilizers Divestiture

Antioxidant and UV Stabilizers Divestiture

Antioxidant and UV Stabilizers Divestiture

SK and Addivant

SK and Addivant

KIK Custom Products Inc. (KIK)

KIK Custom Products Inc. (KIK)

ISEM

ISEM

ISEM

ISEM

ISEM

ISEM

ISEM

ISEM

ISEM

Business Transfer Agreement ("BTA")

Daystar

Daystar

Daystar

USD ($)

USD ($)

USD ($)

Minimum

Maximum

Antioxidant and UV Stabilizers Divestiture

Antioxidant and UV Stabilizers Divestiture

Consumer Divestiture

Consumer Divestiture

item

USD ($)

EUR (€)

USD ($)

EUR (€)

Product line one

Product line one

Product line two

Product line two

USD ($)

USD ($)

USD ($)

UP Chemical

USD ($)

USD ($)

USD ($)

USD ($)

item

USD ($)

EUR (€)

USD ($)

EUR (€)

USD ($)

Acquisitions

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash consideration

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$142

'

'

'

Number of commercialized products to which the entity will have access

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

Ownership interest in a joint venture (as a percent)

'

'

'

'

'

'

'

49.00%

'

'

'

'

'

'

'

50.00%

'

'

'

'

'

'

'

'

'

50.00%

'

'

Cash contributions

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6

'

'

Remaining interest purchased (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50.00%

'

Purchase price for remaining interest

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3

'

Amount of loan reimbursed

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3

Investment in joint venture

13

'

'

13

38

42

'

'

'

'

'

'

'

'

'

'

'

'

29

20

'

'

'

'

'

'

'

'

Number of transactions by joint venture

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

2

'

'

'

'

'

'

'

'

'

'

Number of product lines sold by joint venture

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

2

'

'

'

'

'

'

'

'

'

'

Amount of sale of product lines by joint venture

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

51

38

'

'

'

'

'

'

'

'

'

'

Return of capital received

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20

15

3

2

'

'

'

'

Reduction of purchase price to reflect the resolution of certain pre-closing matters

'

'

'

'

'

'

15

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash consideration on sale of business

'

'

'

'

'

'

300

97

'

'

'

97

'

'

315

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock received as consideration

'

'

'

'

'

'

'

'

'

'

'

'

9

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Seller note received as consideration

'

'

'

'

'

'

'

'

'

'

'

'

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Assumption of pension, environmental and other liabilities

'

'

'

'

'

'

'

91

'

'

'

'

'

8

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Period for Determining Working Capital Based on Average Against which It would be Measured

'

'

'

'

'

'

'

'

'

'

'

'

'

'12 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash consideration paid as part of adjustment

'

'

'

'

'

'

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional disclosures, divestitures

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares of Series A Preferred Stock received as consideration

'

'

'

'

'

'

'

'

'

'

'

'

9.2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Face value of Series A Preferred Stock received as part of the consideration

'

'

'

'

'

'

'

'

'

'

'

'

9

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Series A Preferred Stock dividend rate (as a percent)

'

'

'

'

'

'

'

'

'

7.00%

11.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Pre-tax loss

'

'

'

188

'

'

24

164

164

'

'

164

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

After-tax loss on sale of business

31

3

146

180

'

'

25

155

155

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Non-cash charges

'

'

'

'

'

'

39

121

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Option exercisable period from the closing date under the terms of supply contract

'

'

'

'

'

'

'

'

'

'

'

'

'

'6 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Impairment charge related to property, plant and equipment held for sale

'

'

'

$7

'

'

'

'

'

'

'

'

'

$7

'

'

'

'

'

'

'

'

'

'

'

'

'

'

ACQUISITIONS_AND_DIVESTITURES_2

ACQUISITIONS AND DIVESTITURES (Details 2) (USD $)

3 Months Ended

12 Months Ended

0 Months Ended

3 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

In Millions, unless otherwise specified

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Nov. 28, 2011

Dec. 31, 2011

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Oct. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Apr. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Apr. 30, 2013

Apr. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Corporate

Corporate

Corporate

Tetrabrom Technologies Ltd.

Tetrabrom Technologies Ltd.

Tetrabrom Technologies Ltd.

Consumer Divestiture

Consumer Divestiture

Consumer Divestiture

Consumer Divestiture

Consumer Divestiture

Consumer Divestiture

Antioxidant and UV Stabilizers Divestiture

Antioxidant and UV Stabilizers Divestiture

Antioxidant and UV Stabilizers Divestiture

Antioxidant and UV Stabilizers Divestiture

Antioxidant and UV Stabilizers Divestiture

Antioxidant and UV Stabilizers Divestiture

Antioxidant and UV Stabilizers Divestiture

Antioxidant and UV Stabilizers Divestiture

Antioxidant and UV Stabilizers Divestiture

Antioxidant and UV Stabilizers Divestiture

Antioxidant and UV Stabilizers Divestiture

Antioxidant and Consumer Product businesses

Antioxidant and Consumer Product businesses

Antioxidant and Consumer Product businesses

Corporate

KIK Custom Products Inc. (KIK)

Corporate

Corporate

Forecast

SK and Addivant

Corporate

Corporate

Corporate

Minimum

Maximum

Corporate

Corporate

Corporate

Continuing operations

Continuing operations

Continuing operations

Assets and liabilities of discontinued operations

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash and cash equivalents

'

'

'

'

$2

'

'

'

'

$2

$1

'

'

'

'

'

'

$13

'

'

'

'

'

$2

'

$2

'

'

'

'

'

'

'

'

'

'

'

Accounts receivable, net

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

55

60

'

'

'

'

70

'

61

'

'

'

'

'

'

'

'

'

'

'

Inventories

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

64

70

'

'

'

'

76

'

78

'

'

'

'

'

'

'

'

'

'

'

Current domestic tax assets reversed upon sale

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7

7

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Other current assets, includes foreign deferred tax assets

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8

12

'

'

'

'

2

'

4

'

'

'

'

'

'

'

'

'

'

'

Property, plant and equipment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

63

64

'

'

'

'

48

'

44

'

'

'

'

'

'

'

'

'

'

'

Intangible assets, net

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

195

202

'

'

'

'

14

'

14

'

'

'

'

'

'

'

'

'

'

'

Other assets

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5

5

'

'

'

'

32

'

31

'

'

'

'

'

'

'

'

'

'

'

Assets

4

'

'

'

'

'

'

'

4

'

'

'

'

'

'

'

'

410

420

'

'

'

'

244

'

234

'

'

'

'

'

'

'

'

'

'

'

Accounts payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

16

23

'

'

'

'

39

'

29

'

'

'

'

'

'

'

'

'

'

'

Accrued expenses

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

14

16

'

'

'

'

2

'

4

'

'

'

'

'

'

'

'

'

'

'

Income taxes payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4

'

'

'

'

'

'

1

'

'

'

'

'

'

'

'

'

'

'

Pension and post-retirement health care liabilities

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6

7

'

'

'

'

81

'

80

'

'

'

'

'

'

'

'

'

'

'

Domestic tax liabilities reversed upon sale

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

44

43

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Other liabilities, includes foreign deferred tax liabilities

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

32

35

'

'

'

'

11

'

11

'

'

'

'

'

'

'

'

'

'

'

Liabilities

2

'

'

'

'

'

'

'

2

'

'

'

'

'

'

'

'

112

128

'

'

'

'

133

'

125

'

'

'

'

'

'

'

'

'

'

'

Net Assets

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

298

292

'

'

'

'

111

'

109

'

'

'

'

'

'

'

'

'

'

'

Ownership interest in a joint venture (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

49.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

Term of supply contract

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'2 years

'5 years

'

'

'

Total losses related to supply contracts

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

13

13

'

'

'

'

'

'

'

'

Reconciliation of cash proceeds to pre-tax loss on sale

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash consideration

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

300

'

'

315

'

'

97

'

'

'

'

97

'

'

'

'

'

'

'

'

Pre-closing working capital and other adjustments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-36

'

'

'

'

'

'

'

'

'

'

-10

'

'

'

'

'

'

'

'

Post-closing adjustments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-2

'

'

'

'

'

'

'

'

Cash proceeds

'

'

'

'

'

'

'

'

357

9

8

'

'

'

'

'

'

264

'

'

'

'

'

'

'

'

'

'

85

'

'

'

'

'

'

'

'

Preferred stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9

'

'

'

'

'

'

'

'

Less direct items:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net assets sold or settled, excluding domestic tax liabilities reversed upon sale and included in tax effects

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

335

'

'

'

'

'

'

'

'

'

'

111

'

'

'

'

'

'

'

'

Transaction costs and other

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10

'

'

'

'

'

'

'

'

'

'

5

'

'

'

'

'

'

'

'

Post-closing adjustments, obligations and other, net

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-18

'

'

'

'

'

'

'

'

'

'

8

'

'

'

'

'

'

'

'

Fair value of supply agreements

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

13

13

'

'

'

'

'

'

'

'

Less non-cash items:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Release of AOCL - pension

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5

'

'

'

'

'

'

'

'

'

'

122

'

'

'

'

'

'

'

'

Release of AOCL - cumulative translation adjustment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-44

'

'

'

'

'

'

'

'

'

'

6

'

'

'

'

'

'

'

'

Release of non-controlling interest

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-7

'

'

'

'

'

'

'

'

Pre-tax loss on sale of discontinued operations

'

'

'

'

'

'

'

'

-188

'

'

'

'

'

'

'

'

-24

'

'

'

'

'

-164

-164

'

'

'

-164

'

'

'

'

'

'

'

'

Loss from discontinued operations

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net sales

'

'

'

'

'

'

'

'

531

820

841

'

'

'

'

'

'

408

433

422

'

'

'

'

123

387

419

'

'

'

'

'

'

'

'

'

'

Pre-tax earnings (loss) from discontinued operations

'

'

'

'

'

'

'

'

28

-12

60

'

'

'

'

'

'

24

33

29

'

'

'

'

4

-45

31

'

'

'

'

'

'

'

'

'

'

Income tax benefit

'

'

'

'

'

'

'

'

-3

9

-8

'

'

'

'

'

'

-3

-2

-3

'

'

'

'

'

11

-5

'

'

'

'

'

'

'

'

'

'

Earnings (loss) from discontinued operations, net of taxes

'

'

'

'

'

'

'

'

25

-3

52

'

'

'

'

'

'

21

31

26

'

'

'

'

4

-34

26

'

'

'

'

'

'

'

'

'

'

Net earnings attributable to non-controlling interests

'

'

'

'

'

'

'

'

'

1

-1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1

-1

'

'

'

'

'

'

'

'

'

'

Earnings (loss) from discontinued operations

-3

7

26

-5

1

-13

16

-6

25

-2

51

'

'

'

'

'

'

21

31

26

'

'

'

'

4

-33

25

'

'

'

'

'

'

'

'

'

'

Percentage ownership interest sold

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50.00%

'

50.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Sales price of investment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

38

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Period for receiving proceeds from sale of an investment interest in annual installments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Pre-tax gain on sale of business

'

'

'

'

'

'

'

'

'

'

27

'

'

'

'

27

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loss on sale of discontinued operations:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Pre-tax loss

'

'

'

'

'

'

'

'

-188

'

'

'

'

'

'

'

'

-24

'

'

'

'

'

-164

-164

'

'

'

-164

'

'

'

'

'

'

'

'

Income tax (expense) benefit

'

'

'

'

'

'

'

'

8

'

'

'

'

'

'

'

'

-1

'

'

'

'

'

'

9

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-31

-3

-146

'

'

'

'

'

-180

'

'

'

'

'

'

'

'

-25

'

'

'

'

'

-155

-155

'

'

'

'

'

'

'

'

'

'

'

'

Functional and other expenses allocated to businesses that will not transfer directly under the sale agreements

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Functional and other expenses

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

14

'

'

'

13

15

'

'

'

'

'

'

6

13

15

'

'

'

'

'

Amortization expense

'

'

'

'

'

'

'

'

15

16

22

'

'

'

'

'

'

-8

'

'

'

-14

-16

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net increase

'

'

'

'

'

'

'

'

$97

$100

$105

$12

$12

$14

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$20

$26

$30

RESTRUCTURING_AND_ASSET_IMPAIR2

RESTRUCTURING AND ASSET IMPAIRMENT ACTIVITIES (Details) (USD $)

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

In Millions, unless otherwise specified

Nov. 30, 2011

Dec. 31, 2013

Dec. 31, 2011

Feb. 28, 2013

Feb. 28, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Apr. 30, 2012

Dec. 31, 2012

Dec. 31, 2012

Minimum

Maximum

Industrial Performance Products

Industrial Performance Products

Severance and Related Costs

Severance and Related Costs

Severance and Related Costs

Other Facility Closure Costs

Other Facility Closure Costs

Other Facility Closure Costs

Receivable write-off

Italy

Italy

Industrial Performance Products

Corporate

Industrial Performance Products

Industrial Performance Products

Italy

Italy

Italy

Italy

COGS

Restructuring information

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Pre-tax charges for restructuring

'

$44

'

'

'

$1

$33

$27

'

'

$15

'

'

'

Accelerated depreciation of certain fixed assets

'

1

2

'

'

'

4

'

'

'

'

'

'

'

Accelerated asset retirement obligations

'

1

'

'

'

'

'

'

'

'

'

'

2

'

Pre-tax charges for restructuring to be incurred throughout 2014

'

'

'

7

10

'

'

'

'

'

'

'

'

'

Estimated cost of restructuring plan

3

'

'

'

'

'

'

'

'

'

'

40

'

'

Estimated non-cash cost of restructuring plan

'

'

'

'

'

'

'

'

'

'

'

6

'

'

Pre-tax charge for severance to facility closures, severance and related costs

'

'

'

'

'

'

'

'

5

12

'

'

'

'

Write off of receivable

'

'

'

'

'

'

'

'

'

'

'

'

'

$10

RESTRUCTURING_AND_ASSET_IMPAIR3

RESTRUCTURING AND ASSET IMPAIRMENT ACTIVITIES (Details 2) (USD $)

3 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

In Millions, unless otherwise specified

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Nov. 28, 2011

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2011

Nov. 30, 2011

Tetrabrom Technologies Ltd.

Antioxidant and UV Stabilizers Divestiture

El Dorado , Arkansas facility reorganization initiative

Corporate Restructuring Programs

Corporate Restructuring Programs

Corporate Restructuring Programs

Corporate Restructuring Programs

Corporate Restructuring Programs

Corporate Restructuring Programs

Corporate Restructuring Programs

Corporate Restructuring Programs

Corporate Restructuring Programs

Chemtura AgroSolutions

Severance and Related Costs

Severance and Related Costs

Severance and Related Costs

Severance and Related Costs

Severance and Related Costs

Severance and Related Costs

Other Facility Closure Costs

Other Facility Closure Costs

Other Facility Closure Costs

Other Facility Closure Costs

Other Facility Closure Costs

Reorganization initiatives

Reorganization initiatives

Accrued expenses

Accounts payable

Continuing operations

Continuing operations

Discontinued operations

Discontinued operations

Corporate Restructuring Programs

Corporate Restructuring Programs

Corporate Restructuring Programs

Corporate Restructuring Programs

Corporate Restructuring Programs

Corporate Restructuring Programs

Corporate Restructuring Programs

Corporate Restructuring Programs

Corporate Restructuring Programs

Corporate Restructuring Programs

Corporate Restructuring Programs

Tetrabrom Technologies Ltd.

Continuing operations

Continuing operations

Discontinued operations

Continuing operations

Continuing operations

Discontinued operations

Changes in liabilities established for restructuring programs

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at beginning of period

'

'

'

'

'

'

'

'

'

'

'

'

'

$8

$1

$1

$15

$1

'

'

'

'

'

$8

$1

$1

'

'

'

'

'

'

'

'

'

'

Facility closures, severance and related costs

-14

-3

-11

-14

-3

-2

-6

-42

-11

-3

'

'

'

'

'

3

'

'

42

11

1

6

'

'

'

3

27

6

6

'

'

15

5

1

'

'

Cash payments

'

'

'

'

'

'

'

'

'

'

'

'

'

-33

-10

-3

'

'

'

'

'

'

'

-19

-5

-3

'

'

'

-14

-5

'

'

'

'

'

Reclassifications

'

'

'

'

'

'

'

'

'

'

'

'

'

-2

'

'

'

'

'

'

'

'

'

-2

'

'

'

'

'

'

'

'

'

'

'

'

Balance at end of period

'

'

'

'

'

'

'

'

'

'

'

'

'

16

8

1

15

1

'

'

'

'

'

14

8

1

'

'

'

2

'

'

'

'

'

'

Percentage ownership interest sold

'

'

'

'

'

'

'

'

'

'

50.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50.00%

Pre-tax charge for asset impairments and accelerated depreciation

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3

'

Asset Impairment Review

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Pre-tax charges for impairment

'

'

'

'

11

'

'

7

47

4

'

35

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Impairment charge related to property, plant and equipment held for sale

'

'

'

'

'

'

'

7

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Impairment of property, plant and equipment, net

'

'

'

'

9

'

'

'

'

4

'

26

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Impairment of intangible assets, net

'

'

'

'

2

'

'

'

'

'

'

9

'

'

'

'

'

'

'

'

'

'

3

'

'

'

'

'

'

'

'

'

'

'

'

'

Impairment charge related to property, plant and equipment

'

'

'

'

'

'

'

'

'

$4

'

'

$1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

INVENTORIES_Details

INVENTORIES (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
INVENTORIES	'	'
Finished goods	$288	$280
Work in process	34	27
Raw materials and supplies	93	91
Inventory, net	415	398
Inventory obsolescence reserves	$21	$14

PROPERTY_PLANT_AND_EQUIPMENT_D

PROPERTY, PLANT AND EQUIPMENT (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Property, plant and equipment	'	'	'
Property, plant and equipment, gross	$1,825	$1,728	'
Less: accumulated depreciation	1,101	1,073	'
Property, plant and equipment, net	724	655	602
Depreciation expense	82	80	81
Accelerated depreciation of certain fixed assets	1	'	2
Land and improvements	'	'	'
Property, plant and equipment	'	'	'
Property, plant and equipment, gross	74	67	'
Buildings and improvements	'	'	'
Property, plant and equipment	'	'	'
Property, plant and equipment, gross	216	190	'
Machinery and equipment	'	'	'
Property, plant and equipment	'	'	'
Property, plant and equipment, gross	1,239	1,152	'
Information systems equipment	'	'	'
Property, plant and equipment	'	'	'
Property, plant and equipment, gross	173	183	'
Furniture, fixtures and other	'	'	'
Property, plant and equipment	'	'	'
Property, plant and equipment, gross	29	28	'
Construction in progress	'	'	'
Property, plant and equipment	'	'	'
Property, plant and equipment, gross	$94	$108	'

GOODWILL_AND_INTANGIBLE_ASSETS2

GOODWILL AND INTANGIBLE ASSETS (Details) (USD $)	0 Months Ended				12 Months Ended
In Millions, unless otherwise specified	Jul. 31, 2013	Jul. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
					Industrial Performance Products	Industrial Performance Products
Goodwill by reportable segment	'	'	'	'	'	'
Goodwill at the beginning of the period	'	'	'	'	$267	$264
Accumulated impairments at the beginning of the period	'	'	'	'	-90	-90
Net goodwill at the beginning of the period	'	'	179	177	177	174
Foreign currency translation	'	'	'	'	2	3
Goodwill at the end of the period	'	'	'	'	269	267
Accumulated impairments at the end of the period	'	'	'	'	-90	-90
Net goodwill at the end of the period	'	'	179	177	179	177
Goodwill impairment charge	$0	$0	'	'	'	'

GOODWILL_AND_INTANGIBLE_ASSETS3

GOODWILL AND INTANGIBLE ASSETS (Details 2) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Intangible assets (excluding goodwill)	'	'	'
Gross Cost	$328	$314	'
Accumulated Amortization	-186	-168	'
Net Intangibles	142	146	'
Additions in gross intangible assets	13	'	'
Foreign currency translation	3	'	'
Amortization expense	19	20	22
Estimated amortization expense of intangible assets for the next five fiscal years	'	'	'
2014	18	'	'
2015	16	'	'
2016	11	'	'
2017	11	'	'
2018	11	'	'
Patents	'	'	'
Intangible assets (excluding goodwill)	'	'	'
Gross Cost	91	85	'
Accumulated Amortization	-52	-48	'
Net Intangibles	39	37	'
Trademarks	'	'	'
Intangible assets (excluding goodwill)	'	'	'
Gross Cost	68	68	'
Accumulated Amortization	-34	-31	'
Net Intangibles	34	37	'
Customer relationships	'	'	'
Intangible assets (excluding goodwill)	'	'	'
Gross Cost	42	41	'
Accumulated Amortization	-18	-15	'
Net Intangibles	24	26	'
Production rights	'	'	'
Intangible assets (excluding goodwill)	'	'	'
Gross Cost	46	46	'
Accumulated Amortization	-37	-32	'
Net Intangibles	9	14	'
Other	'	'	'
Intangible assets (excluding goodwill)	'	'	'
Gross Cost	81	74	'
Accumulated Amortization	-45	-42	'
Net Intangibles	$36	$32	'

DEBT_Details

DEBT (Details)

0 Months Ended

3 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

3 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

0 Months Ended

11 Months Ended

12 Months Ended

11 Months Ended

11 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

1 Months Ended

1 Months Ended

Jul. 23, 2013

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Jul. 23, 2013

Dec. 31, 2013

Jul. 18, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Jul. 19, 2013

Jun. 21, 2013

Aug. 31, 2010

Sep. 30, 2013

Dec. 31, 2013

Jul. 31, 2013

Jul. 05, 2013

Jun. 11, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Oct. 31, 2012

Oct. 31, 2013

Aug. 31, 2010

Dec. 31, 2013

Jul. 31, 2013

Jul. 23, 2013

Dec. 31, 2012

Jan. 31, 2014

Dec. 31, 2013

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Sep. 30, 2013

Nov. 10, 2010

Dec. 31, 2013

Dec. 31, 2012

Nov. 30, 2010

Nov. 30, 2013

Nov. 30, 2013

Nov. 30, 2013

Nov. 30, 2013

Nov. 30, 2013

Dec. 31, 2013

Nov. 30, 2013

Nov. 30, 2013

Dec. 31, 2013

Nov. 30, 2013

Nov. 30, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Mar. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

USD ($)

USD ($)

USD ($)

USD ($)

5.75% Senior Notes due 2021

5.75% Senior Notes due 2021

5.75% Senior Notes due 2021

5.75% Senior Notes due 2021

5.75% Senior Notes due 2021

5.75% Senior Notes due 2021

5.75% Senior Notes due 2021

5.75% Senior Notes due 2021

5.75% Senior Notes due 2021

7.875% Senior Notes due 2018

7.875% Senior Notes due 2018

7.875% Senior Notes due 2018

7.875% Senior Notes due 2018

7.875% Senior Notes due 2018

7.875% Senior Notes due 2018

7.875% Senior Notes due 2018

7.875% Senior Notes due 2018

7.875% Senior Notes due 2018

7.875% Senior Notes due 2018

7.875% Senior Notes due 2018

7.875% Senior Notes due 2018

7.875% Senior Notes due 2018

Term Loan Due 2016

Term Loan Due 2016

Term Loan Due 2016

Term Loan Due 2016

Term Loan Due 2016

Term Loan Due 2016

Term Loan Due 2016

Term Loan Due 2016

Term Loan Due 2016

Term Loan Due 2016

Term Loan Due 2016

Term Loan Due 2016

Term Loan Due 2016

Term Loan Due 2016

Term Loan Due 2016

Term Loan Due 2016

Term Loan Due 2016

Term Loan Due 2016

Term Loan Due 2016

Term Loan Due 2016

Term Loan Due 2016

Term Loan Due 2016

Term Loan Due 2016

Term Loan Due 2016

ABL Facility

ABL Facility

ABL Facility

ABL Facility

ABL Facility

ABL Facility

ABL Facility

ABL Facility

ABL Facility

ABL Facility

ABL Facility

ABL Facility

ABL Facility

ABL Facility

ABL Facility

2018 ABL Facility

2018 ABL Facility

2018 ABL Facility

2018 ABL Facility

2018 ABL Facility

2018 ABL Facility

2018 ABL Facility

US ABL Facility

Foreign ABL Facility

China Bank Facility

China Bank Facility

China Bank Facility

Promissory note

Other borrowings

Other borrowings

USD ($)

USD ($)

USD ($)

Redemption prior to July 15, 2016

Redemption after July 15, 2016 prior to July 15, 2017

Redemption after July 15, 2017 prior to July 15, 2018

Redemption after July 15, 2018 prior to July 15, 2019

Redemption after July 15, 2019

Maximum

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Redemption prior to September 1, 2014

Redemption after September 1, 2014 prior to September 1, 2015

Redemption after September 1, 2015 prior to September 1, 2016

Redemption after September 1, 2016

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Subsequent event

Base Rate

Base Rate

Federal Funds rate

Federal Funds rate

Primary rate

Primary rate

Eurodollar rate

Eurodollar rate

Eurodollar rate

Eurodollar rate

LIBOR

LIBOR

Minimum

Maximum

Maximum

Maximum

USD ($)

USD ($)

Federal Funds rate

Federal Funds rate

Primary rate

LIBOR

LIBOR

Minimum

Minimum

Minimum

Maximum

Maximum

Maximum

USD ($)

Base Rate

Eurodollar rate

Minimum

Minimum

Maximum

Maximum

USD ($)

EUR (€)

USD ($)

CNY

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Interest option 1

Interest option 1

Interest option 1

Interest option 1

Interest option 1

Interest option 1

Interest option 1

Interest option 1

Interest option 2

Interest option 2

Interest option 2

Interest option 2

USD ($)

Interest option 2

Interest option 2

Interest option 1

Interest option 1

Interest option 1

Interest option 2

Interest option 1

Interest option 2

Interest option 1

Interest option 2

Base Rate

Eurodollar rate

Base Rate

Eurodollar rate

DEBT

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total Debt

'

'

$898,000,000

$876,000,000

'

$450,000,000

$450,000,000

'

'

'

'

'

'

'

'

'

'

$100,000,000

'

'

$455,000,000

$452,000,000

'

'

'

'

'

'

'

$316,000,000

'

'

$418,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$32,000,000

$6,000,000

Less: Short-term borrowings

'

'

-2,000,000

-3,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

110,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Less; Current portion of other long-term debt

'

'

-5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Less: Current portion of Term Loan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-110,000,000

'

'

-2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total Long-Term Debt

'

'

781,000,000

871,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest rate (as a percent)

'

'

'

'

'

5.75%

'

'

'

'

'

'

'

'

'

'

'

7.88%

'

'

'

7.88%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5.29%

'

'

Unamortized discount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

'

'

'

3,000,000

'

'

'

'

'

'

'

2,000,000

'

'

2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Effective interest rate (as a percent)

'

'

'

'

'

5.83%

'

'

'

'

'

'

'

'

'

'

'

8.90%

'

'

'

8.19%

'

'

'

'

'

'

'

5.39%

'

'

5.70%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt tendered in the offer and solicitation (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

1.33%

'

'

'

'

'

76.56%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total consideration per $1,000 principal amount for debt tendered on or prior to the June 21, 2013

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,117.50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Consent payment per $1,000 principal amount for debt tendered on or prior to the June 21, 2013

'

'

'

'

'

'

'

'

'

'

'

'

'

'

30

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount of debt tendered in the offer and solicitation

'

'

'

'

'

'

'

'

'

'

'

'

'

6,000,000

'

'

'

'

'

348,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Tender offer consideration per $1,000 principal amount for debt tendered on or prior to July 19, 2013

'

'

'

'

'

'

'

'

'

'

'

'

'

1,087.50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate principal amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

455,000,000

'

'

'

'

'

'

'

'

'

'

'

'

295,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

40,000,000

250,000,000

'

7,000,000

'

'

Term of debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'5 years

'

'6 years

'

'

Issue price as a percentage of par value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

99.27%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Discount rate (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Option to increase the size of the facility

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

125,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Term of credit facility

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Charge for loss on early extinguishment of debt

'

-50,000,000

50,000,000

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

50,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Charge for loss on early extinguishment of debt as difference between principal amount and tender offer consideration and consent payments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

42,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Write-off of unamortized discount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from the offering of senior notes utilized for prepayment of principal of term loan

'

'

'

'

45,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash on hand utilized for prepayment of principal of term loan

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Prepayment of principal of debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50,000,000

50,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of principal amount at which the entity may redeem some or all of the notes

'

'

'

'

'

105.75%

'

100.00%

104.31%

102.88%

101.44%

100.00%

'

'

'

'

'

'

'

'

'

'

100.00%

103.94%

101.97%

100.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of redeemable notes that can be redeemed from the proceeds of equity offerings

'

'

'

'

'

'

'

'

'

'

'

'

35.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Redemption price as a percentage of principal amount plus accrued and unpaid interest

'

'

'

'

'

101.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount redeemed

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

354,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Arranger fees written off

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments on Term Loan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

102,000,000

'

'

'

110,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Prepayment premium to be paid if loans are refinanced with certain specified refinancing debt within specified period (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Specified period within which if debt is refinanced with certain specified refinancing debt, it will require payment of prepayment premium

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'6 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Annual amortization rate (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum borrowing capacity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

275,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

175,000,000

60,000,000

'

'

'

'

'

'

Maximum borrowing capacity for letter of credit sub-facility

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

125,000,000

'

'

'

'

'

'

'

'

'

'

'

125,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Secured Leverage Ratio

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Consolidated Interest Coverage Ratio

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Margin over reference rate (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.75%

3.00%

0.50%

0.50%

'

'

1.00%

1.00%

2.75%

4.00%

'

'

'

'

'

'

'

'

'

'

0.50%

0.50%

'

1.00%

'

'

1.75%

2.75%

'

2.25%

3.25%

'

'

'

0.50%

1.50%

1.00%

2.00%

'

'

'

'

'

'

'

'

Reference rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'Base Rate

'Base Rate

'Federal Funds Rate

'Federal Funds Rate

'Prime Rate

'Prime Rate

'Eurodollar Rate

'Eurodollar Rate

'Eurodollar Rate

'Eurodollar Rate

'reserve adjusted LIBOR

'reserve adjusted LIBOR

'

'

'

'

'

'

'

'

'Federal Funds

'Federal Funds

'Prime Rate

'one-month LIBOR

'reserve adjusted LIBOR

'

'

'

'

'

'

'

'base rate

'adjusted Eurocurrency Rate

'

'

'

'

'

'

'

'

'

'

'

'

Margin over alternate reference rate (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.75%

1.50%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Collateral - interest in domestic subsidiaries (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Collateral - interest in non-voting capital stock of foreign subsidiaries (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Collateral - interest in voting capital stock of foreign subsidiaries (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

65.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Trailing period used for calculation of fixed charge coverage ratio

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'12 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fixed charge coverage ratio

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1

'

'

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Available Borrowings level that triggers applicability of fixed charge ratio covenant

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25,000,000

'

'

'

'

'

'

18,000,000

'

'

'

'

'

'

'

Percentage of Aggregate Commitments that triggers applicability of fixed charge ratio covenant

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

'

'

'

'

10.00%

'

'

'

'

'

'

'

Commitment period measurement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'30 days

'

'

'

'

'

'

'30 days

'

'

'

'

'

'

'

Outstanding borrowings

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

17,000,000

'

'

'

Outstanding letters of credit

'

'

14,000,000

14,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

14,000,000

'

'

'

'

'

'

'

'

'

'

'

'

14,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total undrawn availability

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

199,000,000

'

'

'

'

'

'

'

'

'

'

'

'

237,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maturities

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2014

'

'

118,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2015

'

'

11,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2016

'

'

213,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2017

'

'

2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2018

'

'

103,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Thereafter

'

'

451,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Drawdown of term loan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$125,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

LEASES_Details

LEASES (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Minimum rental commitments, primarily for buildings, land and equipment under non-cancelable operating leases, net of sublease income	'	'	'
2014	$10,000,000	'	'
2015	8,000,000	'	'
2016	6,000,000	'	'
2017	5,000,000	'	'
2018	4,000,000	'	'
2019 and thereafter	14,000,000	'	'
Aggregate minimum rental commitments	47,000,000	'	'
Rental expenses under operating leases, net of sublease income	23,000,000	24,000,000	21,000,000
Maximum	'	'	'
Operating leases	'	'	'
Sublease income	$1,000,000	$1,000,000	$1,000,000

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Pre-tax (Loss) Earnings from continuing Operations:	'	'	'
Domestic	($105)	$26	($5)
Foreign	101	103	90
Total pre-tax (loss) earnings from continuing operations	-4	129	85
Domestic	'	'	'
Current	'	'	1
Deferred	-1	'	3
Total domestic	-1	'	4
Foreign	'	'	'
Current	17	23	22
Deferred	2	3	-9
Total foreign	19	26	13
Total	'	'	'
Current	17	23	23
Deferred	1	3	-6
Total income tax expense (benefit)	18	26	17
Expense (benefit) for income taxes from continuing operations that differs from federal statutory rate	'	'	'
Income tax (benefit) expense at the U.S. statutory rate	-1	45	30
Foreign rate differential	-17	-4	-21
Valuation allowances	21	-25	-11
U.S. tax on foreign earnings	26	28	28
Nondeductible reorganizational expenses	'	1	3
Nondeductible expenses, other	7	2	1
Nondeductible stock compensation	1	1	1
Depletion	-3	-3	-2
Income tax credits	-6	-18	-14
Taxes attributable to prior periods	-11	-1	2
Other, net	1	'	'
Total income tax expense (benefit)	18	26	17
Deferred tax assets:	'	'	'
Pension and other post-retirement liabilities	61	151	'
Net operating loss carryforwards	387	389	'
Other accruals	15	23	'
Tax credit carryforwards	128	99	'
Accruals for environmental remediation	29	25	'
Intangibles	5	11	'
Inventories and other	20	21	'
Financial instruments	1	2	'
Total deferred tax assets	646	721	'
Valuation allowance	-529	-628	'
Net deferred tax assets after valuation allowance	117	93	'
Deferred tax liabilities:	'	'	'
Unremitted foreign earnings of subsidiaries	-36	-18	'
Property, plant and equipment	-72	-64	'
Other	-11	-11	'
Total deferred tax liabilities	-119	-93	'
Net deferred tax liability after valuation allowance	-2	'	'
Net current deferred taxes	'	'	'
Other current assets	10	5	'
Other current liabilities	-3	-15	'
Net non-current deferred taxes	'	'	'
Other assets	25	27	'
Other liabilities	($34)	($17)	'

INCOME_TAXES_Details_2

INCOME TAXES (Details 2) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
			Antioxidants	U.S.	U.S.	U.S.	Foreign	Foreign	Foreign
Valuation allowances	'	'	'	'	'	'	'	'	'
Amount of valuation allowances	$529	$628	'	$506	$605	$652	$23	$23	$43
Reduction in valuation allowance	99	67	'	'	'	'	'	'	'
Valuation allowance recorded in income tax (benefit) provision	57	57	'	'	'	'	'	'	'
Valuation allowance recorded in other comprehensive loss	42	10	'	'	'	'	'	'	'
Decrease in pension deferred asset and the associated valuation allowance due to sale of business	'	'	$33	'	'	'	'	'	'

INCOME_TAXES_Details_3

INCOME TAXES (Details 3) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Federal	'	'
Income taxes	'	'
NOL	$974	$972
Cumulative NOL available for use in 2014	372	'
Federal | Minimum	'	'
Income taxes	'	'
NOL annual limitation	59	'
Federal | Maximum	'	'
Income taxes	'	'
NOL annual limitation	77	'
State	'	'
Income taxes	'	'
NOL	1,034	1,165
Foreign	'	'
Income taxes	'	'
NOL	$141	$109

INCOME_TAXES_Details_4

INCOME TAXES (Details 4) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
		Federal	Federal	State	State
Income taxes	'	'	'	'	'
Tax credit carryforwards	'	$125	$96	$3	$3
Increase in deferred tax liability due to repatriation of undistributed earnings of foreign subsidiaries	18	'	'	'	'
Net effect on tax expense as a result of increase in deferred tax liability due to repatriation of undistributed earnings of foreign subsidiaries	0	'	'	'	'
Undistributed earnings of foreign subsidiaries	$756	'	'	'	'

INCOME_TAXES_Details_5

INCOME TAXES (Details 5) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2013	Sep. 01, 1999	Jul. 01, 2005
				Minimum	Maximum	Subsidiaries of Witco	Subsidiaries of Great Lakes
Income taxes	'	'	'	'	'	'	'
Basis difference of investments in the common stock of foreign subsidiaries	'	'	'	'	'	$218	$49
Increase (decrease) in liability for unrecognized tax benefits	3	5	'	'	'	'	'
Reconciliation of beginning and ending amount of unrecognized tax benefits	'	'	'	'	'	'	'
Balance at the beginning of the period	41	46	41	'	'	'	'
Gross (decreases) increases for tax positions taken during current year	-1	'	1	'	'	'	'
Gross increases for tax positions taken during a prior period	1	3	13	'	'	'	'
Gross decreases for tax positions taken during a prior period	'	-1	-5	'	'	'	'
Decreases from the expiration of the statute of limitations	'	'	-1	'	'	'	'
Settlements / payments	'	-10	-1	'	'	'	'
Foreign currency impact	3	3	-2	'	'	'	'
Balance at the end of the period	44	41	46	'	'	'	'
Interest expense related to unrecognized tax benefits	1	1	1	'	'	'	'
Interest accrued related to unrecognized tax benefits	14	13	'	'	'	'	'
Statutes of limitations under foreign and United States jurisdictions	'	'	'	'3 years	'5 years	'	'
Potential decrease in unrecognized tax benefits within the next year	$8	'	'	'	'	'	'

CAPITAL_STOCK_AND_EARNINGS_LOS2

CAPITAL STOCK AND EARNINGS (LOSS) PER COMMON SHARE (Details) (USD $)

0 Months Ended

3 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

8 Months Ended

12 Months Ended

In Millions, except Per Share data, unless otherwise specified

Nov. 12, 2013

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Nov. 08, 2010

Dec. 31, 2013

10-May-13

Jul. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Common Shares

Common Shares

Preferred Stock

Treasury Shares

Treasury Shares

Treasury Shares

Treasury Shares

Treasury Shares

CAPITAL STOCK AND EARNINGS (LOSS) PER COMMON SHARE

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares authorized pursuant to Plan

'

500

'

'

'

500

'

'

'

500

500

'

500

111

'

'

'

'

'

'

Shares to be issued under Plan

'

'

'

'

'

'

'

'

'

'

'

'

'

95.5

'

'

'

'

'

'

Common stock reserved for future issuances under the Plan (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

4.5

'

'

'

'

'

'

Common stock reserved for future issuances under equity compensation plans (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

11

'

'

'

'

'

'

Par value of common stock (in dollars per share)

'

$0.01

'

'

'

$0.01

'

'

'

$0.01

$0.01

'

'

'

'

'

'

'

'

'

Shares issued

'

100.5

'

'

'

100.4

'

'

'

100.5

100.4

'

'

'

'

'

'

'

'

'

Shares held in treasury

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4

4

2.4

Preferred stock, shares authorized

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.3

'

'

'

'

'

Par value of preferred stock (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.01

'

'

'

'

'

Preferred stock, shares outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

Value of common stock authorized to be repurchased

$191

'

'

'

'

'

'

'

'

$291

'

'

'

'

'

$141

$100

'

'

'

Increase in value of common stock authorized to be repurchased

50

'

'

'

'

'

'

'

'

100

'

'

'

'

'

'

'

'

'

'

Number of shares repurchased

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5.8

2.4

'

Value of shares repurchased

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$95

$54

'

Shares distributed from newly authorized shares

'

'

'

'

'

'

'

'

'

'

'

'

100

'

'

'

'

'

'

'

Antidilutive securities excluded from the calculation of diluted earnings (loss) per share

'

'

'

'

'

'

'

'

'

1.3

'

'

'

'

'

'

'

'

'

'

Reconciliation of the shares used in the computation of earnings (loss) per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average shares outstanding - Basic

'

96.6

97.5

98.6

98.2

97.9

97.9

98.9

98.3

97.7

98.2

100.1

'

'

'

'

'

'

'

'

Dilutive effect of common share equivalents

'

'

'

'

'

'

'

'

'

'

0.6

0.2

'

'

'

'

'

'

'

'

Weighted average shares outstanding - Diluted

'

98.1

97.5

99.7

98.2

99

98.2

99.1

99.1

97.7

98.8

100.3

'

'

'

'

'

'

'

'

ACCUMULATED_OTHER_COMPREHENSIV2

ACCUMULATED OTHER COMPREHENSIVE LOSS (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013
Changes in accumulated other comprehensive income (loss) by component	'
Balance at the beginning of the period	($428)
Other comprehensive (loss) income before reclassifications	72
Amounts reclassified from AOCL	76
Net current period other comprehensive (loss) income	148
Balance at the end of the period	-280
Foreign Currency Translation Adjustments	'
Changes in accumulated other comprehensive income (loss) by component	'
Balance at the beginning of the period	47
Other comprehensive (loss) income before reclassifications	-9
Amounts reclassified from AOCL	-51
Net current period other comprehensive (loss) income	-60
Balance at the end of the period	-13
Unrecognized Pension and Other Post-Retirement Benefit Costs	'
Changes in accumulated other comprehensive income (loss) by component	'
Balance at the beginning of the period	-475
Other comprehensive (loss) income before reclassifications	81
Amounts reclassified from AOCL	127
Net current period other comprehensive (loss) income	208
Balance at the end of the period	($267)

ACCUMULATED_OTHER_COMPREHENSIV3

ACCUMULATED OTHER COMPREHENSIVE LOSS (Details 2) (USD $)	3 Months Ended			12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Reclassifications out of AOCL to net earnings	'	'	'	'	'	'
Liquidation of consolidated entities	'	'	'	$13	$21	'
Loss on sale of discontinued operations, net of tax	-31	-3	-146	-180	'	'
(Loss) earnings from continuing operations before income taxes	'	'	'	-4	129	85
Tax on discontinued operations	'	'	'	8	'	'
Total tax	'	'	'	-18	-26	-17
Net (loss) earnings	'	'	'	-177	100	120
Total reclassifications	'	'	'	-76	'	'
Foreign currency translation	'	'	'	'	'	'
Reclassifications out of AOCL to net earnings	'	'	'	'	'	'
Total reclassifications	'	'	'	51	'	'
Foreign currency translation | Amount Reclassified from AOCL	'	'	'	'	'	'
Reclassifications out of AOCL to net earnings	'	'	'	'	'	'
Liquidation of consolidated entities	'	'	'	13	'	'
Loss on sale of discontinued operations, net of tax	'	'	'	38	'	'
Net (loss) earnings	'	'	'	51	'	'
Defined benefit pension plan	'	'	'	'	'	'
Reclassifications out of AOCL to net earnings	'	'	'	'	'	'
Total reclassifications	'	'	'	-127	'	'
Defined benefit pension plan | Amount Reclassified from AOCL	'	'	'	'	'	'
Reclassifications out of AOCL to net earnings	'	'	'	'	'	'
Amortization of prior-service costs	'	'	'	5	'	'
Amortization of actuarial losses	'	'	'	-21	'	'
Loss on sale of discontinued operations, net of tax	'	'	'	-127	'	'
(Loss) earnings from continuing operations before income taxes	'	'	'	-143	'	'
Tax on continuing operations	'	'	'	1	'	'
Tax on discontinued operations	'	'	'	15	'	'
Total tax	'	'	'	16	'	'
Net (loss) earnings	'	'	'	-127	'	'
Total reclassifications	'	'	'	($76)	'	'

STOCK_INCENTIVE_PLANS_Details

STOCK INCENTIVE PLANS (Details)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2010	Dec. 31, 2010
In Millions, unless otherwise specified			2010 LTIP	2010 LTIP
				Maximum
Stock incentive plans	'	'	'	'
Number of shares available for issuance	'	'	11	'
Expiration period	'	'	'	'10 years
Number of shares available for grant	4.9	5.3	'	'

STOCK_INCENTIVE_PLANS_Details_

STOCK INCENTIVE PLANS (Details 2) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
STOCK INCENTIVE PLANS	'	'	'
Stock-based compensation expense	$14	$24	$26
Percentage of stock-based compensation expense allocated to operating segments	23.00%	24.00%	24.00%
SG&A	'	'	'
STOCK INCENTIVE PLANS	'	'	'
Stock-based compensation expense	12	19	21
COGS	'	'	'
STOCK INCENTIVE PLANS	'	'	'
Stock-based compensation expense	1	3	3
Earnings/loss from discontinued operations, net of tax	'	'	'
STOCK INCENTIVE PLANS	'	'	'
Stock-based compensation expense	$1	$2	$2

STOCK_INCENTIVE_PLANS_Details_1

STOCK INCENTIVE PLANS (Details 3) (USD $)	12 Months Ended			1 Months Ended
In Millions, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2011	Mar. 31, 2011
	Stock options	Stock options	Stock options	2013 Awards	2012 Awards	2010 EIP	2010 EIP	2010 EIP	2011 Awards
				NQOs	NQOs	NQOs	NQOs	NQOs	NQOs
Stock incentive plans	'	'	'	'	'	'	'	'	'
Options granted (in shares)	0.4	0.8	2.2	'	'	'	'	0.8	'
Percentage of award vesting	'	'	'	'	'	33.00%	33.00%	33.00%	'
Grants approved (in shares)	'	'	'	0.4	0.8	'	'	'	1.4
Vesting period	'	'	'	'3 years	'3 years	'	'	'	'3 years
Weighted average fair value of options granted (in dollars per share)	$9.92	$8.15	$8.39	'	'	'	'	'	'
Weighted average assumptions	'	'	'	'	'	'	'	'	'
Dividend yield (as a percent)	0.00%	0.00%	0.00%	'	'	'	'	'	'
Expected volatility (as a percent)	51.00%	56.70%	53.80%	'	'	'	'	'	'
Risk-free interest rate (as a percent)	1.00%	1.20%	2.50%	'	'	'	'	'	'
Expected life	'6 years	'6 years	'6 years	'	'	'	'	'	'

STOCK_INCENTIVE_PLANS_Details_2

STOCK INCENTIVE PLANS (Details 4) (USD $)	12 Months Ended
In Millions, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Exercisable	'	'	'
Shares	1.7	'	'
Aggregate Intrinsic Value	'	'	'
Exercised	$4	$1	'
Exercisable	20	'	'
Weighted Average Remaining Contractual Life	'	'	'
Exercisable	'6 years 10 months 24 days	'	'
Stock options	'	'	'
Price Per Share	'	'	'
Outstanding at the beginning of the period, Average (in dollars per share)	$15.79	$15.90	$15.50
Outstanding at the end of the period, Average (in dollars per share)	$16.46	$15.79	$15.90
Shares	'	'	'
Outstanding at the beginning of the year (in shares)	3.1	2.8	0.8
Granted (in shares)	0.4	0.8	2.2
Exercised (in shares)	-0.5	-0.3	'
Lapsed (in shares)	-0.2	-0.2	-0.2
Outstanding at the end of the year (in shares)	2.8	3.1	2.8
Exercisable	'	'	'
Shares	'	1.3	0.7
Aggregate Intrinsic Value	'	'	'
Outstanding	32	17	'
Weighted Average Remaining Contractual Life	'	'	'
Outstanding	'7 years 4 months 24 days	'8 years 3 months 18 days	'9 years 1 month 6 days
Unrecognized compensation expense	'	'	'
Remaining unrecognized compensation expense associated with unvested awards	$3	'	'
Weighted average period for recognition	'2 years	'	'
Stock options | Average	'	'	'
Price Per Share	'	'	'
Granted (in dollars per share)	$20.50	$15.39	$16.03
Exercised (in dollars per share)	$15.83	$15.77	'
Lapsed (in dollars per share)	$16.78	$15.76	$15.91
Exercisable	'	'	'
Price per share	$15.83	$15.81	$15.68

STOCK_INCENTIVE_PLANS_Details_3

STOCK INCENTIVE PLANS (Details 5) (USD $)

12 Months Ended

1 Months Ended

1 Months Ended

1 Months Ended

In Millions, except Per Share data, unless otherwise specified

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Mar. 31, 2013

Mar. 31, 2012

Mar. 31, 2011

Mar. 31, 2011

Mar. 31, 2012

Mar. 31, 2011

Dec. 31, 2010

Feb. 28, 2011

Mar. 31, 2013

Mar. 31, 2013

Mar. 31, 2012

Mar. 31, 2012

Dec. 31, 2013

31-May-12

31-May-12

Restricted stock units

Restricted stock units

Restricted stock units

2010 EIP

2010 EIP

2010 EIP

2011 Awards

2010 EAP

2010 EAP

2010 LTIP

2010 LTIP

2013 Awards

2013 Awards

2012 Awards

2012 Awards

ESPP

ESPP

ESPP

Time-based RSU

Time-based RSU

Time-based RSU

Time-based RSU

Performance-based RSU

Performance-based RSU

Time-based RSU

Time-based RSU

Performance-based RSU

Time-based RSU

Performance-based RSU

Maximum

multiplier

multiplier

Stock incentive plans

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Awards granted (in shares)

'

'

0.4

1.5

1

'

'

0.4

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of award vesting

'

'

'

'

'

33.00%

33.00%

33.00%

'

'

'

'

'

'

'

'

'

'

'

'

Grants approved (in shares)

'

'

'

'

'

'

'

'

0.4

'

'

'

0.1

0.2

0.2

0.6

0.3

'

'

'

Performance multiplier

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

2

'

'

'

Performance measurement period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'

'

'

Vesting period

'

'

'

'

'

'

'

'

'3 years

'

'

'

'2 years

'3 years

'3 years

'3 years

'

'

'

'

Weighted average fair value of options granted (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$27.27

'

$25.38

'

'

'

Number of shares available for issuance

'

'

'

'

'

'

'

'

'

'

1

11

'

'

'

'

'

0.9

1

'

Distribution percentage

'

'

'

'

'

'

'

'

'

57.00%

'

'

'

'

'

'

'

'

'

'

Number of shares distributed

'

'

'

'

'

'

'

'

'

0.6

'

'

'

'

'

'

'

'

'

'

Shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unvested RSU awards at the beginning of the period (in shares)

'

'

1.3

0.9

0.3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cancelled (in shares)

'

'

-0.2

-0.1

-0.1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Granted (in shares)

'

'

0.4

1.5

1

'

'

0.4

'

'

'

'

'

'

'

'

'

'

'

'

Vested (in shares)

'

'

-0.5

-1

-0.3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unvested RSU awards at the end of the period (in shares)

'

'

1

1.3

0.9

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted Average Grant Date Fair Value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unvested RSU awards at the beginning of the period (in dollars per share)

'

'

$17.85

$15.91

$15.50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cancelled (in dollars per share)

'

'

$20.21

$18.04

$15.97

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Granted (in dollars per share)

'

'

$23.18

$17.72

$16

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Vested (in dollars per share)

'

'

$16.07

$15.93

$15.74

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unvested RSU awards at the end of the period (in dollars per share)

'

'

$20.53

$17.85

$15.91

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate Fair Values

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unvested RSU awards at the beginning of the period

'

'

$27

$10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Vested

'

'

8

17

5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unvested RSU awards at the end of the period

'

'

30

27

10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized compensation expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Remaining unrecognized compensation expense associated with unvested awards

'

'

10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average period for recognition

'

'

'2 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares offering per period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.1

'

Number of shares offering per plan year

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.3

'

Percentage of compensation withheld for purchase of shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

Tax Benefits of Stock-Based Compensation Plans

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from exercise of stock options

$8

$5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

PENSION_AND_OTHER_POSTRETIREME2

PENSION AND OTHER POST-RETIREMENT PLANS (Details)

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

In Millions, unless otherwise specified

Jun. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Jun. 30, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

31-May-11

31-May-11

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2012

Dec. 31, 2011

Jun. 30, 2011

Jun. 30, 2011

Dec. 31, 2012

Jun. 30, 2014

Jun. 30, 2014

USD ($)

USD ($)

USD ($)

Antioxidants

Consumer Products

Qualified Domestic Plans

Qualified Domestic Plans

Qualified Domestic Plans

Qualified Domestic Plans

Qualified Domestic Plans

Qualified Domestic Plans

International and Non-Qualified Plans

International and Non-Qualified Plans

International and Non-Qualified Plans

International and Non-Qualified Plans

International and Non-Qualified Plans

International and Non-Qualified Plans

Post-Retirement Health Care Plans

Post-Retirement Health Care Plans

Post-Retirement Health Care Plans

Post-Retirement Health Care Plans

Post-Retirement Health Care Plans

Post-Retirement Health Care Plans

UK pension plans

UK pension plans

UK pension plans

UK pension plans

UK pension plans

UK pension plans

UK pension plans

UK pension plans

UK pension plans

UK pension plans

Forecast

Forecast

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Fixed income securities

Other types of investments

Equity securities

USD ($)

USD ($)

USD ($)

Fixed income securities

Other types of investments

Equity securities

USD ($)

USD ($)

USD ($)

USD ($)

Minimum

Maximum

USD ($)

GBP (£)

USD ($)

GBP (£)

USD ($)

GBP (£)

USD ($)

USD ($)

GBP (£)

USD ($)

UK pension plans

UK pension plans

USD ($)

item

USD ($)

GBP (£)

Pension and other post-retirement benefit plans

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Increase in projected benefit obligations

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$8

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of UK subsidiaries that entered into a definitive agreement with Great Lakes U.K. Limited Pension Plan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1

1

'

'

'

'

'

'

'

'

'

'

Cash contributions by foreign subsidiary

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

95

60

'

'

'

'

'

'

'

'

'

'

Period over which cash contributions are made by UK subsidiary

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'3 years

'

'

'

'

'

'

'

'

'

'

Cash contributions by entity as per definitive agreements with the trustees

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

11

8

24

15

'

49

30

24

'

'

Cash contributions expected to be made by entity as per definitive agreements with the trustees

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

11

8

Expense recognized based on the results of the evaluation of additional benefit obligations

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8

'

'

'

'

'

Gain related to adjustment for plan to SG & A

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

'

'

'

'

'

Change in projected benefit obligation:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Projected benefit obligation at beginning of year

'

'

'

'

'

1,040

971

'

'

'

'

499

420

'

'

'

'

'

124

116

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Service cost

'

'

'

'

'

'

1

1

'

'

'

3

3

3

'

'

'

'

'

1

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest cost

'

'

'

'

'

30

43

46

'

'

'

19

21

22

'

'

'

'

4

5

5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Plan participants' contributions

'

'

'

'

'

'

'

'

'

'

'

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Actuarial (gains) losses

'

'

'

'

'

-69

86

'

'

'

'

11

58

'

'

'

'

'

-20

5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Benefits paid

'

'

'

'

'

-51

-61

'

'

'

'

-19

-19

'

'

'

'

'

-10

-12

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Plan amendments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business divestitures

'

'

'

-315

-12

-327

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Settlements

'

'

'

'

'

'

'

'

'

'

'

-6

-1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Foreign currency exchange rate changes

'

'

'

'

'

'

'

'

'

'

'

11

17

'

'

'

'

'

-2

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Projected benefit obligation at end of year

'

'

'

'

'

623

1,040

971

'

'

'

519

499

420

'

'

'

'

96

124

116

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accumulated benefit obligation at end of year

'

'

'

'

'

622

1,039

'

'

'

'

506

490

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted-average year-end assumptions used to determine benefit obligations:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Discount rate (as a percent)

'

'

'

'

'

4.60%

3.80%

'

'

'

'

4.18%

4.03%

'

'

'

'

'

4.35%

3.56%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Rate of compensation increase (as a percent)

'

'

'

'

'

3.00%

3.00%

'

'

'

'

2.85%

2.77%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Health care cost trend rate (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6.27%

6.47%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ultimate health care cost trend rate (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Period over which health care cost trend rate was assumed to be decreased

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'6 years

'8 years

'

'

'

'

'

'

'

'

'

'

'

'

Effect of one percentage point increase (decrease) in assumed health care cost trend rates on accumulated post-retirement benefit obligation

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Effect of one percentage point increase in assumed health care cost trend rates on accumulated post-retirement benefit obligation

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Effect of one percentage point decrease in assumed health care cost trend rates on accumulated post-retirement benefit obligation

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Effect of one percentage point increase in assumed health care cost trend rates on service and interest cost components

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1

'

'

'

'

'

'

'

'

'

'

'

'

Effect of one percentage point decrease in assumed health care cost trend rates on service and interest cost components

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1

'

'

'

'

'

'

'

'

'

'

'

'

Change in plan assets:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of plan assets at beginning of year

'

'

'

'

'

814

737

'

'

'

'

370

306

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Actual return on plan assets

'

'

'

'

'

51

98

'

'

'

'

30

29

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Employer contribution

'

57

91

'

'

20

40

'

'

'

'

27

39

'

'

'

'

'

10

12

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Plan participants' contributions

'

'

'

'

'

'

'

'

'

'

'

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Benefits paid

'

'

'

'

'

-51

-61

'

'

'

'

-19

-19

'

'

'

'

'

-10

-12

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business divestitures

'

'

'

-233

-6

-239

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Settlements

'

'

'

'

'

'

'

'

'

'

'

-6

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Foreign currency exchange rate changes

'

'

'

'

'

'

'

'

'

'

'

5

15

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of plan assets at end of year

'

'

'

'

'

$595

$814

$737

'

'

'

$408

$370

$306

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Target allocations

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Target allocations (as a percent)

'

'

'

'

'

'

'

'

58.00%

10.00%

32.00%

'

'

'

27.00%

34.00%

39.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

PENSION_AND_OTHER_POSTRETIREME3

PENSION AND OTHER POST-RETIREMENT PLANS (Details 2)

12 Months Ended

3 Months Ended

12 Months Ended

In Millions, unless otherwise specified

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2012

Jun. 30, 2011

Jun. 30, 2011

Dec. 31, 2012

Dec. 31, 2013

Money market funds

Significant Unobservable Inputs (Level 3)

Significant Unobservable Inputs (Level 3)

Significant Unobservable Inputs (Level 3)

Qualified Domestic Plans

Qualified Domestic Plans

Qualified Domestic Plans

Qualified Domestic Plans

Qualified Domestic Plans

Qualified Domestic Plans

Qualified Domestic Plans

Qualified Domestic Plans

Qualified Domestic Plans

Qualified Domestic Plans

Qualified Domestic Plans

Qualified Domestic Plans

Qualified Domestic Plans

Qualified Domestic Plans

Qualified Domestic Plans

Qualified Domestic Plans

Qualified Domestic Plans

Qualified Domestic Plans

Qualified Domestic Plans

Qualified Domestic Plans

Qualified Domestic Plans

Qualified Domestic Plans

Qualified Domestic Plans

Qualified Domestic Plans

Qualified Domestic Plans

Qualified Domestic Plans

Qualified Domestic Plans

Qualified Domestic Plans

Qualified Domestic Plans

Qualified Domestic Plans

Qualified Domestic Plans

International and Non-Qualified Plans

International and Non-Qualified Plans

International and Non-Qualified Plans

International and Non-Qualified Plans

International and Non-Qualified Plans

International and Non-Qualified Plans

International and Non-Qualified Plans

International and Non-Qualified Plans

International and Non-Qualified Plans

International and Non-Qualified Plans

International and Non-Qualified Plans

International and Non-Qualified Plans

International and Non-Qualified Plans

International and Non-Qualified Plans

International and Non-Qualified Plans

International and Non-Qualified Plans

International and Non-Qualified Plans

International and Non-Qualified Plans

International and Non-Qualified Plans

International and Non-Qualified Plans

International and Non-Qualified Plans

International and Non-Qualified Plans

International and Non-Qualified Plans

International and Non-Qualified Plans

International and Non-Qualified Plans

International and Non-Qualified Plans

International and Non-Qualified Plans

International and Non-Qualified Plans

International and Non-Qualified Plans

International and Non-Qualified Plans

International and Non-Qualified Plans

International and Non-Qualified Plans

International and Non-Qualified Plans

International and Non-Qualified Plans

UK pension plans

UK pension plans

UK pension plans

UK pension plans

UK pension plans

UK pension plans

UK pension plans

UK pension plans

Maximum

USD ($)

Alternative Collective funds

Other instruments

USD ($)

USD ($)

USD ($)

Pooled equity

Pooled equity

U.S. government bonds

U.S. government bonds

Pooled fixed income funds

Pooled fixed income funds

Alternative Collective funds

Alternative Collective funds

Other instruments

Other instruments

Cash & cash equivalents

Quoted Prices in Active Markets for Identical Assets (Level 1)

Quoted Prices in Active Markets for Identical Assets (Level 1)

Quoted Prices in Active Markets for Identical Assets (Level 1)

Quoted Prices in Active Markets for Identical Assets (Level 1)

Quoted Prices in Active Markets for Identical Assets (Level 1)

Quoted Prices in Active Markets for Identical Assets (Level 1)

Quoted Prices in Active Markets for Identical Assets (Level 1)

Quoted Prices in Active Markets for Identical Assets (Level 1)

Quoted Prices in Active Markets for Identical Assets (Level 1)

Significant Observable Inputs (Level 2)

Significant Observable Inputs (Level 2)

Significant Observable Inputs (Level 2)

Significant Observable Inputs (Level 2)

Significant Unobservable Inputs (Level 3)

Significant Unobservable Inputs (Level 3)

Significant Unobservable Inputs (Level 3)

Significant Unobservable Inputs (Level 3)

USD ($)

USD ($)

USD ($)

Pooled equity

Pooled equity

U.S. corporate bonds

International government bonds

International government bonds

Pooled fixed income funds

Pooled fixed income funds

Other instruments

Other instruments

Cash & cash equivalents

Cash & cash equivalents

Quoted Prices in Active Markets for Identical Assets (Level 1)

Quoted Prices in Active Markets for Identical Assets (Level 1)

Quoted Prices in Active Markets for Identical Assets (Level 1)

Quoted Prices in Active Markets for Identical Assets (Level 1)

Quoted Prices in Active Markets for Identical Assets (Level 1)

Quoted Prices in Active Markets for Identical Assets (Level 1)

Significant Observable Inputs (Level 2)

Significant Observable Inputs (Level 2)

Significant Observable Inputs (Level 2)

Significant Observable Inputs (Level 2)

Significant Observable Inputs (Level 2)

Significant Observable Inputs (Level 2)

Significant Observable Inputs (Level 2)

Significant Observable Inputs (Level 2)

Significant Observable Inputs (Level 2)

Significant Unobservable Inputs (Level 3)

Significant Unobservable Inputs (Level 3)

Significant Unobservable Inputs (Level 3)

Significant Unobservable Inputs (Level 3)

Significant Unobservable Inputs (Level 3)

USD ($)

GBP (£)

USD ($)

GBP (£)

USD ($)

GBP (£)

USD ($)

International government bonds

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Pooled equity

Pooled equity

Pooled fixed income funds

Pooled fixed income funds

Other instruments

Other instruments

Cash & cash equivalents

USD ($)

USD ($)

U.S. government bonds

U.S. government bonds

USD ($)

USD ($)

Alternative Collective funds

Alternative Collective funds

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Pooled equity

Pooled equity

Cash & cash equivalents

Cash & cash equivalents

USD ($)

USD ($)

Pooled equity

Pooled equity

U.S. corporate bonds

International government bonds

International government bonds

Pooled fixed income funds

Pooled fixed income funds

USD ($)

USD ($)

Pooled fixed income funds

Other instruments

Other instruments

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

plan

PENSION AND OTHER POST-RETIREMENT PLANS

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of plan assets

'

$106

$91

$15

$595

$814

$737

$141

$288

$71

$74

$287

$331

$91

$120

$1

$1

$4

$433

$620

$141

$288

$287

$331

$1

$1

$4

$71

$74

$71

$74

$91

$120

$91

$120

$408

$370

$306

$146

$168

$1

$2

$62

$247

$131

$11

$7

$2

$1

$14

$26

$12

$25

$2

$1

$379

$337

$134

$143

$1

$2

$62

$243

$131

$15

$7

$4

$11

$7

'

'

'

'

'

'

'

'

Cash contributions by entity as per definitive agreements with the trustees

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

11

8

24

15

49

30

24

49

Number of plans

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1

Maturity period of money market instruments

'90 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Investments transferred into pooled equity and fixed income funds due to the change in asset management

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of plan assets at beginning of year

'

106

120

7

595

814

737

141

288

71

74

287

331

91

120

1

1

4

433

620

141

288

287

331

1

1

4

71

74

71

74

91

120

91

120

408

370

306

146

168

1

2

62

247

131

11

7

2

1

14

26

12

25

2

1

379

337

134

143

1

2

62

243

131

15

7

4

11

7

'

'

'

'

'

'

'

'

Transfers to/(from) Level 3

'

-31

-39

8

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Realized gains

'

1

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrealized gains

'

10

9

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Disbursements

'

-1

'

-1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of plan assets at end of year

'

$106

$91

$15

$595

$814

$737

$141

$288

$71

$74

$287

$331

$91

$120

$1

$1

$4

$433

$620

$141

$288

$287

$331

$1

$1

$4

$71

$74

$71

$74

$91

$120

$91

$120

$408

$370

$306

$146

$168

$1

$2

$62

$247

$131

$11

$7

$2

$1

$14

$26

$12

$25

$2

$1

$379

$337

$134

$143

$1

$2

$62

$243

$131

$15

$7

$4

$11

$7

'

'

'

'

'

'

'

'

PENSION_AND_OTHER_POSTRETIREME4

PENSION AND OTHER POST-RETIREMENT PLANS (Details 3)

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

In Millions, unless otherwise specified

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Apr. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2012

Jun. 30, 2011

Jun. 30, 2011

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

USD ($)

USD ($)

USD ($)

Antioxidants

Antioxidants

Antioxidants

Consumer Products

Consumer Products

Consumer Products

Qualified Domestic Plans

Qualified Domestic Plans

Qualified Domestic Plans

Qualified Domestic Plans

Qualified Domestic Plans

Qualified Domestic Plans

International and Non-Qualified Plans

International and Non-Qualified Plans

International and Non-Qualified Plans

UK pension plans

UK pension plans

UK pension plans

UK pension plans

UK pension plans

UK pension plans

UK pension plans

Post-Retirement Health Care Plans

Post-Retirement Health Care Plans

Post-Retirement Health Care Plans

Legacy pension plan

Legacy pension plan

Legacy pension plan

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Discontinued operations

Discontinued operations

Discontinued operations

USD ($)

USD ($)

USD ($)

USD ($)

GBP (£)

USD ($)

GBP (£)

USD ($)

GBP (£)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

SG&A

Discontinued operations

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Funded status, end of year:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of plan assets

'

'

'

'

'

'

'

'

'

$595

$814

$737

'

'

'

$408

$370

$306

'

'

'

'

'

'

'

'

'

'

'

'

'

Benefit obligations

'

'

'

'

'

'

'

'

'

623

1,040

971

'

'

'

519

499

420

'

'

'

'

'

'

'

96

124

116

'

'

'

Net amount recognized

'

'

'

'

'

'

'

'

'

-28

-226

'

'

'

'

-111

-129

'

'

'

'

'

'

'

'

-96

-124

'

'

'

'

Amounts recognized in the Consolidated Balance Sheets at the end of year consist of:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Noncurrent assets

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

30

13

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Current liability

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-9

-8

'

'

'

'

'

'

'

'

-9

-11

'

'

'

'

Noncurrent liability

-246

-386

'

'

'

'

'

'

'

-28

-139

'

'

'

'

-132

-134

'

'

'

'

'

'

'

'

-87

-113

'

'

'

'

Liabilities of discontinued operations

'

'

'

'

'

80

'

'

7

'

87

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net amount recognized

'

'

'

'

'

'

'

'

'

-28

-226

'

'

'

'

-111

-129

'

'

'

'

'

'

'

'

-96

-124

'

'

'

'

Amounts recognized in accumulated other comprehensive loss consist of:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net actuarial loss/(gain)

'

'

'

'

'

'

'

'

'

219

427

'

'

'

'

120

121

'

'

'

'

'

'

'

'

31

54

'

'

'

'

Prior service cost/(credit)

'

'

'

'

'

'

'

'

'

'

1

'

'

'

'

'

1

'

'

'

'

'

'

'

'

-40

-45

'

'

'

'

Net amount recognized

'

'

'

'

'

'

'

'

'

219

428

'

'

'

'

120

122

'

'

'

'

'

'

'

'

-9

9

'

'

'

'

Amount of pension liabilities transferred on actuarial valuation

'

'

'

82

'

'

6

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Estimated amounts that will be amortized from AOCL into net periodic benefit cost (credit) in next fiscal year

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Actuarial loss

'

'

'

'

'

'

'

'

'

10

'

'

'

'

'

5

'

'

'

'

'

'

'

'

'

2

'

'

'

'

'

Prior service credit

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-5

'

'

'

'

'

Total amortization cost (credit)

'

'

'

'

'

'

'

'

'

10

'

'

'

'

'

5

'

'

'

'

'

'

'

'

'

-3

'

'

'

'

'

Cash contributions by entity as per definitive agreements with the trustees

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

11

8

24

15

49

30

24

'

'

'

'

'

'

Cash contributions by entity as per definitive agreements with the trustees

57

91

'

'

'

'

'

'

'

20

40

'

'

'

'

27

39

'

'

'

'

'

'

'

'

10

12

'

'

'

'

Projected benefit obligation in excess of plan assets at end of year:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Projected benefit obligation

876

1,378

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of plan assets

612

887

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Discretionary contributions

'

'

'

'

'

'

'

'

'

10

0

'

'

'

'

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accumulated benefit obligation in excess of plan assets at end of year:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Projected benefit obligation

778

1,225

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accumulated benefit obligation

777

1,223

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of plan assets

611

859

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected Employer Contributions:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2014

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

17

'

'

'

'

'

'

'

'

'

9

'

'

'

'

'

Expected Benefit Payments:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2014

'

'

'

'

'

'

'

'

'

46

'

'

'

'

'

23

'

'

'

'

'

'

'

'

'

9

'

'

'

'

'

2015

'

'

'

'

'

'

'

'

'

46

'

'

'

'

'

23

'

'

'

'

'

'

'

'

'

9

'

'

'

'

'

2016

'

'

'

'

'

'

'

'

'

45

'

'

'

'

'

24

'

'

'

'

'

'

'

'

'

8

'

'

'

'

'

2017

'

'

'

'

'

'

'

'

'

45

'

'

'

'

'

25

'

'

'

'

'

'

'

'

'

8

'

'

'

'

'

2018

'

'

'

'

'

'

'

'

'

45

'

'

'

'

'

26

'

'

'

'

'

'

'

'

'

8

'

'

'

'

'

2019-2023

'

'

'

'

'

'

'

'

'

214

'

'

'

'

'

134

'

'

'

'

'

'

'

'

'

32

'

'

'

'

'

Components of net periodic benefit cost (credit):

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Service cost

'

'

'

'

'

'

'

'

'

'

1

1

'

'

'

3

3

3

'

'

'

'

'

'

'

'

1

1

'

'

'

Interest cost

'

'

'

'

'

'

'

'

'

30

43

46

'

'

'

19

21

22

'

'

'

'

'

'

'

4

5

5

'

'

'

Expected return on plan assets

'

'

'

'

'

'

'

'

'

-45

-54

-56

'

'

'

-23

-22

-18

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortization of prior service cost

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-5

-6

-6

'

'

'

Recognized actuarial losses

'

'

'

'

'

'

'

'

'

14

14

12

'

'

'

5

2

2

'

'

'

'

'

'

'

2

3

2

'

'

'

Curtailment loss recognized

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Settlement loss recognized

'

'

'

'

40

'

'

2

'

32

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-6

-2

4

Net periodic benefit cost

'

'

'

'

'

'

'

'

'

31

4

3

1

2

2

6

4

9

'

'

'

'

'

'

'

1

3

2

'

'

'

Weighted-average assumptions used to determine net cost:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Discount rate (as a percent)

'

'

'

'

'

'

'

'

'

3.80%

4.60%

5.10%

'

'

'

3.89%

4.64%

5.14%

'

'

'

'

'

'

'

3.71%

4.15%

5.14%

'

'

'

Expected return on plan assets (as a percent)

'

'

'

'

'

'

'

'

'

7.50%

7.50%

7.75%

'

'

'

6.53%

6.71%

6.80%

'

'

'

'

'

'

'

'

'

'

'

'

'

Rate of compensation increase (as a percent)

'

'

'

'

'

'

'

'

'

3.00%

4.00%

4.00%

'

'

'

2.77%

3.22%

3.34%

'

'

'

'

'

'

'

'

'

'

'

'

'

Cost of defined contribution plans

$11

$11

$11

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

DERIVATIVE_INSTRUMENTS_AND_HED1

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Details)

12 Months Ended

0 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

3 Months Ended

1 Months Ended

12 Months Ended

In Millions, unless otherwise specified

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Nov. 28, 2011

Dec. 31, 2013

Dec. 31, 2013

Sep. 30, 2013

Apr. 30, 2012

Dec. 31, 2013

Jun. 30, 2013

Sep. 30, 2013

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2013

Dec. 31, 2013

USD ($)

USD ($)

USD ($)

Tetrabrom Technologies Ltd.

Foreign exchange contracts

Forward contract

Forward contract

Forward contract

Forward contract

Forward contract

Put option

Foreign exchange contracts settled

Foreign exchange contracts settled

Foreign exchange contracts settled

Foreign exchange contracts remaining

USD ($)

facility

Euro

Tetrabrom Technologies Ltd.

Tetrabrom Technologies Ltd.

Tetrabrom Technologies Ltd.

Euro

facility

USD ($)

Maximum

Maximum

EUR (€)

USD ($)

USD ($)

Maximum

EUR (€)

USD ($)

USD ($)

facility

USD ($)

installment

Derivative instruments and hedging activities

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Notional amount of option and forward contracts purchased to reduce the risk of currency exposure

'

'

'

'

'

'

€ 25

$25

'

'

€ 25

'

$8

'

'

Gain (loss) due to change in fair market value of derivative contracts

'

'

'

'

2

'

'

'

'

'

'

'

'

'

1

Number of forward contracts purchased to reduce the risk of currency exposure

'

'

'

'

'

2

'

2

'

'

'

'

'

'

'

Gain (loss) due to change in fair market value of foreign exchange forward contracts

'

'

'

'

'

'

'

'

'

1

'

'

'

1

'

Percentage ownership interest sold

'

'

'

50.00%

'

'

'

'

'

'

'

'

'

'

'

Number of contracts settled

'

'

'

'

'

'

'

'

'

'

'

1

'

'

'

Annual installments

'

'

'

'

'

'

'

2

'

'

'

'

'

'

'

Net liability from change in fair market value of foreign exchange contracts accounted for in Consolidated Balance Sheet

'

'

'

'

'

'

'

'

1

'

'

'

'

'

'

Foreign currency contract pre-tax loss

$7

$6

$2

'

'

'

'

'

'

'

'

'

'

'

'

FINANCIAL_INSTRUMENTS_AND_FAIR2

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Financial instruments and fair value measurements	'	'
Total debt	$898	$876
Carrying Amount	'	'
Financial instruments and fair value measurements	'	'
Total debt	898	876
Fair Value	'	'
Financial instruments and fair value measurements	'	'
Total debt	$916	$920

FINANCIAL_INSTRUMENTS_AND_FAIR3

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Details 2) (USD $)	Dec. 31, 2013	Jun. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	Jun. 30, 2013
In Millions, unless otherwise specified			Recurring basis	Recurring basis	Recurring basis
			Level 1	Level 1	Level 3
Fair Value Measurements	'	'	'	'	'
Fair value of asset	'	'	$3	$2	'
Fair value of liability	'	'	3	2	'
Face value of investment in non-public preferred equity securities	'	9	'	'	'
Investment in non-public preferred equity securities	'	'	'	'	4
Amount of transfer of assets out of Level 1 into Level 2	0	'	'	'	'
Amount of transfer of assets out of Level 2 into Level 1	0	'	'	'	'
Amount of transfer of liabilities out of Level 1 into Level 2	0	'	'	'	'
Amount of transfer of liabilities out of Level 2 into Level 1	$0	'	'	'	'

ASSET_RETIREMENT_OBLIGATIONS_D

ASSET RETIREMENT OBLIGATIONS (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Change in the carrying amount of the asset retirement obligations	'	'
Asset retirement obligation balance at beginning of period	$20	$21
Loss on sale of discontinued operations	-2	'
Accretion expense/(benefit) - cost of goods sold	3	-1
Accretion expense - loss from discontinued operations	'	2
Payments	-5	-2
Asset retirement obligation balance at end of period	16	20
Asset retirement obligations included in other liabilities	12	11
Continuing operations	'	'
Change in the carrying amount of the asset retirement obligations	'	'
Asset retirement obligations included in accrued expenses	3	6
Discontinued operations	'	'
Change in the carrying amount of the asset retirement obligations	'	'
Asset retirement obligations included in accrued expenses	$1	$3
Lease termination	'	'
Asset retirement obligations	'	'
Number of facilities to be closed	20	'
Brine and waste disposal facilities	'	'
Asset retirement obligations	'	'
Number of facilities to be closed	90	'
Manufacturing facilities	'	'
Asset retirement obligations	'	'
Number of facilities to be closed	25	'

EMERGENCE_FROM_CHAPTER_11_Deta

EMERGENCE FROM CHAPTER 11 (Details)	Jul. 31, 2012	Mar. 18, 2009
	item	entity
		item
EMERGENCE FROM CHAPTER 11	'	'
Number of US affiliates of the entity that also filed voluntary petitions for relief under Chapter 11	'	26
Number of supplemental distributions made to Holders of Interests	4	4

EMERGENCE_FROM_CHAPTER_11_Deta1

EMERGENCE FROM CHAPTER 11 (Details 2) (USD $)	3 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Reorganization items related to Chapter 11 cases	'	'	'	'
Professional fees and other	'	$1	$4	$16
Severance and closure costs	'	'	'	1
Claim settlements, net	'	'	1	2
Total reorganization items, net	$2	$1	$5	$19

LEGAL_PROCEEDINGS_AND_CONTINGE1

LEGAL PROCEEDINGS AND CONTINGENCIES (Details)

3 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

In Millions, unless otherwise specified

Jun. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Sep. 06, 2013

31-May-11

31-May-11

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2012

Jun. 30, 2011

Jun. 30, 2011

Dec. 31, 2012

Jun. 30, 2014

Jun. 30, 2014

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2008

USD ($)

Environmental

Environmental

Environmental

Environmental

UK pension plans

UK pension plans

UK pension plans

UK pension plans

UK pension plans

UK pension plans

UK pension plans

UK pension plans

UK pension plans

UK pension plans

UK pension plans

CMUK

CMUK

CMUK

USD ($)

USD ($)

USD ($)

Maximum

USD ($)

GBP (£)

USD ($)

GBP (£)

USD ($)

GBP (£)

USD ($)

GBP (£)

USD ($)

Forecast

Forecast

UK pension plans

UK pension plans

UK pension plans

USD ($)

USD ($)

GBP (£)

USD ($)

member

GBP (£)

pensioner

Environmental Liabilities

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of pensioners

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

580

'

Number of members entitled to deferred benefits

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

690

'

Estimated funding deficit

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

£ 95

Cash contributions by foreign subsidiary

'

'

'

'

'

95

60

'

'

'

'

'

'

'

'

'

'

'

'

Period over which cash contributions are made by UK subsidiary

'

'

'

'

'

'3 years

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

Cash contributions by entity as per definitive agreements with the trustees

'

'

'

'

'

'

'

11

8

24

15

49

30

24

'

'

'

'

'

Cash contributions expected to be made by entity as per definitive agreements with the trustees

'

'

'

'

'

'

'

'

'

'

'

'

'

'

11

8

'

'

'

Gain related to adjustment for plan to SG & A

2

'

'

'

'

'

'

2

'

'

'

'

'

'

'

'

'

'

'

Net periodic benefit cost

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8

'

'

Environmental Liabilities that Have Not Been Discharged or Settled

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Period for accrual of probable and reasonable remediation costs on an undiscounted basis

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Penalty

'

'

'

'

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount accrued for environmental liabilities

'

93

84

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Environmental liabilities reflected as accrued expenses

'

18

15

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Environmental liabilities reflected as other liabilities

'

75

69

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reasonably possible ongoing environmental liabilities

'

107

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Pre-tax charge for clean-up costs

'

29

7

6

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments for clean-up costs

'

15

12

37

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Pre-petition liabilities for clean-up costs

'

'

'

27

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Receivables based on contractual agreement

'

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

LEGAL_PROCEEDINGS_AND_CONTINGE2

LEGAL PROCEEDINGS AND CONTINGENCIES (Details 2) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Guarantees	'	'
Outstanding letters of credit	$14	$14
Unconditional purchase obligations primarily for commitments to purchase raw materials and tolling arrangements with outside vendors	'	'
2014	3	'
2015	1	'
2016	1	'
Aggregate unconditional purchase obligations	5	'
Guarantees provided to financial institutions	'	'
Guarantees	'	'
Outstanding guarantees	12	12
Maximum potential future principal and interest payments due under guarantees	2	3
Guarantees provided to financial institutions | Maximum	'	'
Guarantees	'	'
Fair value of guarantees	$1	$1

BUSINESS_SEGMENTS_Details

BUSINESS SEGMENTS (Details) (USD $)

3 Months Ended

12 Months Ended

0 Months Ended

3 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

In Millions, unless otherwise specified

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Nov. 28, 2011

Dec. 31, 2011

Apr. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Operating segments

Operating segments

Operating segments

Antioxidant and Consumer Product businesses

Antioxidant and Consumer Product businesses

Antioxidant and Consumer Product businesses

Tetrabrom Technologies Ltd.

Tetrabrom Technologies Ltd.

Antioxidants

Continuing operations

Continuing operations

Continuing operations

Continuing operations

Continuing operations

Continuing operations

Discontinued operations

Discontinued operations

Discontinued operations

Industrial Performance Products

Industrial Performance Products

Industrial Performance Products

Industrial Performance Products

Industrial Performance Products

Industrial Performance Products

Industrial Performance Products

Industrial Performance Products

Industrial Performance Products

Industrial Performance Products

Industrial Performance Products

Industrial Performance Products

Industrial Performance Products

Industrial Performance Products

Industrial Performance Products

Industrial Performance Products

Industrial Performance Products

Industrial Engineered Products

Industrial Engineered Products

Industrial Engineered Products

Industrial Engineered Products

Industrial Engineered Products

Industrial Engineered Products

Industrial Engineered Products

Industrial Engineered Products

Industrial Engineered Products

Industrial Engineered Products

Industrial Engineered Products

Industrial Engineered Products

Industrial Engineered Products

Industrial Engineered Products

Industrial Engineered Products

Industrial Engineered Products

Industrial Engineered Products

Chemtura AgroSolutions

Chemtura AgroSolutions

Chemtura AgroSolutions

Chemtura AgroSolutions

Chemtura AgroSolutions

Chemtura AgroSolutions

Chemtura AgroSolutions

Chemtura AgroSolutions

Chemtura AgroSolutions

Chemtura AgroSolutions

Chemtura AgroSolutions

Chemtura AgroSolutions

Corporate

Corporate

Corporate

Corporate

Corporate

Corporate

Corporate

Corporate

Corporate

Corporate

Operating segments

Operating segments

Operating segments

Operating segments

Operating segments

Operating segments

Continuing operations

Continuing operations

Continuing operations

Continuing operations

Continuing operations

Petroleum additives

Petroleum additives

Petroleum additives

Urethanes

Urethanes

Urethanes

Operating segments

Operating segments

Operating segments

Continuing operations

Continuing operations

Continuing operations

Continuing operations

Continuing operations

Continuing operations

Bromine based & related products

Bromine based & related products

Bromine based & related products

Organometallics

Organometallics

Organometallics

Operating segments

Operating segments

Operating segments

Continuing operations

Continuing operations

Continuing operations

Continuing operations

Continuing operations

Continuing operations

Tetrabrom Technologies Ltd.

Continuing operations

Continuing operations

Continuing operations

Continuing operations

Continuing operations

Continuing operations

Operating segments

Operating segments

Operating segments

Operating segments

Operating segments

Operating segments

productline

Operating segments

Operating segments

Operating segments

Antioxidant and Consumer Product businesses

Antioxidant and Consumer Product businesses

Antioxidant and Consumer Product businesses

BUSINESS SEGMENT DATA

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of major product lines

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage ownership interest sold

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50.00%

'

'

'

'

'

'

Cash consideration on sale of business

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$97

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net Sales

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net Sales

544

569

590

528

533

546

583

534

2,231

2,196

2,184

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

979

891

939

'

'

'

'

'

689

600

634

290

291

305

'

'

803

896

869

'

'

'

'

'

'

639

730

688

164

166

181

'

'

'

449

409

376

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Operating Income

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

OPERATING INCOME

'

'

'

'

'

'

'

'

98

179

166

252

307

276

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

109

102

116

'

'

'

'

'

'

'

'

'

'

'

'

'

55

140

130

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

88

65

30

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

General corporate expense

'

'

'

'

'

'

'

'

-97

-100

-105

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-12

-12

-14

'

'

'

'

-20

-26

-30

Amortization

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-8

-14

-16

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortization

'

'

'

'

'

'

'

'

-15

-16

-22

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Facility closures, severance and related costs

-14

-3

-11

-14

-3

-2

-6

'

-42

-11

-3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gain on sale of business

'

'

'

'

'

'

'

'

'

'

27

'

'

'

'

'

'

'

27

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Impairment charges

'

'

'

'

'

'

'

'

'

'

-4

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Changes in estimates related to expected allowable claims

'

'

'

'

'

'

'

-2

'

-1

-3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest expense

'

'

'

'

'

'

'

'

-60

-64

-63

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loss on early extinguishment of debt

'

50

'

'

'

'

'

'

-50

-1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Other income, net

'

'

'

'

'

'

'

'

9

20

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reorganization items, net

'

'

'

'

'

'

'

-2

-1

-5

-19

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

(Loss) earnings from continuing operations before income taxes

'

'

'

'

'

'

'

'

-4

129

85

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Depreciation and amortization

'

'

'

'

'

'

'

'

123

139

140

'

'

'

'

'

'

'

'

'

101

100

103

83

81

78

22

39

37

'

'

'

'

'

'

'

'

28

25

26

'

'

'

'

'

'

'

'

'

'

'

'

'

'

43

43

42

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12

13

10

'

'

'

'

18

19

25

'

'

'

Equity Income (Loss)

'

'

'

'

'

'

'

'

'

-4

-1

'

'

'

'

'

'

'

'

'

'

-4

-1

'

'

'

2

7

4

'

'

'

'

'

'

1

-1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-1

-2

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1

-3

-2

'

'

'

'

'

'

'

'

'

'

'

'

'

Segment Assets

2,704

'

'

'

3,030

'

'

'

2,704

3,030

2,855

'

'

'

'

'

'

'

'

'

'

'

'

1,619

1,526

1,441

'

654

718

'

'

'

'

'

'

'

'

591

514

491

'

'

'

'

'

'

'

'

'

'

'

'

'

'

743

693

624

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

285

319

326

1,085

850

696

'

'

'

'

'

'

'

Capital expenditures

'

'

'

'

'

'

'

'

170

149

154

'

'

'

'

'

'

'

'

'

159

136

142

153

126

139

11

13

12

'

'

'

'

'

'

'

'

73

52

35

'

'

'

'

'

'

'

'

'

'

'

'

'

'

73

69

98

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7

5

6

'

'

'

'

6

10

3

'

'

'

Equity Method Investments

$13

'

'

'

$38

'

'

'

$13

$38

$42

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$7

$10

$8

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$4

$6

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$6

$24

$28

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

BUSINESS_SEGMENTS_Details_2

BUSINESS SEGMENTS (Details 2) (USD $)	3 Months Ended								12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Business segments	'	'	'	'	'	'	'	'	'	'	'
Net sales	$544	$569	$590	$528	$533	$546	$583	$534	$2,231	$2,196	$2,184
Property, plant and equipment	724	'	'	'	655	'	'	'	724	655	602
United States	'	'	'	'	'	'	'	'	'	'	'
Business segments	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	944	878	840
Property, plant and equipment	335	'	'	'	341	'	'	'	335	341	343
Canada	'	'	'	'	'	'	'	'	'	'	'
Business segments	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	42	39	40
Property, plant and equipment	62	'	'	'	69	'	'	'	62	69	68
Latin America	'	'	'	'	'	'	'	'	'	'	'
Business segments	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	194	159	139
Property, plant and equipment	14	'	'	'	15	'	'	'	14	15	15
Europe/Africa	'	'	'	'	'	'	'	'	'	'	'
Business segments	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	624	676	682
Property, plant and equipment	217	'	'	'	188	'	'	'	217	188	158
Asia/Pacific	'	'	'	'	'	'	'	'	'	'	'
Business segments	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	427	444	483
Property, plant and equipment	$96	'	'	'	$42	'	'	'	$96	$42	$18

GUARANTOR_CONDENSED_CONSOLIDAT2

GUARANTOR CONDENSED CONSOLIDATING FINANCIAL DATA (Details) (USD $)	3 Months Ended								12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Guarantor condensed consolidating financial data	'	'	'	'	'	'	'	'	'	'	'
Net sales	$544	$569	$590	$528	$533	$546	$583	$534	$2,231	$2,196	$2,184
Cost of goods sold	'	'	'	'	'	'	'	'	1,721	1,615	1,626
Selling, general and administrative	'	'	'	'	'	'	'	'	229	245	269
Depreciation and amortization	'	'	'	'	'	'	'	'	101	100	103
Research and development	'	'	'	'	'	'	'	'	40	41	36
Facility closures, severance and related costs	14	3	11	14	3	2	6	'	42	11	3
Gain on sale of business	'	'	'	'	'	'	'	'	'	'	-27
Impairment charges	'	'	'	'	'	'	'	'	'	'	4
Changes in estimates related to expected allowable claims	'	'	'	'	'	'	'	2	'	1	3
Equity loss	'	'	'	'	'	'	'	'	'	4	1
OPERATING INCOME	'	'	'	'	'	'	'	'	98	179	166
Interest expense	'	'	'	'	'	'	'	'	-60	-64	-63
Loss on early extinguishment of debt	'	50	'	'	'	'	'	'	-50	-1	'
Other income (expense), net	'	'	'	'	'	'	'	'	9	20	1
Reorganization items, net	'	'	'	'	'	'	'	-2	-1	-5	-19
(Loss) earnings from continuing operations before income taxes	'	'	'	'	'	'	'	'	-4	129	85
Income tax expense	'	'	'	'	'	'	'	'	-18	-26	-17
(Loss) earnings from continuing operations	'	'	'	'	'	'	'	'	-22	103	68
(Loss) earnings from discontinued operations, net of tax	'	'	'	'	'	'	'	'	25	-3	52
Loss on sale of discontinued operations, net of tax	-31	-3	-146	'	'	'	'	'	-180	'	'
Net (loss) earnings	'	'	'	'	'	'	'	'	-177	100	120
Less: net loss (earnings) attributable to non-controlling interests	'	'	'	'	'	'	'	'	'	1	-1
Net (loss) earnings attributable to Chemtura	'	'	'	'	'	'	'	'	-177	101	119
ACCUMULATED OTHER COMPREHENSIVE LOSS	'	'	'	'	'	'	'	'	'	'	'
Net (loss) earnings	'	'	'	'	'	'	'	'	-177	100	120
Other comprehensive (loss) income, net of tax:	'	'	'	'	'	'	'	'	'	'	'
Foreign currency translation adjustments	'	'	'	'	'	'	'	'	-60	-6	-35
Unrecognized pension and other post-retirement benefit costs	'	'	'	'	'	'	'	'	208	-76	-35
Comprehensive (loss) income	'	'	'	'	'	'	'	'	-29	18	50
Comprehensive loss (income) attributable to the non-controlling interest	'	'	'	'	'	'	'	'	'	1	-1
Comprehensive (loss) income attributable to Chemtura	'	'	'	'	'	'	'	'	-29	19	49
Eliminations	'	'	'	'	'	'	'	'	'	'	'
Guarantor condensed consolidating financial data	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	-1,813	-1,623	-1,593
Cost of goods sold	'	'	'	'	'	'	'	'	-1,813	-1,623	-1,593
Equity in net earnings (loss) of subsidiaries	'	'	'	'	'	'	'	'	-85	-81	-114
(Loss) earnings from continuing operations before income taxes	'	'	'	'	'	'	'	'	-85	-81	-114
(Loss) earnings from continuing operations	'	'	'	'	'	'	'	'	-85	-81	-114
Net (loss) earnings	'	'	'	'	'	'	'	'	-85	-81	-114
Net (loss) earnings attributable to Chemtura	'	'	'	'	'	'	'	'	-85	-81	-114
ACCUMULATED OTHER COMPREHENSIVE LOSS	'	'	'	'	'	'	'	'	'	'	'
Net (loss) earnings	'	'	'	'	'	'	'	'	-85	-81	-114
Other comprehensive (loss) income, net of tax:	'	'	'	'	'	'	'	'	'	'	'
Comprehensive (loss) income	'	'	'	'	'	'	'	'	'	-81	-114
Comprehensive (loss) income attributable to Chemtura	'	'	'	'	'	'	'	'	-85	-81	-114
Parent Company	'	'	'	'	'	'	'	'	'	'	'
Guarantor condensed consolidating financial data	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	1,443	1,477	1,462
Cost of goods sold	'	'	'	'	'	'	'	'	1,235	1,192	1,195
Selling, general and administrative	'	'	'	'	'	'	'	'	109	120	127
Depreciation and amortization	'	'	'	'	'	'	'	'	29	27	27
Research and development	'	'	'	'	'	'	'	'	15	16	16
Facility closures, severance and related costs	'	'	'	'	'	'	'	'	21	8	1
Impairment charges	'	'	'	'	'	'	'	'	'	'	1
Changes in estimates related to expected allowable claims	'	'	'	'	'	'	'	'	'	1	3
Equity loss	'	'	'	'	'	'	'	'	'	'	1
OPERATING INCOME	'	'	'	'	'	'	'	'	34	113	91
Interest expense	'	'	'	'	'	'	'	'	-69	-69	-72
Loss on early extinguishment of debt	'	'	'	'	'	'	'	'	-50	-1	'
Other income (expense), net	'	'	'	'	'	'	'	'	-20	-17	-10
Reorganization items, net	'	'	'	'	'	'	'	'	-1	-5	-19
Equity in net earnings (loss) of subsidiaries	'	'	'	'	'	'	'	'	85	81	116
(Loss) earnings from continuing operations before income taxes	'	'	'	'	'	'	'	'	-21	102	106
Income tax expense	'	'	'	'	'	'	'	'	'	'	-4
(Loss) earnings from continuing operations	'	'	'	'	'	'	'	'	-21	102	102
(Loss) earnings from discontinued operations, net of tax	'	'	'	'	'	'	'	'	-3	-1	17
Loss on sale of discontinued operations, net of tax	'	'	'	'	'	'	'	'	-153	'	'
Net (loss) earnings	'	'	'	'	'	'	'	'	-177	101	119
Net (loss) earnings attributable to Chemtura	'	'	'	'	'	'	'	'	-177	101	119
ACCUMULATED OTHER COMPREHENSIVE LOSS	'	'	'	'	'	'	'	'	'	'	'
Net (loss) earnings	'	'	'	'	'	'	'	'	-177	101	119
Other comprehensive (loss) income, net of tax:	'	'	'	'	'	'	'	'	'	'	'
Foreign currency translation adjustments	'	'	'	'	'	'	'	'	-18	-11	11
Unrecognized pension and other post-retirement benefit costs	'	'	'	'	'	'	'	'	202	-44	-39
Comprehensive (loss) income	'	'	'	'	'	'	'	'	'	46	91
Comprehensive (loss) income attributable to Chemtura	'	'	'	'	'	'	'	'	7	46	91
Guarantor Subsidiaries	'	'	'	'	'	'	'	'	'	'	'
Guarantor condensed consolidating financial data	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	449	454	435
Cost of goods sold	'	'	'	'	'	'	'	'	389	383	367
Selling, general and administrative	'	'	'	'	'	'	'	'	15	17	14
Depreciation and amortization	'	'	'	'	'	'	'	'	35	44	43
Research and development	'	'	'	'	'	'	'	'	8	7	5
Facility closures, severance and related costs	'	'	'	'	'	'	'	'	1	'	'
Impairment charges	'	'	'	'	'	'	'	'	'	'	1
OPERATING INCOME	'	'	'	'	'	'	'	'	1	3	5
Interest expense	'	'	'	'	'	'	'	'	'	2	1
Other income (expense), net	'	'	'	'	'	'	'	'	'	'	4
Equity in net earnings (loss) of subsidiaries	'	'	'	'	'	'	'	'	'	'	-2
(Loss) earnings from continuing operations before income taxes	'	'	'	'	'	'	'	'	1	5	8
(Loss) earnings from continuing operations	'	'	'	'	'	'	'	'	1	5	8
(Loss) earnings from discontinued operations, net of tax	'	'	'	'	'	'	'	'	23	28	17
Loss on sale of discontinued operations, net of tax	'	'	'	'	'	'	'	'	14	'	'
Net (loss) earnings	'	'	'	'	'	'	'	'	38	33	25
Net (loss) earnings attributable to Chemtura	'	'	'	'	'	'	'	'	38	33	25
ACCUMULATED OTHER COMPREHENSIVE LOSS	'	'	'	'	'	'	'	'	'	'	'
Net (loss) earnings	'	'	'	'	'	'	'	'	38	33	25
Other comprehensive (loss) income, net of tax:	'	'	'	'	'	'	'	'	'	'	'
Foreign currency translation adjustments	'	'	'	'	'	'	'	'	2	1	-2
Unrecognized pension and other post-retirement benefit costs	'	'	'	'	'	'	'	'	'	'	1
Comprehensive (loss) income	'	'	'	'	'	'	'	'	'	34	24
Comprehensive (loss) income attributable to Chemtura	'	'	'	'	'	'	'	'	40	34	24
Non-Guarantor Subsidiaries	'	'	'	'	'	'	'	'	'	'	'
Guarantor condensed consolidating financial data	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	2,152	1,888	1,880
Cost of goods sold	'	'	'	'	'	'	'	'	1,910	1,663	1,657
Selling, general and administrative	'	'	'	'	'	'	'	'	105	108	128
Depreciation and amortization	'	'	'	'	'	'	'	'	37	29	33
Research and development	'	'	'	'	'	'	'	'	17	18	15
Facility closures, severance and related costs	'	'	'	'	'	'	'	'	20	3	2
Gain on sale of business	'	'	'	'	'	'	'	'	'	'	-27
Impairment charges	'	'	'	'	'	'	'	'	'	'	2
Equity loss	'	'	'	'	'	'	'	'	'	4	'
OPERATING INCOME	'	'	'	'	'	'	'	'	63	63	70
Interest expense	'	'	'	'	'	'	'	'	9	3	8
Other income (expense), net	'	'	'	'	'	'	'	'	29	37	7
(Loss) earnings from continuing operations before income taxes	'	'	'	'	'	'	'	'	101	103	85
Income tax expense	'	'	'	'	'	'	'	'	-18	-26	-13
(Loss) earnings from continuing operations	'	'	'	'	'	'	'	'	83	77	72
(Loss) earnings from discontinued operations, net of tax	'	'	'	'	'	'	'	'	5	-30	18
Loss on sale of discontinued operations, net of tax	'	'	'	'	'	'	'	'	-41	'	'
Net (loss) earnings	'	'	'	'	'	'	'	'	47	47	90
Less: net loss (earnings) attributable to non-controlling interests	'	'	'	'	'	'	'	'	'	1	-1
Net (loss) earnings attributable to Chemtura	'	'	'	'	'	'	'	'	47	48	89
ACCUMULATED OTHER COMPREHENSIVE LOSS	'	'	'	'	'	'	'	'	'	'	'
Net (loss) earnings	'	'	'	'	'	'	'	'	47	47	90
Other comprehensive (loss) income, net of tax:	'	'	'	'	'	'	'	'	'	'	'
Foreign currency translation adjustments	'	'	'	'	'	'	'	'	-44	4	-44
Unrecognized pension and other post-retirement benefit costs	'	'	'	'	'	'	'	'	6	-32	3
Comprehensive (loss) income	'	'	'	'	'	'	'	'	'	19	49
Comprehensive loss (income) attributable to the non-controlling interest	'	'	'	'	'	'	'	'	'	1	-1
Comprehensive (loss) income attributable to Chemtura	'	'	'	'	'	'	'	'	$9	$20	$48

GUARANTOR_CONDENSED_CONSOLIDAT3

GUARANTOR CONDENSED CONSOLIDATING FINANCIAL DATA (Details 2) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
In Millions, unless otherwise specified
ASSETS	'	'	'	'
Current assets	$1,487	$1,612	'	'
Property, plant and equipment	724	655	602	'
Goodwill	179	177	'	'
Other assets	314	586	'	'
Total Assets	2,704	3,030	2,855	'
LIABILITIES AND STOCKHOLDERS' EQUITY	'	'	'	'
Current liabilities	486	511	'	'
Long-term debt	781	871	'	'
Other long-term liabilities	438	580	'	'
Total liabilities	1,705	1,962	'	'
Stockholders' equity	999	1,068	1,046	971
Total Liabilities and Stockholders' Equity	2,704	3,030	'	'
Eliminations	'	'	'	'
ASSETS	'	'	'	'
Intercompany receivables	-7,671	-9,412	'	'
Investment in subsidiaries	-7,277	-8,831	'	'
Total Assets	-14,948	-18,243	'	'
LIABILITIES AND STOCKHOLDERS' EQUITY	'	'	'	'
Intercompany payables	-7,671	-9,412	'	'
Total liabilities	-7,671	-9,412	'	'
Stockholders' equity	-7,277	-8,831	'	'
Total Liabilities and Stockholders' Equity	-14,948	-18,243	'	'
Parent Company	'	'	'	'
ASSETS	'	'	'	'
Current assets	559	505	'	'
Intercompany receivables	2,681	3,531	'	'
Investment in subsidiaries	1,530	1,738	'	'
Property, plant and equipment	121	127	'	'
Goodwill	93	92	'	'
Other assets	149	131	'	'
Total Assets	5,133	6,124	'	'
LIABILITIES AND STOCKHOLDERS' EQUITY	'	'	'	'
Current liabilities	244	210	'	'
Intercompany payables	2,944	3,676	'	'
Long-term debt	764	870	'	'
Other long-term liabilities	182	300	'	'
Total liabilities	4,134	5,056	'	'
Stockholders' equity	999	1,068	'	'
Total Liabilities and Stockholders' Equity	5,133	6,124	'	'
Guarantor Subsidiaries	'	'	'	'
ASSETS	'	'	'	'
Current assets	122	213	'	'
Intercompany receivables	2,349	3,065	'	'
Investment in subsidiaries	1,135	1,633	'	'
Property, plant and equipment	214	215	'	'
Goodwill	3	3	'	'
Other assets	44	233	'	'
Total Assets	3,867	5,362	'	'
LIABILITIES AND STOCKHOLDERS' EQUITY	'	'	'	'
Current liabilities	41	69	'	'
Intercompany payables	2,583	3,305	'	'
Other long-term liabilities	52	56	'	'
Total liabilities	2,676	3,430	'	'
Stockholders' equity	1,191	1,932	'	'
Total Liabilities and Stockholders' Equity	3,867	5,362	'	'
Non-Guarantor Subsidiaries	'	'	'	'
ASSETS	'	'	'	'
Current assets	806	894	'	'
Intercompany receivables	2,641	2,816	'	'
Investment in subsidiaries	4,612	5,460	'	'
Property, plant and equipment	389	313	'	'
Goodwill	83	82	'	'
Other assets	121	222	'	'
Total Assets	8,652	9,787	'	'
LIABILITIES AND STOCKHOLDERS' EQUITY	'	'	'	'
Current liabilities	201	232	'	'
Intercompany payables	2,144	2,431	'	'
Long-term debt	17	1	'	'
Other long-term liabilities	204	224	'	'
Total liabilities	2,566	2,888	'	'
Stockholders' equity	6,086	6,899	'	'
Total Liabilities and Stockholders' Equity	$8,652	$9,787	'	'

GUARANTOR_CONDENSED_CONSOLIDAT4

GUARANTOR CONDENSED CONSOLIDATING FINANCIAL DATA (Details 3) (USD $)	3 Months Ended					12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Dec. 31, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
CASH FLOWS FROM OPERATING ACTIVITIES	'	'	'	'	'	'	'	'
Net (loss) earnings	'	'	'	'	'	($177)	$100	$120
Adjustments to reconcile net (loss) earnings to net cash provided by (used in) operations:	'	'	'	'	'	'	'	'
Loss on sale of discontinued operations	31	3	146	'	'	180	'	'
Gain on sale of business	'	'	'	'	'	'	'	-27
Impairment charges	'	'	'	11	'	7	47	4
Reclass of translation adjustment from liquidated entities	'	'	'	'	'	-13	-21	'
Loss on early extinguishment of debt	'	-50	'	'	'	50	1	'
Depreciation and amortization	'	'	'	'	'	123	139	140
Stock-based compensation expense	'	'	'	'	'	14	24	26
Reorganization items, net	'	'	'	'	'	'	1	2
Changes in estimates related to expected allowable claims	'	'	'	'	2	'	1	3
Equity income	'	'	'	'	'	-2	-3	-3
Changes in assets and liabilities, net	'	'	'	'	'	-103	-71	-83
Net cash provided by operating activities	'	'	'	'	'	79	218	182
CASH FLOWS FROM INVESTING ACTIVITIES	'	'	'	'	'	'	'	'
Proceeds from divestments, net	'	'	'	'	'	357	9	8
Payments for acquisitions, net of cash acquired	'	'	'	'	'	-3	'	-35
Capital expenditures	'	'	'	'	'	-170	-149	-154
Net cash provided by (used in) investing activities	'	'	'	'	'	184	-140	-181
CASH FLOWS FROM FINANCING ACTIVITIES	'	'	'	'	'	'	'	'
Proceeds from 2021 Senior Notes	'	'	'	'	'	450	'	'
Payments on 2018 Senior Notes, includes premium on tendering of notes	'	'	'	'	'	-396	'	'
(Payments on) proceeds from Term Loan	'	'	'	'	'	-102	125	'
Proceeds from other long term borrowings	'	'	'	'	'	31	'	'
Payments on other long term borrowings	'	'	'	'	'	-4	'	'
(Payments on) proceeds from other short term borrowings, net	'	'	'	'	'	-1	-3	3
Payments for debt issuance costs	'	'	'	'	'	-12	-2	'
Common shares acquired	'	'	'	'	'	-54	-20	-22
Proceeds from the exercise of stock options	'	'	'	'	'	8	5	1
Net cash (used in) provided by financing activities	'	'	'	'	'	-80	105	-18
CASH AND CASH EQUIVALENTS	'	'	'	'	'	'	'	'
Effect of exchange rates on cash and cash equivalents	'	'	'	'	'	1	2	-4
Change in cash and cash equivalents	'	'	'	'	'	184	185	-21
Cash and cash equivalents at beginning of year	'	'	'	'	180	365	180	201
Cash and cash equivalents at end of year	549	'	'	365	'	549	365	180
Eliminations	'	'	'	'	'	'	'	'
CASH FLOWS FROM OPERATING ACTIVITIES	'	'	'	'	'	'	'	'
Net (loss) earnings	'	'	'	'	'	-85	-81	-114
Adjustments to reconcile net (loss) earnings to net cash provided by (used in) operations:	'	'	'	'	'	'	'	'
Changes in assets and liabilities, net	'	'	'	'	'	85	81	114
Parent Company	'	'	'	'	'	'	'	'
CASH FLOWS FROM OPERATING ACTIVITIES	'	'	'	'	'	'	'	'
Net (loss) earnings	'	'	'	'	'	-177	101	119
Adjustments to reconcile net (loss) earnings to net cash provided by (used in) operations:	'	'	'	'	'	'	'	'
Loss on sale of discontinued operations	'	'	'	'	'	153	'	'
Impairment charges	'	'	'	'	'	'	12	1
Loss on early extinguishment of debt	'	'	'	'	'	50	1	'
Depreciation and amortization	'	'	'	'	'	33	36	36
Stock-based compensation expense	'	'	'	'	'	14	24	26
Reorganization items, net	'	'	'	'	'	'	1	2
Changes in estimates related to expected allowable claims	'	'	'	'	'	'	1	3
Equity income	'	'	'	'	'	'	'	1
Changes in assets and liabilities, net	'	'	'	'	'	-84	-106	-157
Net cash provided by operating activities	'	'	'	'	'	-11	70	31
CASH FLOWS FROM INVESTING ACTIVITIES	'	'	'	'	'	'	'	'
Proceeds from divestments, net	'	'	'	'	'	255	'	8
Capital expenditures	'	'	'	'	'	-20	-21	-24
Net cash provided by (used in) investing activities	'	'	'	'	'	235	-21	-16
CASH FLOWS FROM FINANCING ACTIVITIES	'	'	'	'	'	'	'	'
Proceeds from 2021 Senior Notes	'	'	'	'	'	450	'	'
Payments on 2018 Senior Notes, includes premium on tendering of notes	'	'	'	'	'	-396	'	'
(Payments on) proceeds from Term Loan	'	'	'	'	'	-102	125	'
Proceeds from other long term borrowings	'	'	'	'	'	7	'	'
Payments on other long term borrowings	'	'	'	'	'	-1	'	'
Payments for debt issuance costs	'	'	'	'	'	-12	-1	'
Common shares acquired	'	'	'	'	'	-54	-20	-22
Proceeds from the exercise of stock options	'	'	'	'	'	8	5	1
Net cash (used in) provided by financing activities	'	'	'	'	'	-100	109	-21
CASH AND CASH EQUIVALENTS	'	'	'	'	'	'	'	'
Change in cash and cash equivalents	'	'	'	'	'	124	158	-6
Cash and cash equivalents at beginning of year	'	'	'	'	35	193	35	41
Cash and cash equivalents at end of year	317	'	'	193	'	317	193	35
Guarantor Subsidiaries	'	'	'	'	'	'	'	'
CASH FLOWS FROM OPERATING ACTIVITIES	'	'	'	'	'	'	'	'
Net (loss) earnings	'	'	'	'	'	38	33	25
Adjustments to reconcile net (loss) earnings to net cash provided by (used in) operations:	'	'	'	'	'	'	'	'
Loss on sale of discontinued operations	'	'	'	'	'	-14	'	'
Impairment charges	'	'	'	'	'	7	'	1
Depreciation and amortization	'	'	'	'	'	45	51	50
Changes in assets and liabilities, net	'	'	'	'	'	-27	-37	7
Net cash provided by operating activities	'	'	'	'	'	49	47	83
CASH FLOWS FROM INVESTING ACTIVITIES	'	'	'	'	'	'	'	'
Proceeds from divestments, net	'	'	'	'	'	-2	'	'
Capital expenditures	'	'	'	'	'	-47	-47	-83
Net cash provided by (used in) investing activities	'	'	'	'	'	-49	-47	-83
Non-Guarantor Subsidiaries	'	'	'	'	'	'	'	'
CASH FLOWS FROM OPERATING ACTIVITIES	'	'	'	'	'	'	'	'
Net (loss) earnings	'	'	'	'	'	47	47	90
Adjustments to reconcile net (loss) earnings to net cash provided by (used in) operations:	'	'	'	'	'	'	'	'
Loss on sale of discontinued operations	'	'	'	'	'	41	'	'
Gain on sale of business	'	'	'	'	'	'	'	-27
Impairment charges	'	'	'	'	'	'	35	2
Reclass of translation adjustment from liquidated entities	'	'	'	'	'	-13	-21	'
Depreciation and amortization	'	'	'	'	'	45	52	54
Equity income	'	'	'	'	'	-2	-3	-4
Changes in assets and liabilities, net	'	'	'	'	'	-77	-9	-47
Net cash provided by operating activities	'	'	'	'	'	41	101	68
CASH FLOWS FROM INVESTING ACTIVITIES	'	'	'	'	'	'	'	'
Proceeds from divestments, net	'	'	'	'	'	104	9	'
Payments for acquisitions, net of cash acquired	'	'	'	'	'	-3	'	-35
Capital expenditures	'	'	'	'	'	-103	-81	-47
Net cash provided by (used in) investing activities	'	'	'	'	'	-2	-72	-82
CASH FLOWS FROM FINANCING ACTIVITIES	'	'	'	'	'	'	'	'
Proceeds from other long term borrowings	'	'	'	'	'	24	'	'
Payments on other long term borrowings	'	'	'	'	'	-3	'	'
(Payments on) proceeds from other short term borrowings, net	'	'	'	'	'	-1	-3	3
Payments for debt issuance costs	'	'	'	'	'	'	-1	'
Net cash (used in) provided by financing activities	'	'	'	'	'	20	-4	3
CASH AND CASH EQUIVALENTS	'	'	'	'	'	'	'	'
Effect of exchange rates on cash and cash equivalents	'	'	'	'	'	1	2	-4
Change in cash and cash equivalents	'	'	'	'	'	60	27	-15
Cash and cash equivalents at beginning of year	'	'	'	'	145	172	145	160
Cash and cash equivalents at end of year	$232	'	'	$172	'	$232	$172	$145

SUMMARIZED_UNAUDITED_QUARTERLY2

SUMMARIZED UNAUDITED QUARTERLY FINANCIAL DATA (Details) (USD $)	3 Months Ended								12 Months Ended
In Millions, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
SUMMARIZED UNAUDITED QUARTERLY FINANCIAL DATA	'	'	'	'	'	'	'	'	'	'	'
Net sales	$544	$569	$590	$528	$533	$546	$583	$534	$2,231	$2,196	$2,184
Gross profit	133	121	146	110	127	148	158	148	'	'	'
AMOUNTS ATTRIBUTABLE TO CHEMTURA COMMON SHAREHOLDERS:	'	'	'	'	'	'	'	'	'	'	'
(Loss) earnings from continuing operations, net of tax	13	-44	27	-18	19	22	34	28	-22	103	68
(Loss) earnings from discontinued operations, net of tax	-3	7	26	-5	1	-13	16	-6	25	-2	51
Loss on sale of discontinued operations, net of tax	-31	-3	-146	'	'	'	'	'	-180	'	'
Net earnings (loss)	-21	-40	-93	-23	20	9	50	22	'	'	'
BASIC PER SHARE - ATTRIBUTABLE TO CHEMTURA(i):	'	'	'	'	'	'	'	'	'	'	'
(Loss) earnings from continuing operations, net of tax (in dollars per share)	$0.13	($0.45)	$0.27	($0.18)	'	'	'	'	'	'	'
(Loss) earnings from discontinued operations, net of tax (in dollars per share)	($0.03)	$0.07	$0.26	($0.05)	'	'	'	'	'	'	'
Loss on sale of discontinued operations, net of tax (in dollars per share)	($0.32)	($0.03)	($1.48)	'	'	'	'	'	'	'	'
Net loss (in dollars per share)	($0.22)	($0.41)	($0.95)	($0.23)	'	'	'	'	'	'	'
DILUTED PER SHARE - ATTRIBUTABLE TO CHEMTURA(i):	'	'	'	'	'	'	'	'	'	'	'
(Loss) earnings from continuing operations, net of tax (in dollars per share)	$0.13	($0.45)	$0.27	($0.18)	'	'	'	'	'	'	'
(Loss) earnings from discontinued operations, net of tax (in dollars per share)	($0.03)	$0.07	$0.26	($0.05)	'	'	'	'	'	'	'
Loss on sale of discontinued operations, net of tax (in dollars per share)	($0.32)	($0.03)	($1.46)	'	'	'	'	'	'	'	'
Net loss (in dollars per share)	($0.22)	($0.41)	($0.93)	($0.23)	'	'	'	'	'	'	'
BASIC AND DILUTED PER SHARE - ATTRIBUTABLE TO CHEMTURA	'	'	'	'	'	'	'	'	'	'	'
Earnings from continuing operations, net of tax (in dollars per share)	'	'	'	'	$0.19	$0.22	$0.34	$0.28	($0.23)	$1.04	$0.68
(Loss) earnings from discontinued operations, net of tax (in dollars per share)	'	'	'	'	$0.01	($0.13)	$0.16	($0.06)	$0.26	($0.02)	$0.51
Net (loss) earnings attributable to Chemtura (in dollars per share)	'	'	'	'	$0.20	$0.09	$0.50	$0.22	($1.81)	$1.02	$1.19
Basic weighted - average shares outstanding (in shares)	96.6	97.5	98.6	98.2	97.9	97.9	98.9	98.3	97.7	98.2	100.1
Diluted weighted - average shares outstanding (in shares)	98.1	97.5	99.7	98.2	99	98.2	99.1	99.1	97.7	98.8	100.3
Facility closures, severance and related costs	14	3	11	14	3	2	6	'	42	11	3
Loss on early extinguishment of debt	'	50	'	'	'	'	'	'	-50	-1	'
Changes in estimates related to expected allowable claims	'	'	'	'	'	'	'	2	'	1	3
Reorganization items, net	'	'	'	'	'	'	'	$2	$1	$5	$19

Schedule_II_Valuation_and_Qual1

Schedule II Valuation and Qualifying Accounts (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Allowance for doubtful accounts	'	'	'
Valuation allowances and reserves	'	'	'
Balance at beginning of year	$11	$15	$20
Additions charged to costs and expenses	2	2	5
Deductions	-1	-6	-10
Other	-1	'	'
Balance at end of year	11	11	15
Reserve for customer rebates	'	'	'
Valuation allowances and reserves	'	'	'
Balance at beginning of year	14	14	14
Additions charged to costs and expenses	36	8	28
Deductions	-40	-8	-28
Balance at end of year	$10	$14	$14